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ABSTRACT 
Type 2 diabetes (T2D) is a chronic progressive disorder that is growing in 
pandemic proportions, which can lead to complications that include cardiovascular 
disease, kidney disease and stroke.  Elevated blood glucose levels and insulin 
resistance are key factors in T2D which are characterised by altered muscle and liver 
metabolism due to defective insulin action.  The liver is the major source of 
endogenous glucose, and when hepatic insulin resistance occurs, it causes the liver to 
produce excessive glucose which contributes to hyperglycemia.   
Hepatic glucose production maintains blood glucose levels during fasting and 
periods of high glucose demand, through the metabolic pathways 
gluconeogenesis/glycolysis and glycogenolysis.  Glycolysis and gluconeogenesis are 
competing reciprocal pathways regulated by hormones, which in turn regulate the 
transcription of gluconeogenic genes.  The rate of gluconeogenesis and glycogenolysis 
is increased in T2D, however the molecular mechanisms involved in mediating 
elevated hepatic glucose production in T2D, are poorly understood. 
Metabolic enzymes can be regulated by transcriptional regulation, allosteric 
regulation, and post-translational modifications (PTMs).  PTMs can regulate signalling 
pathways acutely, and provide an elegant feedback mechanism for metabolic pathways 
in response to nutrient availability.  Protein acetylation is a PTM that has been 
identified as playing a key role in regulating several metabolic processes.  Reversible 
acetylation is highly conserved from bacteria to mammals, and recent proteomic 
studies have revealed more than 2000 non-nuclear acetylated proteins.  It has also been 
established that reversible acetylation of metabolic enzymes can directly affect 
metabolic enzyme and pathway activity.  Recent studies have demonstrated that the 
acetylation profile of the metabolic enzyme glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH) plays a role in regulating glucose flux in Salmonella 
enterica.  These studies demonstrated that the GAPDH acetylation profile was 
regulated in response to nutrient availability, where high glucose conditions caused 
hyper-acetylation of GAPDH, which favoured glucose breakdown through glycolysis.  
They also demonstrated that when bacteria were exposed to citrate or acetate 
conditions it resulted in deacetylation of GAPDH, which favoured glucose production 
through gluconeogenesis.   Various proteomic studies have also revealed that 
metabolic enzymes in the human liver, including GAPDH, are acetylated, but the role 
of reversible GAPDH acetylation in mammalian glucose metabolism is unknown. 
Altered acetylation profiles of particular proteins is now strongly regarded as 
a source of dysfunction in several diseases, and the acetylation profile of GAPDH and 
other metabolic enzymes in T2D is unknown.  To date, current approaches to 
glycaemic control in many T2D patients are inadequate, and new therapeutical 
approaches are required.  This study aimed to identify new mechanisms involved in 
the pathogenesis of hyperglycemia and T2D by investigating the acetylation profile of 
GAPDH.  We hypothesised that reversible GAPDH acetylation regulates 
gluconeogenesis, and is reduced in T2D, contributing to elevated hepatic glucose 
production. We further propose that increasing GAPDH acetylation could enhance the 
effects of metformin and further reduce hepatic glucose production in patients with 
T2D, and therefore identification of enzymes controlling GAPDH acetylation could 
have important therapeutic implications. 
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CHAPTER 1 
REVIEW OF THE LITERATURE 
 
 
1.1 INTRODUCTION 
Type 2 diabetes (T2D) is a chronic metabolic disorder that has a significant 
impact on health, life expectancy, and quality of life 1,2.  T2D is a complex disease 
predominantly caused by the body’s ineffective use of insulin, and is often the result of 
excess body weight and physical inactivity1,2.  In Australia T2D is the fastest growing 
chronic condition, and the 6th leading cause of death1.  Lifestyle factors such as obesity 
and physical inactivity are believed to play a major role in the development of T2D, 
although it is now well established and widely accepted, that there is also a complex 
interplay between genetic, nutritional, and environmental factors that lead to  the  
development  of  T2D1,3.  The World Health Organisation (WHO) forecasts that T2D 
and related deaths will double over the next forty years, which correlates with a rise in 
obesity, with 80% of individuals with T2D being obese1,2,4.  For this reason, T2D is 
now emerging as one of the greatest health challenges that humanity will endure in the 
21st century5.   
In Australia T2D is defined by fasting blood glucose levels above 7.0 
mmol/L, and is characterised by insulin deficiency, or resistance in metabolically 
active tissues, and an increase in hepatic glucose production1,6.  Insulin resistance 
leads to chronic hyperglycemia, that disrupts metabolic homeostasis and can cause 
dysregulation of fat, carbohydrate, and protein metabolism6,7.  Insulin resistance 
prevents the uptake of glucose into insulin sensitive tissues such as skeletal muscle 
and fat, which accounts for approximately 80% of glucose disposal, and also 
stimulates the β-cells of the pancreas to release more insulin  in  response  to  the  
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elevated  blood  glucose  levels5,8.  In addition, insulin resistance results in elevated 
de novo synthesis of glucose from the liver, and an increase in the release of fatty 
acids from adipose tissue into the blood stream9.  This results in hyperinsulinemia, 
hyperglycemia, and an accumulation of fatty acids (hyperlipidemia)10. The outcome 
of these combined metabolic deficiencies is a feedback system that further 
exacerbates dysfunctional metabolism, and initiates circulating inflammatory 
factors and oxidative stress11.  Elevated concentrations of non-esterified fatty acids 
(NEFA) inhibit skeletal muscle glucose metabolism while increasing hepatic 
gluconeogenesis, and activating inflammatory factors5.  Increased levels of circulating 
inflammatory cytokines increase adipocyte lipolysis and interfere with the insulin 
signalling cascade5.  In addition, patients with T2D have a defect in lipid oxidation 
and impaired oxidative capacity5. 
T2D leads to acute and long term complications that cause a range of 
serious health problems. Over time, chronic hyperglycemia can lead to an increased 
risk of peripheral arterial and cerebrovascular disease, retinopathy, nephropathy 
and neuropathy1,2. The risk of death for individuals with T2D is approximately 
double that of individuals who do not have T2D, with 50% of individuals 
diagnosed with T2D dying from cardiovascular disease1,2.  The inability of the 
majority of individuals with T2D to make lifestyle modifications, such as consuming 
a healthy diet and participating in regular exercise, means pharmacological 
intervention is required in order to combat the exponential growth of T2D.  There is  
no  cure  for  T2D,  and  the drugs  available  do  not adequately control the symptoms 
of T2D5.  
 The impaired metabolism seen in T2D is complicated by the sheer 
number and complexity of biochemical reactions and metabolic pathways involved, 
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which further complicates pharmacological intervention.  Hepatic glucose production 
is increased in T2D, which contributes to the high blood glucose levels that are a 
defining feature of this disease12,13.  By reducing hepatic glucose production, as seen 
in T2D, there is the potential to reduce blood glucose levels in individuals with T2D.  
Dysfunctional hepatic gluconeogenesis that occurs in T2D is the major source of 
endogenous glucose production in individuals with T2D13.  Gluconeogenesis has been 
shown to be regulated by the expression of a number of metabolic genes and proteins, 
but pharmacological attempts to control the regulation of gluconeogenesis at a 
transcriptional level have been unsuccessful13,14.  In addition, transcriptional regulation 
does not account for the rapid changes that occur in metabolic pathways. Post 
translational modifications (PTMs), such as reversible lysine acetylation, are now 
widely accepted as a potential mechanism involved in the acute regulation of 
metabolism15,16. 
Reversible lysine acetylation is a PTM, which is emerging as a major 
regulator of cellular processes in response to environmental and nutritional stimuli.  In 
particular, acetylation of metabolic enzymes in bacteria has recently been implicated 
as a fundamental component regulating metabolic flux, rate, and direction17-19.  
Acetylation is an abundant PTM, and the acetylation/deacetylation of histones is a 
well-known regulator of transcription18,20.  Only recently has it been revealed that 
acetylation occurs in abundance on non-histone and cytosolic proteins20,21.  In 
particular, most metabolic enzymes can undergo acetylation20,21.  Recent proteomic 
studies carried out to analyse acetylated proteins throughout the whole cell have found 
that as many as 95% of metabolic enzymes can undergo acetylation, with up to 85% 
of gluconeogenic enzymes found to be acetylated in the human liver19-22.  Considering 
the large number of enzymes that are acetylated in the gluconeogenic pathway, 
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acetylation could possibly play an important role in the regulation and dysregulation 
of this pathway.  Recently it was demonstrated in the bacteria Salmonella enterica 
(S.enterica), that acetylated GAPDH increases glycolysis, and deacetylated GAPDH 
increases gluconeogenesis19,22.  It was also shown in S.enterica, that the carbon source 
determined the acetylation profile of GAPDH, where GAPDH acetylation increased 
in glucose rich media, and GAPDH acetylation levels decreased in acetate or citrate 
rich media19. This potentially links the regulation of glucose metabolism to substrate 
availability, which can be connected to both diet and exercise.  Further investigation 
is required to see whether this mechanism of metabolic regulation by reversible 
GAPDH acetylation occurs in mammals.  
The addition of an acetyl moiety to a lysine residue is catalysed by a family 
of enzymes known as the lysine acetyltransferases (KATs)23-25. The removal of an 
acetyl moiety from a lysine residue is catalysed by a family of enzymes called the 
lysine deacetylases (KDACs)23-25.  There are eighteen known human KDACs, which 
are further divided into two groups; the eleven Histone deacetylases (HDACs) which 
are zinc (Zn2+) dependent, and the seven Sirtuins (SIRTs), which are nicotinamide 
adenine dinucleotide (NAD+) dependent23,25.  Altered acetylation profiles of proteins 
is now strongly regarded as a source of dysfunction in several diseases, however, the 
acetylation profile of GAPDH in T2D has not been investigated.  The KDACs 
responsible for the deacetylation of GAPDH in mammals are only partially known.  
Uncovering these proteins, coupled with the knowledge of altered acetylation profiles 
in disease, could hypothetically provide new therapeutic targets26.  
 
1.2 HEPATIC GLUCOSE METABOLISM  
The liver is the primary source of endogenous glucose, and therefore plays 
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a key role in glucose homeostasis13,14. The liver has the capacity to store and generate 
de novo formation of glucose, which is tightly regulated by hormones, in particular 
insulin and glucagon (Figure 1.1)14,27.  Metabolites such as free fatty acids, along 
with 3-carbon compounds such as lactate, alanine, pyruvate and glycerol, also play 
a role in regulating hepatic glucose metabolism14,28.  The liver stores glucose as 
glycogen, which can then be converted back into glucose via glycogenolysis, and 
can also produce glucose via gluconeogenesis (Figure 1.1)14.  In obese individuals 
with T2D, approximately one-third of endogenous glucose is produced by hepatic 
glycogenolysis, with the remaining two-thirds of endogenous glucose produced by 
hepatic gluconeogenesis29.  Gluconeogenesis only occurs in the liver and kidney, 
as glucose 6-phosphatase (G-6-Pase, an enzyme that catalyses the final step in 
gluconeogenesis) is principally found in theses tissues, however non-
gluconeogenic tissues, such as skeletal muscle, can produce glucose that is stored 
as glycogen30.  In order for gluconeogenesis to occur, substrates produced by 
peripheral tissues must be transported to gluconeogenic tissues, in particular the 
liver9.  
Glucose homeostasis is primarily controlled at a hormonal level, where 
passive glucose intake through GLUT2 transporters in the pancreas allows the 
glucose sensitive α and β cells to regulate the secretion of glucagon and insulin, 
respectively27. When blood glucose levels are low, glucagon is secreted, 
stimulating hepatic glucose production. When blood glucose levels are high, insulin 
is secreted, which inhibits hepatic glucose production (Figure 1.1)27. Insulin 
stimulates glucose uptake by peripheral tissues such as skeletal muscle   and   fat,   
and   increases   glycolysis,   glycogenesis,   lipogenesis   and   protein 
synthesis27,31,32.  Insulin does not affect glucose uptake by the liver, but rather  
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Figure 1.1:  Insulin and glucagon regulate hepatic glucose metabolism.  Increased blood glucose 
levels stimulate insulin secretion resulting in increased glycolysis and glycogenesis, and decreased 
glycogenolysis and gluconeogenesis27,33.  When blood glucose levels are low insulin secretion is 
decreased and the secretion of glucagon is increased, resulting in increased glycogenolysis and 
gluconeogenesis, and decreased glycolysis and glycogenesis27. 
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inhibits gluconeogenesis and glycogenolysis27,31,32. Glucose uptake by the liver is 
facilitated by the glucose transporter GLUT2, which passively allows glucose 
movement across the cell membrane when high concentrations of sinusoidal glucose 
are present (Figure 1.2)14. During times of elevated blood glucose levels the liver 
metabolises glucose into energy and substrates such as glycogen and lipids14. When 
blood glucose levels are low the liver maintains blood glucose levels via the 
production of glucose through gluconeogenesis, and the release of glucose from 
stored glycogen via the process of glycogenolysis (Figure 1.1)14. 
In research studies to date the regulation of gluconeogenesis in the liver 
has been primarily defined at a transcriptional level through the regulation of 
insulin and 
glucagon.  Insulin can inhibit gluconeogenesis by preventing the transcription of 
Phosphoenolpyruvate carboxykinase (PEPCK)  and G-6-Pase, and by suppressing 
substrate availability, such as the generation of free fatty acids from adipose 
tissue31,32.  PEPCK, G-6-Pase and Fructose 1,6-bisphosphatase (FBPase) are 
acknowledged as gluconeogenic rate limiting enzymes, where insulin signalling 
results in a decrease in the expression of the PEPCK and G-6-Pase genes (Figure 
1.2)34,35. The reduction in gene expression leads to a decrease in protein levels that 
limits gluconeogenic flux34-36. When hepatic insulin resistance occurs, it results in 
an increase in the expression of gluconeogenic rate limiting enzymes that increase 
the rate of gluconeogenesis, and leads to elevated blood glucose levels. 
Dysfunctional hepatic metabolism in individuals with T2D, namely the increased 
rate of gluconeogenesis due to insulin resistance, is a key factor involved in the 
increase of blood glucose levels in T2D. 
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1.2.1 Hepatic Insulin Resistance 
The mechanisms of hepatic insulin resistance from nutrient overload are 
incompletely understood, however it is widely accepted that there is an association 
with the accumulation of by-products from nutrient overload, specifically lipid 
accumulation (Figure 1.2)37. This induces endoplasmic reticulum (ER) stress, 
inflammatory effects, and other humoral factors, which lead to hepatic insulin 
resistance37,38. Hepatic insulin resistance results in excessive hepatic glucose 
production, further exacerbating the high blood glucose levels seen in  T2D  (Figure  
1.3)37,38.    The principal cause of excessive hepatic  glucose production is 
predominantly due to the increased rate of hepatic gluconeogenesis13.  Hepatic insulin 
resistance inhibits the suppression gluconeogenesis and glycogenolysis, and reduces 
glycogen synthase activation6,7.  This results in reduced glycogen synthesis and 
storage, and excessive hepatic glucose production. 
Several factors have been implicated in the dysregulation of hepatic 
gluconeogenesis due to insulin resistance, such as an increase in the expression of 
gluconeogenic rate limiting enzymes34-36.    There are numerous insults that can cause 
insulin resistance, which can also occur independent of changes to the insulin 
signalling pathway39.  Traditionally, a build-up of fatty acids activates kinase 
pathways that prevent the phosphorylation of proteins involved in the insulin 
signalling pathway (Figure 1.2)40.  However, research by Hoehn et al suggests that 
defects within the insulin signalling pathway that occur in insulin resistance are 
unlikely to contribute to the early development of insulin resistance39. 
Acetylation is a PTM that has been gaining interest, and is now believed 
to be as abundant, and as relevant as phosphorylation. Lysine acetylation is a 
reversible PTM that has only recently been associated with metabolic enzymes41,42.  
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Figure 1.2:  Hepatic insulin signalling pathway, and fatty acid induced insulin resistance in T2D.  
Insulin stimulates the phosphorylation of IRS-2, PI3-K, and Akt-2 which leads to the phosphorylation 
of GSK3 and FOXO.  Phosphorylation of GSK3 increases glycogenesis and the storage of glycogen.  
Phosphorylation of FOXO inhibits the expression of gluconeogenic rate limiting enzymes PEPCK and 
G-6-Pase.  Insulin resistance can occur due to increased delivery of fatty acids from the plasma and a 
build-up of diacylglycerol (DAG) content, which leads to the activation of protein kinase C (PKC-ε), 
decreasing insulin-stimulated IRS-1/IRS-2 tyrosine phosphorylation, PI3K activation, and downstream 
insulin signalling.  These fatty acid induced flaws in insulin signalling causes a decrease in GSK3 and 
FOXO phosphorylation, resulting in a decrease in glycogen synthesis, and an increase in the expression 
of gluconeogenic rate limiting enzymes, increasing gluconeogenesis and hepatic glucose production6.  
IRS-2 = insulin receptor substrate-2, PI3-K = Phosphoinositide 3-kinase, Akt-2 = protein kinase B-2, 
LCFA = long chain fatty acids, GLUT-2 = glucose transporter-2, G6Pase = glucose 6-phosphatase. 
Fatty acids
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Figure 1.3:  Elevated hepatic glucose production due to fatty acid induced insulin resistance.  
Insulin resistance can occur due to an increase in free fatty acid uptake, and results in a build-up of 
gluconeogenic substrates, causing an increase in gluconeogenesis and glycogenolysis33,43.  The outcome 
of all these factors results in an increase in hepatic glucose production. 
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Recent studies have found that a large number of metabolic proteins can be 
acetylated, potentially providing a novel biological mechanism of metabolic 
regulation20.  Certain acetylation profiles of metabolic enzymes could be 
physiologically significant, and it is possible that the acetylation profile of metabolic 
enzymes in diseases, such as T2D, could play a role in dysfunctional metabolism.  
1.3 ACETYLATION 
Lysine acetylation is a reversible PTM that was first documented by Allfrey 
et al in 196444. Reversible acetylation in mammals involves an acetyl group from 
acetyl-CoA that is transferred to the epsilon (ε)-amino group of specific lysine 
residues to form N-acetyl lysine (Figure 1.4)45,46. Lysine acetylation and 
deacetylation modifies the charge present on lysine residues, which modifies the 
overall electrostatic charge of the protein, which can have effects on protein stability, 
activity, and conformation47.  Unmodified lysine residues are positively charged, 
which can modulate protein stability and function by way of hydrogen bonding 
with other amino acid residues45,48.  Recent studies have revealed that a large number 
of cellular proteins, in particular metabolic enzymes, are capable of reversible 
acetylation20,21.  Due to the conservation, and large number of proteins capable of 
acetylation, lysine acetylation of proteins now rivals phosphorylation as a potential 
regulator of multiple cellular processes45,46,49-51.  Acetylation and deacetylation is 
facilitated by KATs and KDACs respectively, however acetylation can also occur 
independent of enzymes.  It has been demonstrated in vitro that physiologic pH and 
acetyl-CoA concentrations are sufficient to cause dose and time dependent, but 
enzyme independent, acetylation of mitochondrial and non-mitochondrial proteins52. 
In 2009 Zhang et al identified a considerable number of lysine acetylated 
orthologs between mammals and Escherichia coli (E.coli), implying that lysine  
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Figure 1.4:  Reversible lysine acetylation.  The positively charged amino acid residue lysine, can be 
acetylated/deacetylated, thereby changing the charge on the lysine tail.  Biochemically, the є-amino 
groups of lysine residues are positively charged, which maintains protein stability via hydrogen bonding 
with neighbouring amino acid residues48.  This can regulate a proteins propensity to interact with other 
residues, or change the activity of an enzyme19.  When acetyl groups are attached to the lysine tail, the 
charge is neutralised, causing a possible shape/activation shift.  Acetyl groups are sourced from the 
acetyl-coenzyme A complex, which plays a key role in many metabolic processes.  
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acetylation is an evolutionarily conserved modification, from bacteria to mammals51. 
This suggests that lysine acetylation has evolved, and has been conserved, as a 
necessary component for a wide variety of cellular events. The number of cellular 
pathways in which lysine acetylation plays a role is only just being recognised now, 
to the point where lysine acetylation has emerged as a PTM that could be as 
physiologically important as phosphorylation46. These revelations have only just 
become apparent due to the improved techniques and technology used to 
investigate acetylation, which is still in its infancy. As the techniques used to 
research acetylation improve and become more readily available, it is predicted that 
it will reveal a vast array of biological mechanisms that are regulated by acetylation45. 
Acetylation  is  best  known  for  its  role  in  regulating  transcription,  
through  the acetylation/deacetylation of histones, where acetylation allows DNA to 
detach from the histones so that transcription factors and RNA polymerases can 
gain access to the DNA16. Acetylation of histones, and its role in regulating 
transcription, has been largely examined over the last fifty years, with little 
consideration for the acetylation of non-nuclear proteins49.   Due to new 
experimental techniques such as stable isotope labelling by amino acids in cell 
culture (SILAC), recent proteomic studies have demonstrated that non-histone 
proteins are extensively acetylated, in particular metabolic enzymes21,53-55. 
Metabolic enzymes were acetylated in both bacteria and mammals, suggesting an 
evolutionary conserved role for acetylation in regulating metabolic direction/flux, 
protein stability, and enzyme activity19,22,56-59. It was also revealed that the majority 
of metabolic enzymes involved in glycolysis and gluconeogenesis can also undergo 
reversible lysine acetylation60. 
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The amount of an enzyme present at any time can be regulated in the long 
term at a transcriptional and translational level, by gene and protein expression, 
however the mechanisms of acute regulation in metabolism that occur due to external 
stimuli have not been completely elucidated34,35. Regulation of proteins and enzymes 
by reversible lysine acetylation could provide an acute mechanism of metabolic 
regulation in response to internal and external stimuli61. 
Acetylation/deacetylation is dependent on the acetyl-CoA/CoA levels, which 
is an intermediate metabolite, and links acetylation to carbon sources, and also the 
supply of nutrients in the diet56,62. The carbon source has been shown to affect the 
acetylation profile of metabolic enzymes, where Wang et al demonstrated in 
S.enterica, that cells grown in glucose rich media have elevated acetylated lysine 
residues compared to cells grown in acetate or citrate rich conditions19. This potentially 
suggests that acetylation is sensitive to nutrient availability, and could play a key role 
in metabolic regulation in response to nutritional overload or depletion.  Excluding 
exogenous sources of acetyl-CoA, such as tryptophan, acetyl-CoA can be synthesised 
through several metabolic pathways, which are also dependent on nutrient 
availability63.  In the mitochondria, pyruvate can be converted to acetyl-CoA by 
pyruvate dehydrogenase, and acetyl-CoA can also be generated from fatty acids via β-
oxidation63,64.  In the cytosol, acetyl-CoA synthetase can synthesise acetyl-CoA from 
acetate, however the majority of acetyl-CoA is synthesised from citrate, which is 
exported out of the mitochondria via the citrate transporter and then converted to 
acetyl-CoA by ATP citrate lyase63,64.  Acetyl-CoA can also be generated from 
acetoacetate and pyrimidine catabolism63.  
Acetylation can modulate the activity of metabolic enzymes, suggesting that 
there could be altered metabolic protein acetylation profiles that may contribute to the 
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pathophysiology of metabolic diseases like T2D48,65,66. How the acetylation profile of 
enzymes in healthy and diseased pathological states affects enzyme activity and 
metabolism remains unclear48.  It is currently unknown whether the acetylation of 
gluconeogenic rate limiting enzymes is altered in T2D, or whether this mechanism 
contributes to elevated hepatic glucose production. 
 
 1.3.1 Metabolic Regulation by Acetylation 
Transcriptional regulation generally occurs over several hours, and can 
only account for long term metabolic responses.  There is a time delay for changes in 
mRNA levels and the equivalent changes in protein levels at a transcriptional level, 
which suggests that there must be other mechanisms that account for the acute 
metabolic changes that occur in response to internal and external stimuli67.  In 
addition, the amount of metabolic enzyme present does not take into account the 
active state of metabolic enzymes, so mechanisms that regulate enzyme activity 
could also be responsible for the acute metabolic responses to external stimuli64. 
Recent studies have found that PTMs play a significant role in metabolic 
regulation16,60.  PTMs can occur rapidly, and are now largely thought to be 
responsible for the acute metabolic changes that occur in response to external 
stimuli16,60.  PTMs can influence the activity, stability, and sub-cellular localisation 
of enzymes, which could explain the regulation of metabolism independent of 
transcriptional regulation.  In addition, there have been several recent studies that have 
demonstrated that transcriptional expression of PEPCK and G-6Pase does not account 
for increased gluconeogenesis12,68,69.  Samuel et al demonstrated that PEPCK and G-
6Pase levels did not change in T2D, or after fasting in control rats68.  Ramnanan et al 
and Edgerton et al showed that maximum physiological levels of insulin could reduce 
hepatic glucose production, and that changing expression levels of PEPCK had no 
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effect on changes in gluconeogenesis12,69.  These findings are in contrast to the 
prevailing theory of gluconeogenic regulation by expression of the traditional rate 
limiting enzymes PEPCK and G-6-Pase, and suggests that other cellular mechanisms 
are responsible for the increased hyperglycemia and gluconeogenesis that occur in 
T2D. 
PTMs of metabolic enzymes could play a key role in regulating metabolism, 
and if dysregulation of PTMs of metabolic proteins can be shown in T2D, this could 
partially account for the dysregulated metabolism seen in T2D.  In particular, if the 
acetylation profile of metabolic enzymes involved in gluconeogenesis is altered in 
T2D, it could contribute to the increased rate of gluconeogenesis and hepatic glucose 
production in T2D. 
 
1.4 GLYCOLYSIS/GLUCONEOGENESIS 
Glycolysis is a catabolic anaerobic pathway, consisting of ten reactions 
connecting ten intermediate metabolites, transforming glucose into lactate and 
pyruvate, releasing energy in the form of adenosine-5'-triphosphate (ATP) and 
nicotinamide adenine dinucleotide (NADH), (Figure 1.5)63.   The end product of 
glycolysis, pyruvate, is shuttled into the mitochondria to fuel the citric acid cycle 
(TCA).  Gluconeogenesis is the reverse reaction of glycolysis, resulting in glucose 
that is generated from pyruvate63.  Gluconeogenesis requires energy in the form of 
ATP to proceed, and is generally restricted to the liver and parts of the kidney63.  
Glycolysis and gluconeogenesis are reciprocal, where enzymes shared by both 
pathways can only allow flux through the glycolytic or gluconeogenic pathway at 
any one time.  The tightly regulated relationship between glycolysis/gluconeogenesis 
and blood glucose levels is dysregulated in T2D, and the molecular mechanisms  
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Figure 1.5:  Glycolysis/gluconeogenesis metabolic pathway, with acetylated enzymes identified by 
proteomics, highlighted in red.  Arrows indicate the direction of a reaction, some of which are 
reversible.  Glycolysis converts glucose to pyruvate, and gluconeogenesis is the reverse of this reaction, 
producing glucose from pyruvate20.  Abbreviations are as follows: G-6-Pase=Glucose-6-phosphatase, 
HK=Hexokinase, GPI=Glucose-6-phosphate isomerase, FBPase=Fructose 1,6-bisphosphatease, PFK-
1=Phosphofruvtokinase-1, ALDB=Aldolase B, TPI=Triose-phosphate isomerise, 
GAPDH=Glyceraldehyde 3-phosphate dehydrogenase, PGK= Phosphoglycerate kinase, 
PGM=Phosphoglycerate mutase, PK=Pyruvate kinase, PC= Pyruvate carboxylase, 
PEPCK=Phosphoenolpyruvate carboxykinase, LDH=Lactate dehydrogenase, and PDH=Pyruvate 
dehydrogenase. 
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involved have not been completely established70.  In individuals with T2D, hepatic 
gluconeogenesis is increased and glycolysis is decreased, and this results in elevated 
hepatic glucose production2,5. 
In addition to the TCA and glycogen pathway, glycolysis/gluconeogenesis 
also fuels several other metabolic pathways such as the pentose phosphate pathway 
(PPP), the hexose monophosphate pathway, and de novo triacylglycerol synthesis.  
Glucose-6-phosphate is the precursor for glycogen synthesis and the PPP, which 
synthesises pyrimidines71.  Dihydroxyacetone phosphate (DHAP) is the precursor for 
glycerol and glycerolipid synthesis72.  Disruption to the glycolytic/gluconeogenic 
pathway can have a knock on effect that can impair the metabolic pathways 
associated with glycolysis/gluconeogenesis.  
Several enzymes in the glycolysis/gluconeogenesis pathway are involved 
only in glycolysis or gluconeogenesis, however most enzymes are involved in both 
glycolysis and gluconeogenesis.  Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) is one such enzyme involved in both glycolysis and gluconeogenesis, and 
could play a role in regulating the balance between these pathways (Figure 1.5). 
1.4.1 Glyceraldehyde 3-Phosphate Dehydrogenase 
(GAPDH) 
GAPDH is a highly expressed protein that catalyses the reversible reaction 
of glyceraldehyde 3-phosphate and NAD+ to D-glycerate 1,3-bisphosphate and 
NADH during glycolysis, and vice versa for gluconeogenesis (Figure 1.5)63,73.  
GAPDH protein levels generally remain constant for specific tissues, so it is possible 
that GAPDH can be altered by PTMs in order to determine GAPDH function and 
activity, and the direction it catalyses glycolysis/gluconeogenesis.  
GAPDH is not traditionally known as a glycolytic/gluconeogenic rate 
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limiting enzyme, and is commonly thought of as simply a housekeeping gene, 
however new research is now revealing that GAPDH is involved in multiple cellular 
processes other than metabolism.  GAPDH is involved in apoptosis, DNA repair, 
endocytosis, microtubule bundling, membrane transport, and several other cellular 
processes74.  PTMs have been found to play a key role in regulating the various 
functions of GAPDH75-78.   For example; acetylation of lysine residues on GAPDH 
that are regulated by substrate availability allow it to interact dynamically with 
microtubules that facilitate membrane transport, and as a transcription factor for S 
phase activation77,79.  Phosphorylation of a tyrosine residue on GAPDH enables 
GAPDH to interact with Rab2, allowing its transport between the golgi apparatus and 
the endoplasmic reticulum73.  The subcellular localisation of GAPDH can be 
mediated by PTMs, and is a key factor in determining the diverse functions of 
GAPDH75-78.  Recent research has shown that P300/CBP-associated factor (PCAF) 
mediated lysine acetylation of human GAPDH K117, K227 and K251 induces 
GAPDH Siah1 binding and translocation to the nucleus77,79.  When GAPDH is 
localised in the nucleus it can act as a transcriptional activator, and can also mediate 
apoptosis77.  Recently it has been demonstrated in bacteria that metabolism can be 
regulated by the acetylation of metabolic enzymes22.  The glycolytic/gluconeogenic 
activity of mammalian GAPDH could also be regulated by acetylation.  
1.4.2 Regulation of Glycolysis/Gluconeogenesis by GAPDH 
Acetylation 
Gluconeogenesis has been shown to be regulated at a transcriptional level, 
and until recently there has been little consideration for other factors that may acutely 
control pathway activity. Insulin is known to initiate phosphorylation of proteins 
such as protein kinase B-2 (Akt-2), glycogen synthase kinase-3 (GSK3), and forkhead 
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box protein O (FOXO), which in turn stimulates glycogenesis, and inhibits the 
expression of genes that encode gluconeogenic metabolic proteins such as PEPCK 
and G-6-Pase (Figure 1.3)31,32.  In the liver, Protein kinase A (PKA) can activate 
liver-type pyruvate kinase (L-PK) by phosphorylation, and also regulates glucose flux 
by regulating the transcription of the L-PK gene in response to nutrient availability80.  
The transcription factor carbohydrate responsive element binding protein (ChREBP), 
which is required for L-PK transcription, is activated by high glucose and inhibited by 
cAMP, where it is phosphorylated by PKA and de-phosphorylated by protein 
phosphatase 2 (PP2A)80.  When ChREBP is phosphorylated in response to glucose, it 
is shuttled into the nucleus allowing the transcription of L-PK, which increases 
carbohydrate metabolism80.  However, transcriptional regulation occurs over several 
hours, and therefore is unlikely to account for the acute metabolic changes that 
occur in response to rapid fluctuations in nutrient availability and external stimuli22,47.  
GAPDH protein and mRNA levels can vary between tissues but remain constant within 
those tissues, therefore GAPDH activity is likely to be regulated by other mechanisms 
such as its subcellular location and PTMs81.  Acetylation could provide a novel 
mechanism for regulating mammalian GAPDH function and activity.   
There are numerous rapid biochemical processes that regulate protein 
activity, such as allosteric regulation and PTMs.  PTMs generally involves an 
enzyme that facilitates the addition or removal of a chemical moiety, thereby 
changing the properties of that protein, influencing interactions with substrates and 
regulatory proteins49.  Tripodi et al, mapped acetylated and ubiquinated enzymes 
involved in central carbon metabolism and identified that the glycolytic pathway has 
the highest concentration of modified lysine residues67.  Recent studies have shown 
that a large number of acetylated proteins in both prokaryotes and eukaryotes are 
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metabolic enzymes, and that nearly all metabolic enzymes can be acetylated21,42.  
Gluconeogenic enzymes such as GAPDH could be likely candidates for the 
regulation of glycolysis/gluconeogenesis by reversible lysine acetylation.  Denu et 
al  demonstrated that acetylation of the glycolytic enzyme phosphoglycerate mutase 1 
(PGM) increased its glycolytic activity, and that under glucose restriction, SIRT 1 
levels increased leading to deacetylation of PGM and a reduction in PGM glycolytic 
activity82. 
It has been demonstrated in S.enterica that acetylation of GAPDH is 
regulated by nutrient availability, which determines the direction of the 
glycolytic/gluconeogenic metabolic pathway19,22.  They demonstrated that when cells 
were supplemented with glucose, acetylation was elevated, and when supplemented 
in acetate or citrate rich conditions, acetylation was reduced19,22.  This mechanism of 
regulation by reversible acetylation has not been demonstrated in mammals or 
hepatic tissues.  It has been observed that human GAPDH is activated by K254 
acetylation in response to high glucose83.  Lei et al demonstrated that human GAPDH 
K254 was acetylated by PCAF and deacetylated by HDAC5 in vitro, and that 
deacetylation of K254 reduced tumour growth in vivo83.  However, it has recently been 
demonstrated that HDAC5 does not possess deacetylase activity84,85.  There is now a 
large body of evidence that suggests that the class IIa HDACs do not possess 
deacetylase activity, and recent studies have demonstrated that the class IIa HDACs 
deacetylase activity is actually via the recruitment of other deacetylases84,85.   HDAC5 
has been shown to interact with the HDAC3 complex to initiate deacetylation of target 
substrates, so therefore HDAC5 could deacetylate mammalian GAPDH via the 
recruitment of the HDAC3 complex84,85.  Acetylation of additional GAPDH lysine 
residues could play a role in regulating GAPDH activity, and their role in glucose 
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metabolism has not been investigated.   
The role of mammalian GAPDH acetylation in hepatic glucose metabolism is 
incomplete, in particular its role in T2D.  In addition, the KDACs and KATs 
responsible for the deacetylation of GAPDH in mammals remains speculative, and 
it is presently controversial as to whether high levels of acetyl-CoA facilitates 
acetylation by means of an equilibrium reaction independent of KATs49.  
 
1.4.3 Regulation of GAPDH Acetylation 
Previous research has demonstrated that reversible acetylation of metabolic 
enzymes, in particular GAPDH, is largely regulated by substrate availability.  It has 
been shown in bacteria that GAPDH acetylation increases in response to elevated 
glucose, and that deacetylation occurs in response to low glucose and increased acetate 
or citrate19,83.  These changes in substrates could then determine the activity of specific 
KATs and KDACs that are responsible for the acetylation and deacetylation of 
metabolic enzymes such as GAPDH. 
KATs and KDACs are a family of enzymes involved in acetylation and 
deacetylation respectively.  These enzymes are grouped into classes depending on their 
sub-cellular localisation, known functions, and substrate reactivity.  Changes in NAD+ 
and Zn+ substrate availability determines KDAC activity and is directly linked to 
metabolism, creating a feedback loop.  GAPDH that is participating in 
glycolysis/gluconeogenesis is predominantly found in the cytosol, and therefore 
acetylation of metabolically active GAPDH could be regulated by cytosolic KATs 
and KDACs25,86,87.  SIRT2 and HDAC6 are the KDACs that are predominantly 
localised in the cytoplasm, although the majority of KDACs can shuttle between the 
nucleus, cytosol, and organelles25,86,87.  In previous research, HDAC6 has been shown 
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to regulate glucocorticoid-induced hepatic gluconeogenesis, by mediating the 
glucocorticoid receptor88.   
Recent in vitro studies have suggested that human GAPDH K254 is 
deacetylated by HDAC5 in response to low glucose83.  However, this was not shown 
in vivo, and several studies have demonstrated that the class IIa HDACs (HDAC4, 5, 
7, and 9) do not possess deacetylation activity84,85.  These studies also demonstrated 
that HDAC4 and HDAC5 bind to the HDAC3 N-CoR/SMRT complex via their C-
terminal domains to initiate deacetylase activity through HDAC384,85.  Therefore 
HDAC5 could regulate mammalian GAPDH deacetylation, but this would only occur 
via the recruitment of the HDAC3 N-CoR/SMRT complex.  Furthermore, the activity 
of KATs, KDACs, and the acetylation profile of human GAPDH in T2D is unknown.  
1.4.4 GAPDH Acetylation in T2D 
There is growing potential for the use of KDAC inhibitors to be used in T2D 
to treat elevated blood glucose levels.  Previous research has demonstrated that during 
fasting or calorie restriction SIRT1 is activated and induces hepatic gluconeogenesis 
by increasing the transcription of PEPCK, G-6-Pase, and FBPase by deacetylation of 
PGC-1, FOXO1, and signal transducer and activator of transcription 3 (STAT3)89.  It 
has also been demonstrated that hepatic glucose production, and fasting blood glucose 
levels, are reduced in SIRT1 anti-sense oligonucleotide rats, providing rationale for 
KDAC inhibitors to treat T2D90. 
If the acetylation profile of rate limiting metabolic enzymes determines the 
direction of glycolysis and gluconeogenesis, then it is also possible that altered 
acetylation profiles of these enzymes may contribute to diseases such as T2D 
(Figure 1.6). The enzymes that are responsible for the acetylation/deacetylation of 
particular metabolic enzymes could be manipulated to rescue the altered 
 24 
 
acetylation profiles that might occur in T2D.  If KDACs that deacetylate 
gluconeogenic enzymes can be identified, and deacetylation of these enzymes is 
shown to increase hepatic glucose production, then specific KDAC inhibitors could 
be developed to reduce blood glucose levels in T2D. 
1.5 SUMMARY 
Impaired hepatic glucose metabolism in T2D is characterised by insulin 
resistance and excessive hepatic de novo production of glucose, contributing to 
elevated blood glucose levels in T2D.  Dysregulated hepatic metabolism as a 
result of insulin resistance, is the primary source of excessive glucose production 
that contributes to the elevated blood glucose levels seen in T2D.  The mechanisms 
that underlie elevated hepatic gluconeogenesis and glucose production in T2D are 
not completely understood. If hepatic glucose production in T2D could be reduced, 
then it could lower blood glucose levels, and alleviate many of the serious 
complications associated with chronic hyperglycemia. 
Glycolysis/gluconeogenesis occurs in the cytosol of cells, and therefore 
the proteins and enzymes involved are subject to changes in cellular conditions 
within the cytosol63,73.  Organisms must quickly adapt to these fluctuations in 
nutrient availability and environmental variability.  PTMs such as lysine 
acetylation are now recognised as regulators of multiple cellular processes, 
including metabolism, and possibly hepatic glucose production via 
gluconeogenesis4 5 , 9 1 . Reversible lysine acetylation influences metabolic processes 
independent of transcription, and has emerged as a regulator of several cellular 
processes such as cell motility, protein degradation, and recently, metabolic enzyme 
activity91. Disruption to these PTM signalling pathways, and alterations to the  
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Figure 1.6: Proposed mechanism of human GAPDH regulation by acetylation.  Acetylated GAPDH 
increases glycolysis, removing glucose from the blood.  Deacetylated GAPDH increases 
gluconeogenesis and increases blood glucose levels, which could play a role in the dysfunctional 
metabolism that occurs in T2D. 
 
 
 
acetylation profile of proteins, could potentially play a role in diseases such as 
T2D.  Acetylation could be as relevant as phosphorylation and it is likely that 
acetylation, along with other PTMs, acts collectively to regulate a wide range of 
protein functions and cellular processes48. Advances in molecular techniques will 
enable more precise methods for investigating acetylation, and it is likely that there 
is cross talk between lysine acetylation and other modifications such as 
phosphorylation, which provides an even more complex picture23,92,93.  
GAPDH is a multidimensional protein with diverse functions, that could play 
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a role in regulating glycolysis/gluconeogenesis, and there has been little research 
done on mammalian GAPDH acetylation and its role in hepatic glucose metabolism.  
It has also been shown that there is a link between nutrient availability, acetylation 
and metabolic regulation50.  However further studies are required to demonstrate 
that these mechanisms of metabolic regulation occur in mammals in vivo.  The 
acetylation profile of metabolic enzymes in disease, such as GAPDH, also remain 
unidentified. This project investigated whether altered acetylation profiles of the 
metabolic enzyme GAPDH are contributing to increased gluconeogenesis in T2D. 
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CHAPTER 2 
THE ROLE OF GAPDH LYSINE RESIDUES IN THE 
REGULATION OF GLUCOSE METABOLISM 
 
 
2.1 INTRODUCTION 
T2D is inadequately controlled by the current drugs available, and with 
increasing diagnoses of T2D, additional methods of pharmacological intervention are 
required94.  The aim of this thesis is to identify novel metabolic regulatory mechanisms 
in the glycolytic/gluconeogenic pathway that are disrupted in T2D, which could aid in 
the development of new pharmacological interventions.  GAPDH is a highly expressed 
metabolic enzyme, which catalyses glycolytic and gluconeogenic reactions.  Previous 
studies have shown in bacteria that high glucose supplemented media stimulated 
GAPDH acetylation and increased glycolysis19,22.  It was also demonstrated in bacteria 
that citrate or acetate supplemented media decreased acetylation of GAPDH, thereby 
increasing gluconeogenesis19,22.  Further work is required to determine whether this 
mechanism of metabolic regulation by reversible GAPDH acetylation also occurs in 
mammalian hepatocytes.  In addition, there are twenty six lysine residues on GAPDH, 
and further research is required to determine which lysine sites undergo acetylation 
and play a role in regulating glycolysis/gluconeogenesis.  
Recent proteomic studies using mouse and human liver have demonstrated 
that mouse GAPDH K115, K160, K225, and K252 (human K117, K162, K227 and 
K254) can undergo reversible acetylation77,79,83.  Lei et al demonstrated that human 
GAPDH K254 (equivalent of rat GAPDH K252, Figure 2.1.1) is acetylated acutely in 
response to high glucose in vitro, and that GAPDH K254Q in vivo reduced tumour 
growth, where lysine residues mutated to glutamine have been traditionally used in 
acetylation biology to mimic acetylated lysine83.  Other studies have demonstrated that 
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acetylation of rat GAPDH K225 and human GAPDH K117, K227, and K251 
(equivalent of rat K115, K225, and K249 respectively, Figure 2.1.1) regulate GAPDH 
nuclear translocation and apoptosis77,79.  However these studies have not linked 
acetylation of rat GAPDH K115, K160, and K225 to glycolysis/gluconeogenesis.   
 
 
 
Figure 2.1.1:  Rat, mouse, and human GAPDH protein sequence and pairwise alignment95.  (A) 
Rat, mouse and human GAPDH protein sequence sourced from NCBI data bank.  Rat GAPDH (333aa) 
accession: NP_058704.1.  Mouse GAPDH (333aa) accession: AAH83149.1.  Human GAPDH (335aa) 
accession: NP_001276674.1.  (B) Pairwise alignment generated with Clustal. 
 
Therefore the aim of this study was to determine whether rat GAPDH 
acetylation sites K115, K160, K225, and K252 play a metabolic regulatory role in rat 
hepatocytes.  Human hepatic GAPDH crystallography has shown that amino acid 
A
B
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residues 1-151 and 315-335 are part of the GAPDH NAD+ binding domain, and that 
residues 152-314 make up the GAPDH catalytic domain95.  Therefore rat GAPDH 
lysine residues (K115R, K160R, K225R, and K252R), that have been identified in 
proteomic studies, are located in both the NAD+ binding domain and the catalytic 
domain19-21.  This suggests that the catalytic activity of mammalian GAPDH, and 
the ability of mammalian GAPDH to bind NAD+, could be disrupted by mutation of 
these lysine residues.   
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2.2 METHODS 
2.2.1 Cloning 
 All plasmids were generated by GenScript, USA, using rat GAPDH in either 
pIRES-Hyg3 (Clontech, #631620), pIRES-Neo (Clonetech, #631621), or pEGFP-N1 
(Clontech, #6085-1) vectors.  Clones (1μl) were transformed using Subcloning 
Efficiency DH5α (Invitrogen, #18265-017) per manufactures instructions.  Bacteria 
were selected in either 25μg/ml kanamycin or 100μg/ml carbenicillin.  DNA plasmid 
purification was performed using a GeneJET plasmid miniprep kit (Thermo Scientific, 
#K0503) per manufactures instructions. 
 Single mutations to rat GAPDH residues K115, K160, K225, and K252 to 
arginine were generated, and in addition a plasmid was generated that had all four rat 
GAPDH residues K115, K160, K225, and K252 mutated to arginine (4KR GAPDH).  
Mutation of lysine to arginine has been traditionally used in acetylation biology to 
mimic deacetylated lysine.  Mutation of lysine to glutamine has been traditionally used 
in acetylation biology to mimic acetylated lysine.  
 Rat GAPDH (accession: NP_058704.1), mouse GAPDH (accession: 
AAH83149.1), and human GAPDH (accession: NP_001276674.1) sequences were 
sourced from the National Center for Biotechnology Information.  Pairwise alignment 
was generated using Clustal with the Jalview software program96.  
2.2.2 Cell culture 
Rat FAO hepatoma cells were used in these studies, as they are a well 
characterised in vitro model of immortalised mammalian hepatocytes that have been 
frequently used in metabolic studies97.  FAO hepatocytes are particularly useful for 
investigating the regulation of gluconeogenesis, because glucose production is not 
generated from glycogenolysis, since the glycogen content of FAO cells is extremely 
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low under basal conditions97.  Rat FAO immortalised hepatoma hepatocytes and 
monkey fibroblast-like immortalised kidney cells were grown in 75cm2 flasks at 37°C 
and 5% CO2.  FAO cells were grown in RPMI 1640 (Life Technologies, #11875), 
supplemented with 10% FBS.  COS7 cells were grown in DMEM (Life Technologies, 
#11995-065) supplemented with 10% FBS.  Cells were transfected with the plasmid 
pIRES-Hyg3 with no tag, or pEGFP-N1 with N terminal GFP, using lipofectamine 
LTX (Life Technologies, #11668019), and then selected in hygromycin 1:200 (70μM).  
Transfected cell lines included GAPDH WT, single lysine to arginine mutants GAPDH 
K115R, GAPDH K160R, GAPDH K225R, GAPDH K252R, and quad mutant 
GAPDH K115, 160, 225, 252R (4KR; GenScript). Assays were carried out when cells 
were ׽ͺͲǦ90% confluent. 
2.2.3 Protein extraction 
Cells were harvested in 500μl of lysis buffer containing SIRT and HDAC 
inhibitors (see appendix A), and homogenised (Kema Keur Pro 200) at 33,000 rpm for 
20 seconds.  Samples were centrifuged at 12,000 rpm for 10 minutes at 4°C, and the 
supernatant was collected and stored at -80°C.  Total protein was determined by 
Bicinchoninic Acid Assay (BCA – Pierce, #23225) with a xMarkTM spectrophotometer 
(BioRad).  
2.2.4 Immunoprecipitation 
Immunoprecipitation (IP) was performed by diluting 1000μg of protein in 
lysis buffer to a total volume of 500μl, and adding 1μg of anti-GAPDH antibody (Cell 
Signalling Technology, #2118).  The antibody-protein lysate was then incubated at 
4°C on a rotating wheel for 24 hours.  100μl of 50% protein-A agarose beads (Thermo 
Scientific, #20333) was added to antibody-protein lysate and incubated at room 
temperature on a rotating wheel for 4 hours.  The protein-antibody-bead complex was 
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then centrifuged at 13,000 rpm for 2 minutes, and the supernatant was collected and 
stored at -80°C.  The beads were then washed in IP buffer (see appendix A), and 
centrifuged at 13,000 rpm for 1 minute and the supernatant discarded.  This step was 
repeated three times.  The beads were then washed in milli-Q water and centrifuged at 
13,000 rpm, and the supernatant was discarded.  35μl of 2X loading buffer 
(ThermoFisher, #39000) was added to the beads, then heated at 95°C for 5 minutes, 
and run on SDS-PAGE. 
2.2.5 Immunoblotting 
SDS-PAGE was conducted using 1.5mm thick mini 8% Tris-HCl separating 
gels (see appendix A) in 1X running buffer (see appendix A), at 100V for 2 hours.  A 
PageRuler pre-stained protein ladder (Thermo Scientific, #SM0671) was used to 
determine molecular weight.  Gels were transferred to a polyvinylidene difluoride 
membrane (PVDF) in 1X Transfer buffer (see appendix A), at 100 V for 100 minutes 
at 4°C.  PVDF membranes were then blocked in blocking solution (1% BSA in TBST) 
for 1 hour, and probed for 24 hours at 4°C with primary antibody (1:1000).  PVDF 
membranes were then washed in TBST and probed for 1 hour with secondary antibody 
(1:10,000).  Blots were imaged using a Chemidoc XRS (BioRad) and 
chemiluminescence (Invitrogen #WP20005). 
2.2.6 Confocal imaging 
Transfected FAO and COS7 cells were transferred to 35mm glass bottom 
culture dishes (MatTek, #P35G-0-14-C).  Four hours later, cells were washed in PBS 
and stained in 1ml of media with DAPI (300nm), for 1 hour.  Live cells were visualized 
at 37°C using a FluoView FV10i laser scanning confocal microscope (Olympus) at 
X500.  DAPI was visualized at an excitation wavelength of 350nm, and an emission 
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wavelength of 470nm.  EGFP was visualized at an excitation wavelength of 488nm, 
and an emission wavelength of 509nm. 
2.2.7 Computational structural imaging 
 GAPDH structure and lysine residue locations were generated by Dr Victor 
Streltsov, CSIRO Manufacturing Flagship, Parkville, Australia.  GAPDH structure 
was simulated from the closest structure by sequence on the protein data bank (PDB, 
http://www.rcsb.org/pdb/home/home.do), the structure of 1J0X ‘Crystal structure of 
rabbit muscle glyceraldehyde-3-phosphate dehydrogenase’. 
2.2.8 Metabolic profiling 
The cellular bioenergetics profile of FAO hepatocytes was assessed using a 
Seahorse XF24 Flux Analyser (Seahorse Bioscience).  The XF24 Flux Analyser 
measures the oxygen consumption rate (OCR), from which substrate dependent 
oxidation, basal mitochondrial respiration, ATP turnover, uncoupled respiration, 
maximum respiratory capacity, and spare respiratory capacity can be determined. The 
XF24 Flux Analyser also measures the extra cellular acidification rate (ECAR), from 
which basal and maximum glycolysis can be determined.  Cells were seeded into a 24-
well XF24 cell culture microplate (Seahorse Bioscience) at a density of 50,000 cells 
per well, and incubated for 24 hours.  Cells were washed and incubated in 600μl of 
unbuffered DMEM (containing 25mM glucose, 1mM pyruvate and 1mM glutamate) 
pH 7.4, at 37 °C in a non-CO2 incubator (1 hour prior to bioenergetics assessment). 
Six basal OCR measurements were performed using the Seahorse analyser, and three 
measurements were repeated following injection of oligomycin (1μM), carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 1μM) and antimycin-A 
(1μM). ECAR was determined from data collected at basal and oligomycin 
measurement points.  Following completion of the assay, cell number was determined 
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using the CyQuant® Cell Proliferation Assay kit (Molecular Probes) according to 
manufacturer's instructions, or total protein was determined using BCA (Pierce, 
#23225). 
Analysis of glucose, glutamate, pyruvate and palmitate oxidation was 
performed using 24-well Seahorse V7 plates that were seeded with FAO mutant cell 
lines as specified above.  Cells were washed and then resuspended in assay running 
media for glucose oxidation (1 x KHB, 25mM glucose), glutamate oxidation (1 x 
KHB, 2 X GlutaMAX, Life Technologies), pyruvate oxidation (1 x KHB, 2mM 
pyruvate), and palmitate oxidation (1 x KHB, 200μM palmitate, 500μM carnitine).  
Basal oxidative energetics were established after ten measurements.  Following 
completion of the assay, cell number was determined using the CyQuant® Cell 
Proliferation Assay kit (Molecular Probes) according to manufacturer's instructions, 
or total protein was determined using BCA (Pierce, #23225). 
2.2.9 Glucose production assay 
All treatments of transfected hepatocytes were for 24 or 36 hours in glucose 
and serum-free RPMI 1640 media supplemented with 2mM sodium pyruvate, 20mM 
sodium l-lactate and 0.1% BSA (glucose production media; GP media).  Cells were 
treated with either insulin (0.1nM) or forskolin (20μM).  Forskolin was used as a 
glucagon mimetic in vitro, as FAO cells have resistance to glucagon98.  Glucose 
produced by the cells was measured by collecting 40μl of media from each well, which 
was then combined with 250μl of 0.12M NaH2PO4·2H2O pH 7.0 assay buffer, 
(1mg/mL phenol, 0.5mg/mL 4-aminoantipyrine, 1.6 units/mL peroxidise, and 
10 units/mL glucose oxidase).  This solution was incubated for 25 minutes at 37 °C 
and then absorbance was measured at 490nm. Cells were lysed in 100μl 0.03% SDS 
and protein was quantified using BCA (Pierce, #23225).   
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2.2.10 GAPDH activity 
A colourmetric assay was used to measure GAPDH activity based on the 
oxidation of NADH to NAD in the gluconeogenic direction, and vice versa for the 
glycolytic direction (Figure 2.2.1).  NADH absorbance is measured at 340nm which 
declines over time in the gluconeogenic direction, and increases over time in the 
glycolytic direction.  Protein was extracted from transfected cells (GFP tagged) in lysis 
buffer supplied with GAPDH activity assay kit (ScienCell, #8148), and gluconeogenic 
GAPDH analysis was performed following the manufactures instructions.  Glycolytic 
GAPDH activity was measured using the ScienCell assay kit, substituting the 
gluconeogenic reagents with the glycolytic precursor’s glyceraldehyde-3phosphate 
(50mM), sodium-arsenate (1M), and nicotinamide adenine dinucleotide (NAD+, 
10mM). 
 
Figure 2.2.1:  GAPDH activity assay pathway.  The glycolytic/gluconeogenic direction for the 
GAPDH activity assay is determined by substrate availability.  For every cycle of glycolysis two units 
of NADH are produced, and for every cycle of gluconeogenesis two units of NADH are oxidised to 2 
units of NAD.  NADH absorbance is measured at 340nm. 
GFPGAPDH
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GLUCONEOGENIC ACTIVITY
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ADP
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Measurements were made every 3 minutes up to 15 minutes, and then at 60 
minutes, at 340nm using a xMarkTM spectrophotometer (BioRad).  GAPDH activity 
was calculated by normalising to GAPDH quantity determined by GFP tag 
fluorescence (excitation wavelength of 488nm, and an emission wavelength of 
509nm), and to a GAPDH standard curve using recombinant GAPDH (ScienCell, 
#8148h).   
2.2.11 Oil Red-O  
Cells were grown to confluence in 6-well plates, then washed and fixed in 4% 
paraformaldehyde for 1 hour at room temperature.  Cells were then washed in 60% 
isopropanol and stained with Oil Red-O (see appendix A) for 1 hour.  Cells were then 
washed in milli-Q water three times and imaged at X200 on an axioskop 2 microscope 
(Zeiss).  Quantification of neutral lipids was determined using ImageJ following nature 
protocols, Imaging of neutral lipids by oil red O for analyzing the metabolic status in 
health and disease, 2013, section 15B99. 
2.2.12 RT-PCR 
RNA was extracted from rat GAPDH mutant cell lines using RNeasy columns 
(Qiagen, #74104) according to the manufacturer’s instructions.  cDNA was generated 
from 1μg of RNA using SuperScript III Reverse Transcription Kit (Life Technologies, 
#18080093) according to the manufacturer’s instructions.  Gene expression levels 
were quantitated using SYBR Green PCR Master Mix (Life Technologies, #4385610), 
using the primers listed below.  Primer sequences were designed on the National 
Center for Biotechnology information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) as follows:   
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glucose-6-phosphatase: (FWD) 5’-CTTGTGGTTGGGATACTGG-3’ 
 (REV) 5’-GAGGCTGGCATTGTAGATG-3’ 
glucokinase: (FWD) 5’-GAGCAGAAGGGAACAACATC-3’ 
 (REV) 5’-TGGCGGTCTTCATAGTAGC-3’ 
PEPCK:  (FWD) 5’-AGCCATGTGCAACTCATGCA-3’ 
  (REV) 5’-CTCGGTGCCACCTGAAACA-3’ 
Changes in expression were normalized to an Oligreen standard curve (Life 
Technologies, #O7582) as per manufacturer’s instructions.  5μl of each standard and 
sample was run in triplicate on a black 96 well fluorescence plate, scanned at excitation 
485nm and emission 538nm, using a FlexStation II-384 (Molecular Devices). 
2.2.13 Statistical analyses 
Standard curves were generated using Microsoft Excel 2013, and statistical 
analysis was conducted using SPSS 20 and MiniTab 16.  A Kolmogorov-Smirnov test 
was performed to determine normality and distribution.  For data that was not normally 
distributed, a non-parametric test (Kruskal–Wallis test) was used to compare means.  
To compare means for normally distributed data a two tailed T-Test was used, where 
equal variance was assumed if Levene’s significance was greater than 0.05.  For 
normally distributed data, one-way and two-way ANNOVA was used to compare 
groups using Games Howell method (equal variances not assumed), or Fisher's Least 
Significant Difference method (equal variances assumed).  Results are presented as 
mean ± SEM, and P < 0.05 was considered statistically significant. 
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2.3 RESULTS 
2.3.1 GAPDH residues K115, K160, K225, and K252 are positioned on the surface 
of GAPDH.  The structure of GAPDH was generated from crystallography of rabbit 
muscle GAPDH.   Human 1U8F overlayed with rat 2VYN and rabbit 1J0X (from 
PDB) structures shows that the rat, rabbit and human GAPDH structures are very 
similar. Some differences between rat, rabbit and human are mainly in NAD+ binding 
domains at residues 1-151 with RSM distance matches of 3.3A, while catalytic 
domains 152-314 align very well with RMS of 0.35A.  Residues corresponding to 160, 
225, and 252 in rat and rabbit GAPDH are at the same positions as in human.  Lys 225 
is at the entrance to the cleft formed by the tetramer.  Rat GAPDH lysine residues 225 
and 252 form part of the catalytic region of GAPDH, and are exposed on the surface 
where they could play an important role in protein-protein interactions (Figure 2.3.1).  
2.3.2 Total GAPDH acetylation is not reduced in GAPDH mutants.  Total GAPDH 
acetylation and expression in FAO stable transfected pIRES-Hyg3 GAPDH mutant 
cells, was determined by immunoprecipitation and immunoblotting.  FAO stable 
transfected pIRES-Hyg3 rat GAPDH mutant cells were used for all experiments in this 
chapter, excluding the GAPDH activity assay, where FAO transient transfection with 
pEGFP-N1 rat GAPDH mutants were used.  Immunoblotting of GAPDH stable 
mutants showed that GAPDH expression was not changed relative to α-tubulin 
expression (Figure 2.3.2 A).  Total GAPDH acetylation was unchanged between non-
transfected FAO, and across all FAO stable transfected mutants (Figure 2.3.2 B).  This 
highlights the importance of using site specific acetyl-lysine antibodies, and has 
implications for interpreting acetyl-lysine blots using pan acetyl-lysine antibodies.  
2.3.3 WT GAPDH and 4KR GAPDH are localised in the cytoplasm.  Previous 
studies have showed that acetylation of GAPDH can regulate its cellular localisation75-
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78,100,101.  To determine whether mutation of lysine residues found to be acetylated in 
human liver to arginine alters GAPDH localisation, WT GAPDH-GFP and 4KR 
GAPDH-GFP expressing FAO and COS7 cells were stained with DAPI (300nM), for 
1 hour and visualised at X500 using a confocal microscope.  WT GAPDH and 4KR 
GAPDH were predominantly located throughout the cytoplasm not the nucleus (Figure 
2.3.3). 
2.3.4 Lysine residues that are acetylated determine GAPDH 
glycolytic/gluconeogenic activity in vitro.  To determine whether mutation of lysine 
residues alters GAPDH activity, a colourmetric assay with substrates limiting GAPDH 
activity to either the glycolytic or gluconeogenic direction was performed.  FAO cells 
were transiently transfected with pEGFP-N1 GAPDH mutants, so that GAPDH 
activity could be normalised to GFP fluorescence to represent units of GAPDH per 
well.  Glycolytic GAPDH activity was reduced in K115R, K160R, K225R, K252R, 
and 4KR GAPDH mutant FAO cells compared with WT GAPDH FAO cells (Figure 
2.3.4 B).  Gluconeogenic GAPDH activity was increased in K225R, K252R, and 4KR 
GAPDH mutant FAO cells compared with K115R, K160R, and WT GAPDH FAO 
cells (Figure 2.3.4 C). 
2.3.5 Basal glucose production is increased in K225R, K252R and 4KR mutant 
GAPDH cell lines.  To determine whether glucose production is altered in GAPDH 
lysine mutants, cells were seeded into 48 well plates and grown in GP media for 24 
hours.  Consistent with the GAPDH activity in these mutants, FAO GAPDH mutant 
cells K225R, K252R and 4KR produced more glucose than FAO WT cells and FAO 
mutant cells K115R and K160R (Figure 2.3.5). 
2.3.6 Glycolytic flux is reduced in K225R, K252R and 4KR mutant GAPDH cell 
lines.  To determine whether reduced GAPDH acetylation impairs glycolysis, ECAR 
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was measured to assess glycolytic flux.  Consistent with the reciprocal nature of 
glycolysis/gluconeogenesis, ECAR was significantly reduced in the K225R, K252R 
and 4KR mutant GAPDH FAO cells compared with K115R, K160R, and WT GAPDH 
FAO cells (Figure 2.3.6).   
2.3.7 Insulin suppresses glucose production and forskolin increases glucose 
production in mutant GAPDH FAO cells.  To determine whether hormonal control 
of glucose production is altered in GAPDH mutants, cells were seeded into 48 well 
plates and grown in GP media treated with insulin (0.1nM) or forskolin (20μM) for 36 
hours.  Insulin suppressed glucose production in all cell lines compared with basal WT 
GAPDH glucose production (Figure 2.3.7).  Forskolin increased glucose production 
in all cell lines compared with basal WT GAPDH glucose production (Figure 2.3.7).  
Cells expressing 4KR GAPDH were hypersensitive to forskolin, resulting in a 2-fold 
increase in glucose production compared with WT GAPDH cells that had been treated 
with forskolin (Figure 2.3.7). 
Increases in gluconeogenesis and decreases in glycolysis appeared to be 
maximised in the 4KR GAPDH mutants compared to the single mutation mutants, 
where the combination of GAPDH residues K225 and K252 in the catalytic region, 
and K115 in the NAD+ binding domain, collectively impair glycolysis and increase 
gluconeogenesis.  Based on the results to this point, additional characterisation was 
performed only in WT GAPDH and 4KR GAPDH mutant cell lines. 
2.3.8 Basal and maximum glycolysis is reduced in 4KR GAPDH cell lines.  Data 
generated to date in this chapter suggests that GAPDH could be rate limiting for 
glycolytic/gluconeogenic flux.  This is in contrast to dogma in the literature suggesting 
that expression of key gluconeogenic genes is rate limiting.  Therefore, basal and 
maximal glycolytic flux was assessed to determine whether basal and maximum 
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glycolytic capacity is altered in 4KR GAPDH mutants, where ECAR was measured 
basally and in the presence of oligomycin (1μM).  Basal ECAR and maximal 
glycolytic capacity were reduced in 4KR GAPDH FAO cells compared with WT 
GAPDH FAO cells (Figure 2.3.8 A).  Maximal glycolytic capacity was significantly 
greater than basal glycolytic rates in WT GAPDH cells, while there was no difference 
between basal and maximal glycolytic rate in 4KR GAPDH cells (Figure 2.3.8 A). 
To determine whether these effects are independent of transcriptional 
regulation of key gluconeogenic genes, the mRNA expression of traditional rate 
limiting enzymes phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-
phosphatase (G-6-Pase), and glucokinase (GK) was measured using qRT-PCR.  There 
was no significant change in PEPCK, G-6-Pase and GK expression levels between 
WT GAPDH and 4KR GAPDH mutant FAO cells (Figure 2.3.8 B, C, and D).  
2.3.9 Mitochondrial respiration is unchanged in 4KR GAPDH mutant FAO cells.  
The oxygen consumption rate (OCR) was measured in the presence of mitochondrial 
inhibitors oligomycin, FCCP, and antimycin A, to determine overall mitochondrial 
function in WT and 4KR GAPDH cells.  OCR was unchanged in 4KR GAPDH 
compared with WT GAPDH (Figure 2.3.9 A).  Basal mitochondrial respiration, ATP 
turnover, uncoupled respiration (proton leak), maximal mitochondrial respiratory 
capacity, and spare respiratory capacity was unchanged in 4KR GAPDH mutant FAO 
cells compared with WT GAPDH cells (Figure 2.3.9 B).   
2.3.10 Glucose and palmitate dependent oxidation is impaired in 4KR GAPDH 
mutant FAO cells.  To determine whether substrate dependent oxidation is altered in 
4KR GAPDH mutants, either pyruvate, palmitate, glutamine or glucose in KHB buffer 
were used to determine specific substrate dependent OCR in FAO mutant cells.  
Glucose dependent OCR was reduced in 4KR GAPDH mutant cells compared with 
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WT GAPDH cells (Figure 2.3.10 A).  Palmitate dependent OCR was reduced in 4KR 
GAPDH mutant cells compared with WT GAPDH cells (Figure 2.3.10 B).  Glutamine-
dependent OCR was unchanged in 4KR GAPDH mutant cells compared with WT 
GAPDH (Figure 2.3.10 C).  As the end product of glycolysis, pyruvate is also a key 
substrate for mitochondrial oxidative metabolism.  Oxidation of pyruvate was 
unchanged in WT GAPDH and 4KR GAPDH cells (Figure 2.3.10 D). 
2.3.11 Lipid accumulation is increased in 4KR GAPDH mutant FAO cells.  To 
determine whether the reduction in palmitate oxidation was associated with lipid 
accumulation with 4KR GAPDH, Oil Red-O stain was used to visualise neutral lipids 
in WT GAPDH and 4KR GAPDH cell lines (Figure 2.3.11 A).  Lipid deposits were 
greater in 4KR GAPDH FAO cells compared with WT GAPDH FAO cells, P<0.05 
(Figure 2.3.11 B). 
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Figure 2.3.1: Crystal structure of one monomer of rabbit muscle glyceraldehyde-3-phosphate 
dehydrogenase, generated from PDB.  Monomer of GAPDH, which forms a tetramer, displaying the 
NAD+ binding site and lysine residues 115, 160, 225, and 252. 
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Figure 2.3.2:  GAPDH expression and total GAPDH acetylation in WT and mutant GAPDH FAO 
cells.  (A)  GAPDH expression in FAO hepatocytes stable transfected with pIRES-Hyg3 GAPDH 
mutants.  (B)  GAPDH immunoprecipitation representing total GAPDH acetylation in FAO hepatocytes 
stable transfected with pIRES-Hyg3 GAPDH mutants.  Data represented as %non-transfected, mean ± 
SEM, n=8 replicates per group.  Results not statistically significant. 
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2.3.3: FAO WT GAPDH-GFP and FAO 4KR GAPDH-GFP confocal imaging (magnification 
X500).  (A) WT GAPDH-GFP FAO cells and 4KR GAPDH-GFP FAO cells were stained with DAPI 
(300nM) and imaged by confocal microscopy at (magnification X500).  (B) WT GAPDH-GFP COS7 
cells and 4KR GAPDH-GFP COS7 cells were stained with DAPI (300nM) and imaged by confocal 
microscopy at (magnification X500). 
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Figure 2.3.4:  FAO WT GAPDH-GFP and FAO mutant GAPDH-GFP activity.  (A) GFP 
expression of pEGFP-N1 GAPDH mutants.  (B) Glycolytic GAPDH activity.  (C) Gluconeogenic 
GAPDH activity.  All data represented as %WT GAPDH activity.  All data represented as mean ± SEM, 
n=8 replicates per group.  * Significantly different from WT GAPDH, P < 0.05. 
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Figure 2.3.5:  FAO WT GAPDH and FAO mutant GAPDH glucose production assay.  GAPDH 
stable cell lines were grown in GP media for 36 hours, and total glucose produced was measured.  All 
data represented as %WT GAPDH, mean ± SEM, n=8 replicates per group.  * Significantly different 
from WT GAPDH, P < 0.05. 
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Figure 2.3.6:  FAO WT GAPDH and FAO mutant GAPDH extra cellular acidification rate 
(ECAR).  ECAR was measured in a Seahorse Bio-Analyser using DMEM running buffer.  All data 
represented as %WT GAPDH, mean ± SEM, n=8 replicates per group.  * Significantly different from 
WT GAPDH, P < 0.05. 
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Figure 2.3.7:  FAO WT GAPDH and FAO mutant GAPDH, insulin and forskolin treated glucose 
production assay.  WT GAPDH and mutant GAPDH cell lines were treated with either 20μM forskolin 
or 0.1nM insulin in GP media, and glucose production was measured after 36 hours.  All data 
represented as %WT GAPDH basal glucose production, mean ± SEM, n=8 replicates per group.  # 
Significantly different from WT GAPDH basal glucose production, P < 0.05.  * Significantly different 
from single GAPDH mutants, P < 0.05. 
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Figure 2.3.8: FAO WT GAPDH and FAO 4KR GAPDH basal and maximum glycolysis and 
mRNA expression.  (A) Basal glycolysis was determined by averaging six measurements of basal 
ECAR, and maximum glycolysis was determined by averaging three measurements in the presence of 
oligomycin (1μM).  Data represented as %WT GAPDH, mean ± SEM, n=10 replicates per group.  * 
Significantly different from WT GAPDH, P < 0.05.  # Significantly different from WT GAPDH basal 
glycolysis, P < 0.05.  (B) PEPCK mRNA expression normalised to WT GAPDH, (C) Glucokinase 
mRNA expression normalised to WT GAPDH, (D) G-6-Pase mRNA expression normalised to WT 
GAPDH.  All data represented as mean ± SEM, n=10 replicates per group.    
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Figure 2.3.9:  FAO WT GAPDH and FAO 4KR GAPDH OCR and mitochondrial respiration.  
(A) Oxygen consumption rate.  (B) Mitochondrial energetics.  All data represented as mean ± SEM, 
n=10 replicates per group.  Results not statistically significant. 
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Figure 2.3.10:  FAO WT GAPDH and FAO 4KR GAPDH substrate dependent OCR.  (A) Glucose 
dependent OCR, (B) Palmitate dependent OCR, (C) Glutamate dependent OCR, (D) Pyruvate 
dependent OCR.  All data represented as %WT GAPDH.  All data represented as mean ± SEM, n=10 
replicates per group.  * Significantly different from WT GAPDH, P < 0.05. 
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Figure 2.3.11:  FAO WT GAPDH and FAO 4KR GAPDH Oil Red-O stain (Magnification X200).  
(A) WT GAPDH and 4KR GAPDH cells were fixed and stained with Oil Red-O. (B) Densitometry 
quantification of neutral lipids, P<0.05.  n=6 replicates per group. 
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2.4 DISCUSSION 
Reversible acetylation of metabolic enzymes is now considered to play a key 
role in the regulation of metabolism22,45,58,102.  Reversible GAPDH acetylation in 
bacteria has been shown to regulate glycolysis/gluconeogenesis based on substrate 
availability, however the lysine residues involved are not completely known19,22.  
GAPDH lysine residues have also been shown to be acetylated in the liver of humans, 
thus the purpose of this study was to determine the role of these GAPDH lysine 
residues on aspects of hepatocyte metabolism.  Based on previous studies, rat GAPDH 
residues K115, K160, K225 and K252 that have been shown to undergo reversible 
acetylation, were mutated to arginine to mimic deacetylation19-21,79.  This study showed 
that mutation of lysine residues on GAPDH to arginine, increased gluconeogenic 
GAPDH activity and glucose production, and reduced ECAR and glycolytic GAPDH 
activity.  In addition, palmitate and glucose oxidation was impaired, and lipid 
accumulation was higher in 4KR GAPDH.  These results occurred independent of 
transcriptional regulation.    
The total acetylation of the 4KR GAPDH and single lysine GAPDH 
mutations was not reduced compared to the WT GAPDH mutants (Figure 2.3.2 B).  
This suggests that measuring total GAPDH acetylation using pan acetyl-lysine 
antibodies is not representative of the four lysine residues that have been mutated.  Site 
specific acetyl-lysine antibodies are therefore required to accurately determine the 
acetylation status of rat GAPDH residues K115, K160, K225, and K252.  Site specific 
antibodies are currently being generated but were not available for submission of this 
thesis.  In addition, a point of consideration is that lysine residues undergo several 
different types of acyl PTMs, which could be affected by mutation to arginine, and this 
needs to be considered when interpreting the data64. 
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The sub-cellular localisation of GAPDH has been shown to play an important 
role in determining the functional properties of GAPDH78.  GAPDH that participates 
in transcription and apoptosis is located in the nucleus and GAPDH that participates 
in glycolysis/gluconeogenesis is located in the cytosol78.  Previous research has shown 
that acetylation of GAPDH can determine its subcellular localisation.  Ventura et al 
demonstrated that acetylation of human GAPDH residues K117, K227, and K249 
(equivalent of rat K115, K225, and K249, Figure 2.1.1) in response to apoptotic stimuli 
are required for GAPDH translocation to the nucleus, where acetylation of K160 
initiates apoptosis73,76,79.  Using confocal microscopy, WT GAPDH and 4KR GAPDH 
were primarily located in the cytosol (Figure 2.3.3), demonstrating that 4KR GAPDH 
was still localised to the region of the cell where the glycolytic/gluconeogenic 
processes occur.  The cytosolic localisation of GAPDH appears to be perinuclear and 
requires further investigation to determine the nature of this GAPDH cytosolic 
localisation. 
GAPDH activity in the gluconeogenic direction was increased in K225R, 
K252R, and 4KR GAPDH mutants compared with WT GAPDH (Figure 2.3.4 C).  This 
correlated with the ECAR and GP data that showed a decrease in glycolysis and an 
increase in glucose production, respectively, in the K225R, K252R, and 4KR GAPDH 
mutants (Figures 2.3.5 and 2.3.6).  This suggests that rat GAPDH K225 and K252 
acetylation plays a regulatory role in glycolysis/gluconeogenesis.  GAPDH activity in 
the glycolytic direction was reduced in all mutant GAPDH cell lines compared with 
WT GAPDH (Figure 2.3.4 B).  This does not correspond with the ECAR data, where 
ECAR was not reduced in K115R and K160R mutants.  This could be explained by 
increased contribution to ECAR from other metabolic pathways, possibly by the TCA 
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cycle which contributes a proton each cycle, thereby contributing to cellular 
acidification and therefore ECAR.   
Chronic measurement of glucose production showed that K225R, K252R, 
and 4KR GAPDH mutants produced more glucose than WT GAPDH (Figure 2.3.5). 
The rat GAPDH K115R and K160R GAPDH mutants had no effect on glucose 
production compared with WT GAPDH (Figure 2.3.5).  In addition, ECAR was 
reduced in K225R, K252R, and 4KR GAPDH mutants compared with WT GAPDH 
(Figure 2.3.6).  ECAR was not reduced in K115R and K160R mutations compared 
with WT GAPDH (Figure 2.3.6).  Together these results indicate that reversible 
acetylation of GAPDH K225 and K252 could play a more significant 
glycolytic/gluconeogenic regulatory role then GAPDH K115 and K160.   
These findings support the hypothesis that site-specific acetylation of 
GAPDH drives glycolysis, and that deacetylated GAPDH drives gluconeogenesis.  
Further investigation into the structural changes that occur to GAPDH when these 
lysine residues are acetylated/deacetylated could reveal whether these effects alter the 
binding of GAPDH with intermediary metabolite substrates. Jenkins and Tanner 
showed through crystallography of human hepatic GAPDH that amino acid residues 
1-151 and 315-335 are part of the GAPDH NAD+ binding domain, and that residues 
152-314 make up the GAPDH catalytic domain103.  Therefore residue K115 is within 
the NAD+ binding domain and residues K160, K225 and K252 are within the catalytic 
domain, so therefore the 4KR GAPDH mutant has mutations within the NAD+ and 
catalytic binding domains.  Combined with the findings in this study, this suggests that 
rat GAPDH K225 and K252, which are located in the catalytic domain and on the 
surface of GAPDH, are important for the regulation of glycolysis/gluconeogenesis.  
Furthermore, rat GAPDH K225 lies within the cleft formed by the GAPDH tetramer, 
 57 
 
which appears to have important properties for protein-protein binding.  Rat GAPDH 
K225 has already been implicated in Siah-1 binding, and alterations to cleft shape and 
charge following acetylation/deacetylation of rat GAPDH K225 coupled with K252 
could play a role in the interaction of GAPDH with intermediary metabolites77.  
Further research will be required to determine whether K225 and K252 acetylation 
favours binding of glyceraldehyde 3-phosphate and glycolysis, and whether K225 and 
K252 deacetylation favours binding to D-glycerate 1,3-bisphosphate and 
gluconeogenesis. The results so far indicate that the combination of deacetylated lysine 
residues in the 4KR GAPDH mutant amplifies the effects of glucose production and 
ECAR that are seen in the single mutations of K115R, K160R, K225R and K252R.  
This could suggest that multiple deacetylated residues increase the disruption to the 
NAD+ and catalytic binding domains.  Further research which focuses on the 4KR 
mutant is likely to provide greater insight into characterising the effect of reduced 
GAPDH acetylation on hepatocyte metabolism.   
Glucose production was measured in the presence of insulin and forskolin to 
determine the role of GAPDH lysine residues that can be acetylated on the hormonal 
regulation of glycolysis/gluconeogenesis.  Forskolin is a plant compound that activates 
the cAMP pathway, and was used as a glucagon mimetic, as FAO cells are resistant to 
glucagon104.  Insulin was still able to suppress elevated glucose production in the 4KR 
GAPDH mutant, presumably through transcriptional regulation or protein degradation.  
However, the 4KR GAPDH mutant was hypersensitive to forskolin compared to WT 
GAPDH, increasing glucose production 4-fold (Figure 2.3.7).  The sensitivity to 
forskolin could be due to the glycolytic inability of 4KR GAPDH, where WT GAPDH 
could have both gluconeogenesis and glycolysis occurring alternatively over twenty 
four hours, thereby reducing the amount of glucose produced.  This is significant in 
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terms of T2D, as research has shown that increased glucagon action is the main driver 
behind increased hepatic glucose production105-107.  
Basal ECAR reflects the rate at which protons are produced by metabolic 
pathways, with the majority of protons produced by glycolysis, therefore ECAR is a 
proxy measure of glycolysis.  Basal glycolysis was reduced in the 4KR GAPDH 
mutants compared with WT GAPDH (Figure 2.3.8 A).  Maximum glycolytic capacity 
is the maximum rate of lactate produced from glycolysis when the mitochondrial ATP 
synthase is inhibited.  WT GAPDH had an increase in maximal glycolytic capacity 
compared with basal glycolysis, while there was no difference between basal and 
maximal glycolysis in 4KR GAPDH (Figure 2.3.8 A).  The 4KR GAPDH mutants also 
had reduced maximum glycolytic capacity compared with WT GAPDH (Figure 2.3.8 
A).  This result further indicates that glycolysis is impaired in the 4KR GAPDH 
mutant, and suggests that lysine modification of GAPDH is rate limiting for 
glycolysis/gluconeogenesis.   
Another factor to take into account is the shift in ATP demand and synthesis.  
One cycle of the glycolytic pathway generates two ATP, and one cycle of the 
gluconeogenesis pathway requires two units of ATP to produce one unit of glucose.  
The reduction in glycolysis and the increase in gluconeogenesis in 4KR GAPDH 
suggests that 4KR GAPDH cells have an increased demand for ATP compared with 
WT GAPDH cells.  Therefore other metabolic pathways must be compensating for the 
increased demand for ATP that is required to facilitate the increase in gluconeogenesis, 
and the reduction in ATP that is generated from glycolysis.  Measuring the OCR and 
mitochondrial flux showed that there was no change in OCR and basal mitochondrial 
respiration between 4KR GAPDH and WT GAPDH (Figures 2.3.9 A and B).  ATP 
turn over, uncoupled respiration, maximum mitochondrial respiration, and spare 
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respiratory capacity were also unchanged (Figure 2.3.9 B).  This data demonstrates 
that a reduction in GAPDH acetylation does not have a detrimental effect on 
mitochondrial function and oxidative phosphorylation.  Oxidative phosphorylation is 
the most likely source of ATP to replace the ATP required to support the increased 
rate of gluconeogenesis in 4KR GAPDH mutants, however OCR was not increased in 
4KR GAPDH cells (Figure 2.3.9 A).  Alternative glucose pathways, such as the 
pentose phosphate pathway, could be compensating for the increased demand for ATP 
by the 4KR GAPDH mutants.    
Oil Red-O staining showed that lipid deposits were increased in the 4KR 
GAPDH mutants compared with WT GAPDH (Figure 2.3.11).  This demonstrates that 
there could be either a reduction in lipid oxidation, or an increase in lipid synthesis, or 
a combination of both.  A reduction in lipid oxidation could be a result of TCA cycle 
cataplerosis used to drive gluconeogenesis, reducing intermediary metabolites in the 
TCA cycle, which would have a knock on effect limiting TCA cycle reactions and 
ultimately β-oxidation.  An increase in lipogenesis could also result from glucose being 
shunted from glycolysis and GAPDH to dihydroxyacetone phosphate, and into 
glycerol, then onto glycerolipids (Figure 2.4.1).  There are metabolic reactions 
involved in palmitate oxidation that require ATP to proceed, which could be consumed 
by the gluconeogenic pathway in the 4KR GAPDH cells, thereby reducing the ability 
of those cells to metabolise palmitate.  The increased demand for ATP in 4KR GAPDH 
hepatocytes could be depriving other metabolic pathways of ATP, such as palmitate 
metabolism, thereby altering or impairing those pathways.  Further investigation using 
glucose tracers and metabolomics will be required to confirm these mechanisms. 
Substrate dependent OCR was used to further characterise metabolic 
alterations in 4KR GAPDH cells.  Glucose-dependent OCR was reduced in 4KR 
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GAPDH mutants compared with WT GAPDH (Figure 2.3.10 A).  This suggests that 
the inability of the 4KR GAPDH mutant to proceed in the glycolytic direction has 
reduced the amount of intermediary metabolites below GAPDH, such as pyruvate and 
acetyl-CoA, causing a reduction in OCR.  This can be rescued by substituting glucose 
with pyruvate, as pyruvate-dependent OCR was not different between WT and 4KR 
GAPDH expressing cells (Figure 2.3.10 D).  This provides further evidence that 
metabolic function downstream of acetyl-CoA is normal provided there are precursor 
substrates available (Figure 2.4.1).  However, under normal conditions where pyruvate  
 
Figure 2.4.1:  4KR GAPDH metabolic pathway hypothesis.  4KR GAPDH is blocked in the 
glycolytic direction but gluconeogenesis is increased.  Lipid metabolism is impaired in 4KR GAPDH 
cells. 
 
is not present in supra-physiological amounts, and other substrates are available, 
pyruvate OCR in 4KR GAPDH cells could be decreased, as the available pyruvate 
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would likely be required to fuel the increased rate of gluconeogenesis.  Further 
demonstration that the TCA cycle is functional downstream of acetyl-CoA was shown 
where glutamine-dependent OCR was unchanged between 4KR GAPDH and WT 
GAPDH (Figure 2.3.10 C).  Palmitate-dependent OCR is reduced in 4KR GAPDH 
mutants compared with WT GAPDH (Figure 2.3.10 B), which could help explain the 
increase in lipids in the 4KR GAPDH mutants.  A limitation to this method of 
measuring substrate dependent oxidation though is the contribution by endogenous 
substrates to the OCR.  
To confirm that the increase in gluconeogenesis and decrease in glycolysis is 
not attributed to transcriptional regulation of rate limiting enzymes, the mRNA of key 
gluconeogenic and glycolytic genes PEPCK, G-6-Pase, and Glucokinase was 
determined, and found to be unchanged between 4KR GAPDH and WT GAPDH 
(Figure 2.3.8 B, C, and D).  These results indicate that transcription of key 
gluconeogenic genes is not affected by GAPDH acetylation, and suggests that the 
increase in glucose production and subsequent decrease in glycolysis occurs due to 
altered enzymatic activity independent of transcriptional regulation. 
In conclusion these results suggest that mutation of four rat GAPDH lysine 
residues K115, K160, K225, and K252 to arginine, which cannot be acetylated, leads 
to a reduction in glycolysis and subsequent increase in gluconeogenesis independent 
of transcriptional regulation.  The results suggest that there is no change in oxidative 
phosphorylation in the 4KR GAPDH mutant that could be compensating for the 
elevated ATP demands required for increased gluconeogenesis.  The results also 
suggest that lipid metabolism is impaired in the 4KR GAPDH, resulting in increased 
lipid accumulation.  Glucose/lipid tracer studies and metabolomics would be required 
to confirm some of the findings above, in particular to determine where lipid 
 62 
 
metabolism is impaired, and why lipid accumulates in the 4KR GAPDH mutants.  
Tracer studies could also determine the fate of glucose in the 4KR GAPDH mutants. 
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CHAPTER 3 
MEDIATORS OF GAPDH 
ACETYLATION/DEACETYLATION 
 
3.1 INTRODUCTION 
Previous research has established in bacteria that deacetylation of GAPDH 
regulates glycolysis in response to nutrient availability, but how GAPDH is 
deacetylated in mammals is not completely known19,58,83,108.  The KDACs that 
deacetylate mammalian hepatic GAPDH, and the mechanisms that regulate those 
KDACs, are currently unknown.  The KATs add acetyl groups to lysine residues, and 
the KDACs; Sirtuins (SIRTs) and Histone Deacetylases (HDACs), remove acetyl 
groups. There are currently eighteen known KDACs and twenty two KATs that have 
been identified in human and mouse cells64.  The KDACs consist of two distinct 
families, the seven NAD+ dependent SIRTs and the eleven Zn2+ dependent HDACs, 
which together are known to deacetylate in excess of two thousand proteins25.  The 
ability of these moonlighting proteins to deacetylate multiple proteins can make them 
a difficult therapeutical target, however there has been some success with KDAC 
inhibitors and cancer87,109.   
The KATs and KDACs of mammalian hepatic GAPDH lysine residues K115, 
K160, K225, and K252 are unknown.  Previous research has established that human 
GAPDH K254 (equivalent of rat K252, Figure 2.1.1) is acetylated by P300/CBP-
associated factor (PCAF) and deacetylated by HDAC5 in response to glucose 
signalling in vitro, however it is not known whether this mechanism occurs in vivo, 
and if PCAF/HDAC5 also acetylates/deacetylates other GAPDH lysine residues83.  In 
addition, it is now well established that the class IIa HDACs do not possess deacetylase 
activity, and actually recruit other KDACs in order to deacetylate proteins84,85.  If 
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HDAC5 does regulate the deacetylation of human GAPDH K254 it could do this via 
the recruitment of the HDAC3-SMRT/N-CoR complex, however this multi-protein 
complex is largely nuclear84,85. 
HDACs are a family of eleven deacetylases that are predominantly located in 
the nucleus, however HDAC6 is located primarily in the cytoplasm outside of the 
mitochondria, where glycolysis/gluconeogenesis occurs110.  HDAC6 is a class IIb 
HDAC that is localised to the cytosol, and is highly expressed in the heart and the 
gluconeogenic tissues liver and kidney, with the highest expression of HDAC6 
occurring in the liver88,110,111.  HDAC6 is known to play a significant role in 
microtubule-dependent cell motility via deacetylation of tubulin, and is also important 
for the degradation of misfolded proteins110,111.  HDAC6 localisation in the cytosol 
makes it an ideal candidate for GAPDH deacetylation, as GAPDH is predominantly 
found in the cytosol, which is the location of glycolysis/gluconeogenesis110-112.  This 
suggests that HDAC6 could be a potential regulator of glycolysis/gluconeogenesis via 
the deacetylation of metabolic enzymes.  SIRTs have also been shown to play an 
important role in metabolism, in addition, SIRT1 and SIRT2 have cytosolic 
localisation and high liver expression15,82,89,90.  In particular, SIRT1 has been 
implicated in hepatic glucose production, where SIRT1 knockdown in liver decreases 
basal hepatic glucose production and increases hepatic insulin responsiveness in 
diabetic rats90.  SIRT2 also deacetylates known HDAC6 protein targets such as α-
tubulin, which suggests that GAPDH could also have multiple deacetylases113.  Studies 
in this thesis have focused on HDAC6 as a potential GAPDH deacetylase, however 
further work is currently underway to determine whether SIRT1 and SIRT2 are 
GAPDH deacetylases.  
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Previous research has established that HDAC6 plays a regulatory role in 
metabolism88,114-117.  Kintsher et al demonstrated that HDAC6 modified 
glucocorticoid-induced hepatic gluconeogenesis by regulating glucocorticoid receptor 
nuclear translocation88.  It has also been demonstrated that HDAC6 is required for 
glucocorticoid-mediated hepatic gene expression88.  Therefore the first aim of this 
study was to determine whether HDAC6 deacetylase activity regulates 
glycolysis/gluconeogenesis, and whether regulation occurs via the deacetylation of 
GAPDH. 
By using a dominant negative form of HDAC6 (DN HDAC6) with no 
deacetylase activity, and a wild type (WT HDAC6), the effect of the deacetylase 
activity of HDAC6 on metabolism can be investigated.  If HDAC6 is involved in 
GAPDH deacetylation, HDAC6 could be implicated in the dysregulation of 
metabolism via the deacetylation of GAPDH, resulting in impaired blood glucose 
homeostasis and hyperglycaemia in T2D.  Specific HDAC6 inhibitors could then be 
used in combination with metformin to further reduce blood glucose levels. 
For the last fifty years metformin has been the most widely used drug to treat 
T2D, but its mechanism of action is controversial, and a source of ongoing debate118.  
The current theories for the potential molecular mechanism of metformin action 
include; inhibition of the mitochondrial complex I, activation of AMPK, inhibition of 
mitochondrial glycerophosphate dehydrogenase, inhibition of glucagon-induced 
elevation of cAMP and consequent activation of PKA119-122.  Metformin reduces 
hepatic glucose production, thereby reducing blood glucose levels in patients with 
T2D.  However, additional medication is often required, and not all patients can 
tolerate metformin.  Therefore the second aim of this study was to determine whether 
metformin action in 4KR GAPDH cells is impaired in relation to WT GAPDH cells. 
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3.2 METHODS 
3.2.1 Liver protein extraction, immunoprecipitation, and immunoblotting 
All protein extraction, immunoprecipitation, and immunoblotting were 
performed as outlined in Chapter Two. 
3.2.2 Cell culture 
Rat FAO hepatocytes were grown in 75cm2 flasks at 37°C and 5% CO2.  FAO 
cells were grown in RPMI 1640 (Life Technologies, #11875), supplemented with 10% 
FBS.  Assays were carried out when cells were ׽ͺͲǦ90% confluent. 
 
3.2.3 DN HDAC6 construct 
 Histidine residues 216 in deacetylase domain one, and 611 in deacetylase 
domain two, were mutated to alanine to remove HDAC6 deacetylase activity to 
generate dominant negative HDAC6 (Figure 3.2.1).  pEGFP.N1-HDAC6.DC 
(catalytic deficient DN HDAC6) was a gift from Tso-Pang Yao (Addgene, #36189)123.  
pEGFP.N1-HDAC6 (WT HDAC6) was a gift from Tso-Pang Yao (Addgene, 
#36188)123. 
 
Figure 3.2.1: DN HDAC6 construct.  Histidine residues 216 in deacetylase domain one, and 611 in 
deacetylase domain two, were mutated to alanine to remove HDAC6 deacetylase activity.  NES = 
nuclear export signal, DD1 = deacetylase domain 1, DD2 = deacetylase domain 2, SE14 = Ser/Glu 
tetradecapeptide domain, ZnF-UBP = zinc-finger ubiquitin binding domain. 
DD1 DD2 ZnF-
UBP
NES SE14
Deacetylase activity
Nuclear 
exclusion
Cytoplasmic 
Anchoring
Ubiquitin 
Binding.
216 bp: 
H→A
611 bp: 
H→A
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3.2.4 Transfection  
FAO cells were stably transfected and grown in RPMI 1640 supplemented 
with 10% FBS (Sigma-Aldrich), and 1:200 hygromycin (70μM) or 1:200 neomycin 
(70μM).  Cells were incubated at 37°C and 5% CO2.  Cells were transfected with the 
plasmid pIRES-Hyg3 (Clontech, #631620), or pIRES-neo3 (Clontech, #631621), 
using lipofectamine LTX (Life Technologies), and then selected in hygromycin or 
neomycin.  Transfected cell lines included WT HDAC6, DN HDAC6, WT GAPDH, 
single lysine mutants GAPDH K115R, GAPDH K160R, GAPDH K225R, GAPDH 
K252R, and quad mutant 4KR GAPDH (Genscript). 
 
3.2.5 Glucose production assay 
All treatments of hepatocytes were for 24 or 36 hours in glucose and serum-
free RPMI 1640 media supplemented with 2mM sodium pyruvate, 20mM sodium l-
lactate and 0.1% BSA (GP media).  Glucose produced by the cells was measured by 
collecting 40μl of media from each well, which was then combined with 250μl of 
0.12M NaH2PO4·2H2O pH 7.0 assay buffer (1mg/mL phenol, 0.5mg/mL 4-
aminoantipyrine, 1.6 units/mL peroxidise and 10 units/mL glucose oxidase).  This was 
incubated for 25 minutes at 37 °C and the absorbance was measured at 490nm. Cells 
were lysed in 100μl 0.03% SDS, and protein was quantified using BCA (Pierce, 
#23225).  Results are expressed as μg glucose per mg protein.  Cells were treated with 
either insulin (0.1nM), forskolin (20μM), metformin (200μM), NAM (10mM), or TSA 
(10μM). 
3.2.6 Metabolic profiling 
The cellular bioenergetics profile of transfected FAO hepatocytes was 
assessed using a Seahorse XF24 Flux Analyser (Seahorse Bioscience).  Cells were 
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seeded into a 24-well XF24 cell culture microplate (Seahorse Bioscience) at a density 
of 50,000 cells per well, and incubated for 24 hours.  Cells were washed and incubated 
in 600μl of unbuffered DMEM (containing 25mM glucose, 1mM pyruvate and 1mM 
glutamate) pH 7.4, at 37 °C in a non-CO2 incubator (1 hour prior to bioenergetics 
assessment). Six basal OCR measurements were performed using the Seahorse 
analyser, and measurements were repeated following injection of oligomycin (1μM), 
FCCP (1μM) and antimycin-A (1μM).  ECAR was determined from data collected at 
basal measurement points.  Following completion of the assay, cell number was 
determined using the CyQuant® Cell Proliferation Assay kit (Molecular Probes) 
according to manufacturer's instructions, or total protein was determined using BCA 
(Pierce, #23225). 
3.2.7 Statistical analyses 
Standard curves were generated using Microsoft Excel 2013, and statistical 
analysis was conducted using SPSS 20 and MiniTab 16.  A Kolmogorov-Smirnov test 
was done to determine normality and distribution.  For data that was not normally 
distributed, a non-parametric test (Kruskal–Wallis test) was used to compare means.  
To compare means for normally distributed data a two tailed T-Test was used, where 
equal variance was assumed if Levene’s significance > 0.05.  For normally distributed 
data, one-way and two-way ANOVA was used to compare groups using Games 
Howell method (equal variances not assumed) or Fisher's Least Significant Difference 
method (equal variances assumed).  Results are presented as mean ± SEM, and P < 
0.05 was considered significant. 
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3.3 RESULTS 
3.3.1 Overexpression of HDAC6 reduces α-tubulin acetylation.  HDAC6 is known 
to deacetylate α-tubulin, therefore α-tubulin acetylation was used as a proxy measure 
of HDAC6 expression and to determine whether DN HDAC6 deacetylase activity had 
been inhibited.  Over expression of WT HDAC6 reduced α-tubulin acetylation, while 
α-tubulin acetylation in cells over expressing DN HDAC6 was similar to non-
transfected cells (Figure 3.3.1).   
3.3.2 KDAC inhibitors reduce glucose production in WT GAPDH FAO cells, but 
not 4KR GAPDH FAO cells.  Glucose production was measured after treatment with 
KDAC inhibitors to determine whether HDACs, SIRTs, or both regulate glucose 
production in a GAPDH dependent manner.  WT GAPDH and 4KR GAPDH FAO 
cells were treated in GP media with either vehicle (DMSO), NAM (10mM, SIRT 
inhibitor), or TSA (10μM, HDAC inhibitor) for twenty four hours, and then the media 
was assayed for glucose.  Non-specific KDAC inhibitors, NAM and TSA, reduced 
glucose production in WT GAPDH cells compared with vehicle, but did not 
significantly reduce glucose production in 4KR GAPDH cells compared with vehicle 
(Figure 3.3.2). 
3.3.3 DN HDAC6 reduces glucose production and increases ECAR.  TSA is a 
HDAC inhibitor that could not reduce glucose production in 4KR GAPDH cells, 
suggesting that HDACs could potentially deacetylate GAPDH.  HDAC6 was 
investigated as a potential GAPDH deacetylase based on its subcellular localisation to 
the cytosol, where GAPDH that participates in glycolysis/gluconeogenesis is located.   
FAO cells were transfected with either WT HDAC6 or DN HDAC6, and then exposed 
to GP media for 24 hours to determine whether HDAC6 has an effect on glucose 
production.  DN HDAC6 cells produced less glucose compared with WT HDAC6 cells 
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(Figure 3.3.3 A).  Basal and maximum glycolysis was determined with a Seahorse Bio-
Analyser using oligomycin (1μM), where  DN HDAC6 cells had increased basal and 
maximum glycolysis compared with WT HDAC6 cells (Figure 3.3.3 B). 
3.3.4 DN HDAC6 increases OCR, basal mitochondrial respiration, ATP turn 
over, and uncoupled respiration.  To determine whether HDAC6 can regulate 
mitochondrial respiration and OCR, DN HDAC6 and WT HDAC6 cells were run on 
a Seahorse Bio-Analyser.  DN HDAC6 cells had elevated OCR compared with WT 
HDAC6 (Figure 3.3.3 C).  Basal mitochondrial respiration, ATP turn over and 
uncoupled respiration was increased in DN HDAC6 cells compared with WT HDAC6 
cells (Figure 3.3.3 D). 
3.3.5 DN HDAC6 reduces glucose production in WT GAPDH co-expressing cells, 
but not 4KR GAPDH co-expressing cells.  To determine whether HDAC6 could 
affect glucose production through GAPDH deacetylation, WT and 4KR GAPDH FAO 
cells were co-transfected with WT or DN HDAC6 plasmids, and assayed for glucose 
production.  Glucose production was reduced in DN HDAC6/WT GAPDH cells 
compared with WT HDAC6/WT GAPDH cells (Figure 3.3.4).  However, in DN 
HDAC6/4KR GAPDH cells glucose production was increased compared with WT 
HDAC6/WT GAPDH and DN HDAC6/WT GAPDH (Figure 3.3.4). 
3.3.6 HDAC6 opposes the insulin response and promotes the forskolin response.  
Glucose production was measured in GAPDH and HDAC6 co-expressing cells after 
treatment with insulin and forskolin to determine whether DN HDAC6 could reduce 
glucose production in 4KR GAPDH co-expressing cells.  WT GAPDH/DN HDAC6 
cells treated with insulin had reduced glucose production compared with WT 
GAPDH/WT HDAC6 cells treated with insulin (Figure 3.3.5).  WT GAPDH/DN 
HDAC6 cells treated with forskolin had reduced glucose production compared with 
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WT GAPDH/WT HDAC6 cells treated with forskolin (Figure 3.3.5).  WT and DN 
HDAC6 cells expressing 4KR GAPDH treated with forskolin had elevated glucose 
production compared with WT GAPDH/WT HDAC6 cells treated with forskolin 
(Figure 3.3.5).  
3.3.7 Total GAPDH acetylation was not altered by HDAC6 overexpression.  Total 
GAPDH acetylation was measured in WT HDAC6 and DN HDAC6 overexpressing 
FAO cells to determine whether HDAC6 is a GAPDH deacetylase.  Total GAPDH 
acetylation was not altered by DN HDAC6 or WT HDAC6 compared with FAO 
control (Figure 3.3.6).  
3.3.8 Metformin reduced glucose production further in WT GAPDH cells 
compared with 4KR GAPDH cells.  WT and 4KR GAPDH FAO cells were treated 
with metformin (200μM) in GP media for 24 hours to determine whether GAPDH 
acetylation could further reduce glucose production in combination with metformin.  
Metformin reduced glucose production in both WT GAPDH and 4KR GAPDH cells 
compared with vehicle, independent of GAPDH acetylation (Figure 3.3.7).  However, 
glucose production was lower in WT GAPDH cells treated with metformin compared 
with 4KR GAPDH cells treated with metformin (Figure 3.3.7).   
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Figure 3.3.1: α-tubulin acetylation in WT HDAC6 and DN HDAC6 expressing FAO cells.  
Immunoblot of HDAC6, α-tubulin and acetylated α-tubulin in FAO cells expressing WT HDAC6 and 
DN HDAC6 compared to control FAO cells (CON).   
 
 
WT HDAC6             DN HDAC6                 CON
HDAC6
α-tubulin
AcK-α-tubulin
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Figure 3.3.2: FAO WT GAPDH and FAO 4KR GAPDH KDAC inhibited GP assay.  Glucose 
production was measured in WT GAPDH FAO cells and 4KR GAPDH FAO cells after 24 hours, in the 
presence of either the SIRT inhibitor NAM (10mM), or the HDAC inhibitor TSA (10μM).  All data 
represented as mean ± SEM, n=8 replicates per group.  * Significantly different from WT GAPDH 
under the same treatment, P < 0.05.  # Significantly different from Vehicle, P < 0.05. 
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Figure 3.3.3: FAO WT HDAC6 and FAO DN HDAC6 energetics.  (A) Glucose production was 
measured in WT HDAC6 FAO cells and DN HDAC6 FAO cells after 24 hours, n=24 replicates per 
group.  (B) Basal glycolysis was determined by averaging six measurements of basal ECAR, and 
maximum glycolysis was determined by averaging three measurements in the presence of oligomycin 
(1μM), represented as ECAR per 50K cells, n=10 replicates per group.  (C) OCR was determined by 
averaging ten readings over 1.5 hours.  Data represented as OCR per 50K cells, n=10 replicates per 
group.  (D) Mitochondrial energetics.  Data represented as OCR per 50K cells, n=10 replicates per 
group.  All data represented as mean ± SEM.   * Significantly different from WT HDAC6, P < 0.05.   
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Figure 3.3.4: HDAC6 mutant/GAPDH mutant co-expressing FAO cell GP assay.  HDAC6/GAPDH 
mutant FAO co-expressing cells were incubated in GP media for 24 hours and analysed for glucose 
produced. Data represented as %WT GAPDH/WT HDAC6, mean ± SEM, n=12 replicates per group.  
* Significantly different from WT HDAC6/WT GAPDH, P < 0.05. 
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Figure 3.3.5: HDAC6 mutant/GAPDH mutant co-expressing FAO cell forskolin and insulin 
treated GP assay.  HDAC6/GAPDH mutant co-expressing FAO cells were incubated in GP media with 
either insulin (0.1nM) or forskolin (20μM) for 24 hours and analysed for glucose. All data represented 
as %WT GAPDH/WT HDAC6 basal glucose production, mean ± SEM, n=6 replicates per group.  # 
Significantly different from WT HDAC6/WT GAPDH basal glucose production, P < 0.05.  † 
Significantly different from WT GAPDH/WT HDAC6 insulin treatment, P < 0.05.  * Significantly 
different to WT GAPDH/ WT HDAC6 forskolin treatment, P < 0.05.  
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Figure 3.3.6: GAPDH acetylation in WT HDAC6 and DN HDAC6 expressing FAO cells.  
Immunoprecipitation of GAPDH blotted for acetyl-lysine and GAPDH from FAO cells expressing WT 
HDAC6 and DN HDAC6 compared with control FAO cells (CON).      
 
 
IP:GAPDH/WB:AcK
IP:GAPDH/WB:GAPDH
WT HDAC6             DN HDAC6                 CON
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Figure 3.3.7: Metformin treated FAO WT GAPDH and FAO 4KR GAPDH GP assay. GAPDH 
mutant FAO cells were incubated in GP media, with either metformin (MET, 200μM) or vehicle (Veh, 
water), for 24 hours and analysed for glucose. All data represented as mean ± SEM, n=12 replicates per 
group.  * Significantly different from WT GAPDH, P < 0.05.  # Significantly different from vehicle, P 
< 0.05. 
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3.4 DISCUSSION 
Acetylation has emerged as an important, and highly conserved regulatory 
PTM, which has recently been shown in bacteria to play a regulatory role in metabolic 
flux19.  Chapter Two in this thesis demonstrated that mutation of GAPDH residues 
K115, K160, K225, and K252 to arginine increased glucose production in vitro.  The 
acetylation and deacetylation of proteins is facilitated by KATs and KDACs 
respectively, and the KATs and KDACs that acetylate and deacetylate mammalian 
GAPDH are unknown.  In humans there are currently eighteen known KDACs; seven 
SIRTs and eleven HDACs.  The KDACs are further broken down into four groups; 
Class I (HDAC1, 2 and 3), Class IIa (HDAC4, 5, 7 and 9), Class IIb (HDAC6 and 10), 
Class III (SIRT1 to 7) and Class IV (HDAC11)25.  The majority of these KDACs have 
the ability to shuttle between the nucleus and the cytosol, however HDAC6, HDAC10 
and SIRT2 are primarily localised to the cytosol25.   
The KATs and KDACs that acetylate and deacetylate mammalian hepatic 
GAPDH lysine residues K115, K160, K225, and K252 are unknown.  Lei et al 
demonstrated that HDAC5 deacetylated human GAPDH K254 in vitro, however this 
has not been demonstrated in vivo, and the deacetylase activity of HDAC5 is 
speculative83.  There are now several studies that have shown that the class IIa HDACs 
do not have deacetylase activity, and actually deacetylate proteins via the recruitment 
of other deacetylases, such as HDAC384,85.  It has also been shown that in response to 
glucagon, the class IIa HDACs in the liver are rapidly dephosphorylated and 
translocated to the nucleus, where they influence glucose production by associating 
with promoters of gluconeogenic enzymes124.  It was demonstrated that the HDAC4/5 
complex recruits HDAC3, resulting in transcriptional induction of genes via 
deacetylation and activation of FOXO transcription factors124. 
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KDACs play a role in glucose metabolism via GAPDH deacetylation, as 
demonstrated in this chapter, where the KDAC inhibitors NAM and TSA, reduced 
glucose production in WT GAPDH cells but not in 4KR GAPDH cells (Figure 3.3.2).  
HDAC and SIRT inhibition was unable to significantly reduce glucose production in 
4KR GAPDH cells, suggesting that acetylation of K115, K160, K225, and K252 was 
required for their impact on glucose metabolism (Figure 3.3.2).    This establishes that 
KDACs have the ability to influence glucose metabolism, and also demonstrates that 
4KR GAPDH glucose production did not decrease in the presence of KDAC inhibitors, 
suggesting that GAPDH is potentially deacetylated by both SIRTs and HDACs.  
To determine likely candidates for the deacetylation of GAPDH, the cytosolic 
localisation of HDAC6, HDAC10, and SIRT2 was considered, and suggests that they 
could be GAPDH KDACs based on their sub-cellular location.  The reduction in 
glucose production in the presence of NAM and TSA suggests that both SIRTs and 
HDACs are involved in glucose production, and of the eighteen known KDACs, 
SIRT2 and HDAC6 are the predominant cytosolic KDACs.  SIRT2 and HDAC6 have 
been shown to deacetylate α-tubulin, and both could be GAPDH deacetylases111,113.  
HDAC6 was investigated as it is a potential GAPDH deacetylase that has cytosolic 
localisation, and has already been implicated in glucose metabolism as a modifier of 
glucocorticoid-induced hepatic gluconeogenesis88.  HDAC6 has been shown to 
regulate hepatic gluconeogenesis by regulating the glucocorticoid receptor, and has 
been shown to be required for mitochondrial metabolic activity88,114,115,125. Therefore 
HDAC6 was investigated in this study due to its cytosolic localisation, and previous 
studies that have implicated HDAC6 in glucose production.  Furthermore, the highest 
expression of HDAC6 is in the liver, which further suggests that HDAC6 has a role in 
hepatocyte functions88.     
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HDAC6 has been shown to deacetylate α-tubulin, and acetylation of α-tubulin 
was increased in DN HDAC6 expressing cells (Figure 3.3.1), but total GAPDH 
acetylation was not affected by DN HDAC6 expression (Figure 3.3.6)111.  However, 
site specific antibodies are required to determine whether the acetylation of the lysine 
residues of interest are altered by DN HDAC6 expression.  Based on these findings, 
this study measured glycolysis and gluconeogenesis in FAO cells in response to 
genetic manipulation of HDAC6 deacetylase activity.  WT HDAC6 FAO cells had 
elevated glucose production compared with DN HDAC6 FAO cells (Figure 3.3.3 A), 
in addition, WT HDAC6 FAO cells had reduced basal and maximum glycolysis 
compared with DN HDAC6 cells (Figure 3.3.3 B).  This suggests that HDAC6 plays 
a role in glycolysis/gluconeogenesis, possibly by deacetylating metabolic proteins, 
resulting in an increase in gluconeogenesis and glycogenolysis, while also reducing 
glycolysis.  It is still unknown whether HDAC6 deacetylates GAPDH, however an 
association between glucose metabolism and HDAC6 has been demonstrated88. 
The OCR was increased in DN HDAC6 FAO cells compared with WT 
HDAC6 cells (Figure 3.3.3 C), and basal mitochondrial respiration, ATP turnover, and 
uncoupled respiration was also increased in the DN HDAC6 cells compared with WT 
HDAC6 cells (Figure 3.3.3 D).  This suggests that HDAC6 has a metabolic regulatory 
effect, and demonstrates that HDAC6 can reduce mitochondrial respiration.  The exact 
mechanisms involved in the reduction of mitochondrial respiration by HDAC6 
requires further investigation, but based on the results in this thesis it would suggest 
that ATP and substrate availability is reduced, resulting in decreased flux through 
glycolysis and the TCA cycle.  Due to the small number of KDACs and the large 
number of proteins that undergo deacetylation, it is probable that HDAC6 has several 
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proteins that it regulates directly, or indirectly via deacetylation, which could include 
other glycolytic/gluconeogenic enzymes.  
DN HDAC6 suppressed glucose production in cells co-expressing WT 
GAPDH compared to WT HDAC6/WT GAPDH cells, but DN HDAC6 did not 
suppress glucose production in cells co-expressing 4KR GAPDH (Figure 3.3.4).  
These results suggest that there could be an association between HDAC6 and GAPDH, 
where removing the deacetylase activity of HDAC6 reduces glucose production in WT 
GAPDH cells but not in 4KR GAPDH cells.  This suggests that HDAC6 either 
regulates glucose production through GAPDH, or that DN HDAC6 is not able to 
overcome metabolic alterations that occur in 4KR GAPDH cells.  This further supports 
Figure 3.3.2 where TSA and NAM had little effect on 4KR GAPDH glucose 
production, suggesting that GAPDH is deacetylated by SIRTs and HDACs.  
Conversely, HDAC6 could exert these effects independent of GAPDH. 
Insulin could still suppress glucose production in HDAC6/GAPDH co-
expressing cells, but 4KR GAPDH cells that co-expressed WT HDAC6 and DN 
HDAC6 were still hypersensitive to forskolin (Figure 3.3.5).  However, glucose 
production was lower in WT GAPDH/DN HDAC6 insulin treated cells compared with 
WT GAPDH/WT HDAC6 insulin treated cells, suggesting that HDAC6 opposes the 
insulin response (Figure 3.3.5).  DN HDAC6/WT GAPDH co-expressing cells had 
reduced glucose production under forskolin treatment compared with WT 
HDAC6/WT GAPDH co-expressing cells treated with forskolin (Figure 3.3.5).  In 
addition, WT and DN HDAC6 cells co-expressing 4KR GAPDH had significantly 
higher glucose production in response to forskolin compared with WT GAPDH/WT 
HDAC6 forskolin treated cells (Figure 3.3.5).  The decrease in glucose production in 
DN HDAC6 forskolin treated cells is lost in 4KR GAPDH co-expressing cells, which 
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suggests that the forskolin response mediated through HDAC6 occurs via GAPDH 
deacetylation. 
This study has demonstrated that mutation of GAPDH K115, K160, K225, 
and K252 to arginine in 4KR GAPDH cells has a similar GP and ECAR phenotype to 
FAO cells expressing WT HDAC6.  This suggests that HDAC6 plays a regulatory role 
in glycolysis/gluconeogenesis, potentially via GAPDH deacetylation.  Further work is 
required to determine the metabolic pathways and mechanisms that underlie the 
metabolic regulation by HDAC6.  It may be possible that there are more than one 
deacetylase that have the potential to deacetylate GAPDH, which is supported by the 
NAM and TSA suppressed glucose production data (Figure 3.3.2), and furthermore 
the substrates that regulate these deacetylases require further investigation.   
WT GAPDH and 4KR GAPDH FAO cells were treated with metformin for 
twenty four hours in GP media to determine whether the efficacy of metformin was 
reduced when GAPDH acetylation was reduced.  Metformin was able to reduce 
glucose production in both WT GAPDH cells and 4KR GAPDH cells, however 
glucose production was lower in WT GAPDH cells compared with 4KR GAPDH cells 
(Figure 3.3.7).  This demonstrates that the effects of metformin are independent of 
GAPDH acetylation, and that there could be additional therapeutic value in targeting 
mechanisms that regulate GAPDH acetylation in combination with metformin.  If this 
can be shown in vivo then GAPDH deacetylase inhibitors could be used in combination 
with metformin to further lower blood glucose levels in T2D. 
These results suggest that HDAC6 regulates glucose metabolism, and further 
elucidation of the role of GAPDH acetylation and HDAC6 in hepatic glucose 
metabolism could uncover this signalling axis as a novel therapeutic target for the 
treatment of T2D in combination with metformin.   HDAC6 activity in T2D is 
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unknown, and it would be interesting to see whether HDAC6 activity is increased in 
T2D and contributing to elevated gluconeogenesis.  However, HDAC6 deacetylates 
several proteins so there must be other factors that interact with HDAC6, which would 
allow HDAC6 deacetylase activity towards GAPDH to be increased while HDAC6 
deacetylase activity to other proteins, such as α-tubulin, remains normal.  Further 
investigation is required to determine whether GAPDH is specifically deacetylated by 
HDAC6, and if so, which lysine residues are deacetylated by HDAC6.  Site specific 
antibodies and stable isotope labelling of amino acids in cell culture (SILAC) could be 
used to determine which lysine residues are deacetylated under different conditions or 
treatments.  Further work is also required to determine how GAPDH is acetylated, 
whether it is enzymatically acetylated or if it is an un-catalysed mass action reaction.  
If it is enzymatically acetylated, then the KAT(s) responsible could be identified, and 
then inhibited, or activated, in combination with a KDAC inhibitor to treat T2D. 
In conclusion, the enzyme(s) responsible for the deacetylation/acetylation of 
GAPDH are still unknown.  However, WT HDAC6 can regulate 
glycolysis/gluconeogenesis similar to the regulation seen by 4KR GAPDH, and is a 
potential GAPDH deacetylase, although this requires further investigation.  Metformin 
can reduce glucose production further in vitro when GAPDH is acetylated, and this 
now needs to be investigated in vivo.  Together these results support the notion that 
HDAC6 could deacetylate GAPDH, and that reduced GAPDH acetylation increases 
gluconeogenesis. 
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CHAPTER 4 
REGULATION OF GAPDH ACETYLATION 
 
 
4.1 INTRODUCTION 
Obesity can cause insulin resistance that results in elevated gluconeogenesis 
and hepatic glucose production, which contributes to chronic hyperglycemia and 
T2D29,126.  This has now become a global challenge, and the pathophysiology behind 
the dysregulated metabolism that occurs in T2D is incompletely understood.  The 
acetylation status of metabolic enzymes in disease is largely unknown, but it is now 
emerging as a potential and promising therapeutic target25.  Previous studies in this 
thesis have shown that mutation of GAPDH lysine residues to arginine, mimicking a 
deacetylated state, results in an increase in gluconeogenesis in vitro.  Results from 
Chapter Two demonstrated that GAPDH is a rate limiting enzyme for 
glycolysis/gluconeogenesis in FAO cells through reversible acetylation.  WT GAPDH 
favoured glycolysis and 4KR GAPDH, which mimics GAPDH deacetylation at 
residues K115, K160, K225, and K252, favoured gluconeogenesis.  In addition, the 
acetylation status of GAPDH in FAO cells appears to play a role in lipid metabolism.  
Results from Chapter Three demonstrated that SIRTs and HDACs are potential 
GAPDH deacetylases, and that HDAC6 regulates glycolysis/gluconeogenesis, 
possibly via deacetylation of GAPDH. 
It has been shown in bacteria that GAPDH acetylation is regulated by KDACs 
and KATs in response to nutrient availability19,22,57.  Bacterial GAPDH acetylation is 
increased in response to an increase in glucose, and GAPDH acetylation is reduced in 
response to reduced glucose and increased acetate/citrate19,22,57.  The factors that 
regulate GAPDH acetylation in mammals is unclear, but previous research using 
 86 
 
human GAPDH in vitro has shown that acetylation of GAPDH K254 increased in 
response to an increase in glucose83.  Li et al demonstrated in HEK 293T cells that 
acetylation of human GAPDH K254 increased after exposure to high glucose (25mM) 
compared to low glucose (1.5mM) over several hours (6-24 hours)83.  The regulation 
of hepatic GAPDH in vivo is unknown, and it is unclear whether the physiological 
factors that regulate glucose production in vivo can also regulate hepatic GAPDH 
acetylation.  Previous research has demonstrated that in response to nitric oxide human 
GAPDH lysine residues 117, 227, and 251 become acetylated79.  This results in S-
nitrosylation of GAPDH and Siah-1 binding, abolishing its catalytic activity, which 
causes GAPDH translocation to the nucleus where it can induce apoptosis77,78,127.  As 
the factors that regulate the acetylation of hepatic GAPDH in vivo are unknown, the 
first aim of this study was to determine whether GAPDH acetylation in vitro is altered 
by glucose, and whether GAPDH acetylation in mice was altered by hormones and 
nutrient availability, which are known to regulate hepatic glucose homeostasis in 
humans.  In humans, insulin, glucagon and glucocorticoids have been shown to 
regulate hepatic glucose homeostasis in response to nutrient availability, which 
becomes impaired in diseases such as T2D5,7,28,29,128,129. 
The acetylation profile of GAPDH in diseases is not established, and the 
acetylation profile of GAPDH could be altered in certain diseases where glucose 
metabolism is dysregulated, such as cancer and T2D.  It has been demonstrated that 
human GAPDH acetylated at K254 is important in cell proliferation, and that mutation 
of K254 to glutamine or arginine restricted glycolysis and xenografted tumour growth 
(A549 cells)83.  However the acetylation profile of GAPDH in cancers is unknown, 
but it could be important in cancer biology as the majority of cancers overexpress 
GAPDH and exhibit the Warburg effect130.  Given that the metabolic phenotype of 
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FAO hepatoma cells expressing 4KR GAPDH was similar to aspects of liver 
metabolism in T2D, this suggests that there could be an altered GAPDH acetylation 
profile in insulin resistant liver compared to normal liver28,29.  As the acetylation 
profile of hepatic GAPDH in obesity and T2D has not previously been investigated, 
the second aim of this study was to determine whether hepatic GAPDH acetylation 
was reduced in T2D, and in diet-induced obese mice (DIO).   
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4.2 METHODS 
4.2.1 Total GAPDH acetylation assay 
 Non-transfected FAO cells were grown to 80% confluence in 10cm2 cell 
culture dishes, as per Chapter Two.  To determine whether glucose altered GAPDH 
acetylation, cells were exposed to glucose free media or high glucose media (25mM) 
for thirty minutes, and then harvested for immunoprecipitation as per Chapter Two.  
To determine whether GAPDH acetylation was altered by hormones that regulate 
glucose homeostasis, cells were treated with vehicle (DMSO), insulin (0.1nM), or 
forskolin (20μM) for thirty minutes, and then harvested for immunoprecipitation as 
per Chapter Two.   
4.2.2 Permits and ethical approval 
Approval for animal experimentation was obtained from the Deakin 
University Animal Welfare Committee (A70-2009, GO4-2013 and G15-2014). 
4.2.3 Mice experimental design 
All mice were purchased from the Animal Resource Center in Western 
Australia, and arrived at Deakin University at eight weeks of age.  Mice were contained 
in a controlled environment at Deakin University animal house at 22°C, on a twelve 
hour light/dark cycle.  All mice were administered a diet of standard chow for eight 
weeks before dietary intervention, and water was consumed ad libitum throughout all 
animal studies.  For animal study one, male C57BL6 mice (n=48) were used to 
investigate the regulation of hepatic GAPDH acetylation to determine whether 
GAPDH acetylation is regulated by hormones or nutrient availability.  For animal 
study two, male db/db -/- (T2D, n=8) and db/db +/- (control, n=8) mice were used to 
investigate whether GAPDH acetylation was altered in T2D.  For animal study three, 
male C57BL/6 mice that were fed a HFD (43% energy intake from fat, n=8) or standard 
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laboratory chow (n=8) for eight weeks, were used to investigate whether diet induced 
obesity (DIO) altered GAPDH acetylation.  At sixteen weeks of age mice from animal 
studies one, two, and three were killed humanely by cervical dislocation, in the fed 
state, and the livers were immediately excised and snap frozen in liquid nitrogen and 
stored at -80°C.  
For animal study one, male C57BL/6 mice (n=48) maintained on a standard 
chow diet were used to determine the effect of fasting (16 hours, n=8), re-feeding (16 
hour fast followed by 30 minute re-feed, n=8), insulin (0.75U/Kg, n=8), glucagon 
(15μg/Kg, n=8), or norepinephrine (100ng/Kg, n=8) on GAPDH acetylation.  Insulin, 
glucagon, norepinephrine, and vehicle (saline of comparable volume to hormone 
injections) were administered via intraperitoneal injection, and blood glucose was 
measured via tail cut and blood spot using an ACCU-CHEK Performa glucose meter 
(ROCHE) pre and post feeding/injection.  The animals were killed humanely 15 
minutes post injection or 30 minutes post re-feeding, and the livers were immediately 
excised and snap frozen in liquid nitrogen and stored at -80°C. 
4.2.4 Liver protein extraction, immunoprecipitation, and immunoblotting 
All protein extraction, immunoprecipitation, and immunoblotting were 
performed as outlined in Chapter Two. 
4.2.5 Statistical analyses 
Standard curves were generated using Microsoft Excel 2013, and statistical 
analysis was conducted using SPSS 20 and MiniTab 16.  A Kolmogorov-Smirnov test 
was performed to determine normality and distribution.  For data that was not normally 
distributed, a non-parametric test (Kruskal–Wallis test) was used to compare means.  
To compare means for normally distributed data a two tailed T-Test was used, where 
equal variance was assumed if Levene’s significance > 0.05.  For normally distributed 
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data, one-way and two-way ANOVA was used to compare groups using Games 
Howell method (equal variances not assumed) or Fisher's Least Significant Difference 
method (equal variances assumed).  Results are presented as mean ± SEM, and P < 
0.05 was considered statistically significant. 
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4.3 RESULTS 
4.3.1 Total GAPDH acetylation in FAO hepatocytes was unchanged by glucose, 
insulin, and forskolin.  To determine whether GAPDH acetylation is regulated by 
factors that regulate hepatic glucose production in vitro, FAO cells were exposed for 
thirty minutes to insulin (0.1nM), forskolin (10μM), low and high glucose (0mM and 
25mM), and then assayed for total GAPDH acetylation.  Total GAPDH acetylation 
was not altered after exposure to glucose free media or high glucose media for thirty 
minutes (Figure 4.3.1 A).  There were no differences in total GAPDH acetylation after 
treatment with insulin and forskolin compared with vehicle (Figure 4.3.1 B). 
4.3.2 Insulin, glucagon and norepinephrine do not regulate GAPDH acetylation 
in vivo.  Insulin, glucagon, and norepinephrine are key hormones that regulate hepatic 
glucose metabolism in mammals.  To determine whether hepatic GAPDH acetylation 
is regulated by these hormones, C57BL/6 mice were administered insulin (0.75U/Kg, 
n=8), glucagon (30μg/Kg, n=8) or nor-epinephrine (100ng/Kg, n=8) in the fed state by 
intraperitoneal injection.  The livers were excised fifteen minutes post-injection and 
analysed for GAPDH acetylation.  Akt is involved in insulin signalling and regulation 
of gluconeogenesis, and phosphorylation of serine 473-Akt suggested that the insulin 
pathway had been activated by these hormones (Figure 4.3.2 A).  Phosphorylation of 
serine-133 CREB suggested pathways downstream of glucagon and nor-epinephrine 
signalling were activated (Figure 4.3.2 A).  There was no significant change in total 
GAPDH acetylation after insulin, glucagon or nor-epinephrine administration 
compared with vehicle (Figure 4.3.2 B). 
4.3.3 Total GAPDH acetylation was unchanged by fasting and re-feeding.  To 
determine whether GAPDH acetylation is altered in more physiological states of 
hepatic glucose regulation, C57BL/6 mice (n=16) were fasted overnight (17:00-9:00) 
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and n=8 were killed, and n=8 were re-fed then killed thirty minutes later.  The livers 
were excised and analysed for glucagon and insulin signalling pathway activity, and 
GAPDH acetylation.  PKA is involved in glucagon signalling and is a regulator of 
gluconeogenesis, and PKA was phosphorylated at threonine-197 in fasted mice, which 
suggests activation of the glucagon pathway (Figure 4.3.3 A).  Akt phosphorylation 
was not detected, suggesting that the insulin pathway was not activated in fasted or fed 
mice (Figure 4.3.3 A).  Blood glucose levels increased after re-feeding (Figure 4.3.3 
B), and there was no difference in GAPDH acetylation in fasted mice compared with 
fed mice (Figure 4.3.3 C).   
4.3.4 Hepatic GAPDH acetylation is reduced in T2D.  To investigate the acetylation 
profile of hepatic GAPDH in T2D, db/db mice were used as a model of T2D.  
Consistent with this model, whole body mass and fasting blood glucose levels were 
increased in db/db -/- compared with db/db +/- mice (Figure 4.3.4 A and B).  Hepatic 
total GAPDH acetylation was reduced in db/db -/- mice compared with db/db +/- mice 
(Figure 4.3.4 C).    
4.3.5 Global hepatic lysine acetylation is unchanged in T2D.  To determine global 
hepatic lysine acetylation, liver lysate from db/db -/- and db/db +/- mice was run on 
SDS-PAGE and blotted for acetyl-lysine or acetylated α-tubulin, and then normalised 
to total α-tubulin.  There was no significant change in global acetylation or acetylated 
α-tubulin in liver lysate from db/db +/- mice compared with db/db -/- mice (Figures 
4.3.5 A and B). 
4.3.6 Hepatic GAPDH acetylation is reduced in mice on a high fat diet.  To 
investigate the acetylation profile of hepatic GAPDH in obesity independent of T2D, 
DIO C57BL/6 mice were used as a model of obesity.  Whole body mass was increased 
in mice on a HFD compared with mice on a CHOW diet (Figure 4.3.6 A).  Blood 
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glucose levels were normal and were not different between mice on a HFD and mice 
on a CHOW diet (Figure 4.3.6 B).  C57BL/6 mice on a HFD had reduced hepatic 
GAPDH acetylation compared with C57BL/6 mice on a standard CHOW diet (Figure 
4.3.6 C).   
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Figure 4.3.1:  GAPDH acetylation in FAO cells after exposure to high glucose, insulin (Ins) and 
forskolin (Fors).  Cells were immunoprecipitated for GAPDH and immunoblotted for total acetylation.  
(A) FAO GAPDH acetylation in 0mM and 25mM glucose media after thirty minutes.  Data expressed 
as %0mM.  (B)  FAO GAPDH acetylation after exposure to vehicle (Veh, DMSO), insulin (0.1nM), 
and forskolin (20μM).  Data expressed as %Veh.  All data represented as mean ± SEM, n=22 replicates 
per group.  Results not statistically significant. 
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Figure 4.3.2:  Hepatic GAPDH acetylation in C57BL/6 mice after injection with either insulin 
(ins), glucagon (gluc), norepinephrine (n-epi), or vehicle (veh).  Fifteen minutes post-injection, 
mouse livers were removed and homogenised in lysis buffer containing TSA and NAM.  (A)  Liver 
lysates were western blotted for total and phospho-specific Akt and CREB.  (B) Liver lysates were 
immunoprecipitated for GAPDH and western blotted for GAPDH and acetyl-lysine.  Lysine-acetylated 
GAPDH was normalised to total GAPDH and expressed as %veh.  All data are represented as mean ± 
SEM, n=8 replicates per group. 
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Figure 4.3.3:  GAPDH acetylation in fasted and re-fed C57BL/6 mice.  (A)  Liver lysates were 
immunoblotted for total and phospho-specific Akt and PKA to confirm that the glucagon pathway was 
activiated after fasting.  (B)  Blood glucose levels were measured in fasted C57BL/6 mice and thirty 
minutes post-feeding.  (C) Hepatic GAPDH acetylation in fasted and re-fed mice.  All data represented 
as mean, ± SEM, n=8 replicates per group.  * denotes statistically different to fasted mice, P < 0.05.  
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Figure 4.3.4:  Hepatic GAPDH acetylation in db/db +/- (control) and db/db -/- (T2D) mice.  Liver 
lysates from db/db +/- and db/db -/- mice were immunoprecipitated for GAPDH, and then western 
blotted for GAPDH and acetyl-lysine.  (A) Whole body mass.  (B) Fasting blood glucose.  (C) Lysine-
acetylated GAPDH was normalised to total GAPDH and expressed as %db/db +/-.  All data are 
represented as mean ± SEM, n=8 replicates per group. * denotes statistically different to db/db +/-, P < 
0.05.  
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Figure 4.3.5:  Global hepatic lysine acetylation and acetylated-tubulin levels in db/db +/- (CON) 
and db/db -/- (T2D) mice.  Whole liver cell lysates from control and T2D mice were run on an SDS-
PAGE, and probed using an acetyl-lysine, acetylated α-tubulin, and α-tubulin antibodies.  (A) Global 
acetylation was normalised to α-tubulin and expressed as %CON.  (B) The amount of acetylated α-
tubulin was normalised to total α-tubulin and expressed as %CON.  All data are represented as mean, ± 
SEM, n=8 replicates per group.   
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Figure 4.3.6: Hepatic GAPDH acetylation in mice fed CHOW versus mice fed a HFD.  Liver lysate 
from CHOW fed and HFD fed mice were immunoprecipitated for GAPDH, and then western blotted 
for GAPDH and acetyl-lysine.  (A) Whole body mass.  (B) Blood glucose.  (C) Lysine-acetylated 
GAPDH was normalised to total GAPDH and expressed as %CHOW.  All data represented as mean ± 
SEM, n=8 replicates per group. * denotes statistically different to CHOW, P < 0.05.  
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4.4 DISCUSSION 
Elevated hepatic de novo glucose production is the primary source of 
endogenous glucose in T2D, and a major contributor to hyperglycemia73.  Reducing 
hepatic blood glucose output could reduce blood glucose levels and alleviate 
symptoms of hyperglycemia.  Results from Chapter Two demonstrated that the 
acetylation profile of GAPDH can regulate glycolysis/gluconeogenesis in vitro.  
Specifically, mutation of GAPDH lysine residues to arginine, to mimic their 
deacetylation, increased glucose production and lipid accumulation. 
This study has demonstrated that total hepatic GAPDH acetylation was 
reduced in db/db -/- (T2D) mice compared to db/db +/- (Control) mice (Figure 4.3.4 
C).  This is the first study to show that hepatic GAPDH acetylation is altered in T2D, 
and together with our previous findings in this thesis suggests that deacetylated hepatic 
GAPDH could play a role in the dysregulated metabolism that occurs in T2D.  A clear 
limitation to these findings is that the acetylation site(s) dysregulated in T2D are 
unknown at present, and further work will be required to identify which specific 
hepatic GAPDH lysine residues are deacetylated in T2D.  It is also unclear from this 
data whether the reduced GAPDH acetylation observed in T2D could potentially result 
in a pathophysiological effect, such as hyperglycemia.  In previous chapters of this 
thesis it has been shown that the combined deacetylation of rat GAPDH lysine residues 
K115, K160, K225 and K252 resulted in an increase in gluconeogenesis and glucose 
production in vitro.  However, it was also demonstrated that total GAPDH acetylation 
was not reduced in 4KR GAPDH FAO cells compared to WT GAPDH FAO cells, 
which further suggests that the reduction in GAPDH acetylation in T2D and DIO, may 
be the result of additional deacetylated lysine residues on GAPDH.  GAPDH has 
twenty six lysine residues, and it is possible that the deacetylation, or other acyl PTMs, 
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of the majority of these lysine residues is required to exert an affect in vivo, which 
could result in increased glucose production.    
Hepatic GAPDH acetylation was also reduced in DIO mice, which suggests 
that hepatic GAPDH acetylation is regulated in vivo by nutrient availability (Figure 
4.3.6 C).  Chronic exposure to diets high in fat could lead to a reduction in hepatic 
GAPDH acetylation, causing an increase in hepatic glucose production, which could 
progress to hyperglycemia and T2D.  However, the blood glucose levels in the mice 
on a HFD were not increased compared to mice on CHOW (Figure 4.3.6 B).  This 
suggests that reduced GAPDH acetylation in DIO may not result in a measurable 
pathophysiological defect.  However, it is also possible that the normal blood glucose 
levels seen in mice on a HFD compared to control mice, may be a result of a greater 
rate of glucose disposal.  These results demonstrate that hepatic GAPDH acetylation 
is reduced in obesity and T2D in vivo, but further work is required to determine if the 
altered acetylation profile of GAPDH is a pathophysiological factor in T2D and DIO.  
The reduced in vivo acetylation of hepatic GAPDH in T2D could play a role in elevated 
gluconeogenesis and hepatic glucose production.  Further work is needed to identify 
the specific hepatic GAPDH lysine residue that are deacetylated on a HFD to 
determine whether they match the deacetylated residues in T2D, and whether 
gluconeogenesis is increased in T2D and mice on a HFD.  
Increased mitochondrial acetylation and increased acetylation of histones has 
been shown to occur in T2D and DIO, and although hepatic GAPDH acetylation was 
reduced in T2D, there was no significant change seen in global hepatic acetylation or 
acetylated α-tubulin in T2D (Figure 4.3.6 A and B)103,104,131,132.  This demonstrates that 
total acetylation is not reduced in T2D and that the hepatic GAPDH deacetylation that 
occurs in T2D is independent of global deacetylation/acetylation events.  It is likely 
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that there are alterations in acetylation, whether acetylation is reduced or increased, 
throughout the various tissues and cellular compartments in diseased states that could 
disrupt pathway signalling.  Acetylated α-tubulin levels are unchanged in T2D, which 
demonstrates that α-tubulin acetylation and the KATs/KDACs responsible for 
acetylating/deacetylating α-tubulin, are not altered in T2D.  HDAC6, along with 
SIRT2, are known α-tubulin deacetylases111,113,133-137.  Interpreting the data from this 
chapter would suggest that the activity of these α-tubulin deacetylases is not increased 
in T2D.  However, the eighteen known KDACs are responsible for deacetylating in 
excess of 2000 proteins, so there are likely other factors, such as PTMS and protein 
complex formations/interactions, which are also involved in determining the 
deacetylation of specific proteins by HDAC6 and SIRT220,21,64,65.  This would allow 
for HDAC6 or SIRT2 activity to be increased, where it could have normal 
deacetylation properties for α-tubulin in T2D, but elevated deacetylation of other 
proteins in T2D, such as GAPDH. 
Previous research has demonstrated that bacterial GAPDH acetylation is 
regulated in response to nutrient availability19,58.  GAPDH acetylation did not change 
significantly after thirty minutes in FAO cells exposed to low and high glucose media, 
suggesting that GAPDH acetylation is not regulated by glucose in mammalian cells 
(Figure 4.3.1 A).  In addition, GAPDH acetylation did not change in FAO cells after 
treatment with insulin and forskolin, compared with vehicle (Figure 4.3.1 B).  The 
studies in this chapter suggest that GAPDH acetylation is not regulated by hormones 
in vivo, and remains unchanged during fasting and re-fed states (Figures 4.3.2 and 
4.3.3).  However the in vivo and in vitro studies in this chapter require further 
investigation, and a time course analysis of GAPDH acetylation after feeding or 
injection with insulin and glucagon could demonstrate rapid fluctuations in GAPDH 
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acetylation.  SILAC has been used in multiple proteomic and acetylation studies, and 
can also be used to determine lysine residues that are targeted by specific 
KDACs19,45,138.  A potential limitation to these results using FAO cells is that they are 
a cancer cell line and glycolysis could be clamped, or constitutive to an extent, and is 
not regulated by the usual signalling processes. It is possible that GAPDH acetylation 
is not regulated by nutrient availability or hormones, and that the deacetylation of 
GAPDH in T2D and mice on a HFD is a pathological factor that does not have a 
physiological role.  Furthermore, these results are based on acute regulation rather than 
chronic regulation as seen in DIO mice, or in db/db mice. 
There were several limitations to this study, in particular the determination of 
total GAPDH acetylation using pan acetyl-lysine antibodies, and the design of the 
animal study based on ethical and time restrictions.  The current pan acetyl-lysine 
antibodies are not reliable, and the epitope recognized by a particular pan acetyl-lysine 
antibody may not be compatible with the acetylated lysine residue within the protein 
that are under investigation139.  Pan acetyl-lysine antibodies may also show 
batch̻to̻batch variability, in terms of both target specificity and enrichment 
efficiency that limits experimental reproducibility, and complicates the interpretation 
of results64.  Site specific acetyl-lysine antibodies are required to confirm whether the 
rat GAPDH lysine sites 115, 160, 225, and 252 from Chapter Two are indeed 
deacetylated in T2D and DIO.  Individual site specific acetyl-lysine antibodies to 
GAPDH K115, K160, K225, and K252 are currently being generated for this project.  
Site specific antibodies for all twenty six GAPDH lysine residues, and SILAC 
procedures, would be useful to determine the acetylation profile of lysine residues in 
T2D, and at various time points under the influence of different substrates such as 
glucose and insulin.  The fluctuations of lysine residues from an acetylated state to a 
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deacetylated state are likely to occur rapidly, and the acetylation profile of lysine 
residues cannot be determined conclusively from a single time point.  In the case of 
T2D and DIO, it may be that the fluctuations between acetylated and deacetylated 
lysine are negligible, where a deacetylated lysine state is favoured.  Further 
investigation into the KDACs responsible for the deacetylation of lysine residues in 
diseased states could potentially explain the reduction in fluctuations of those lysine 
residues back to an acetylated state.     
In conclusion, the results shown in this chapter demonstrate that total hepatic 
GAPDH acetylation is reduced in T2D, and could contribute to the increased rate of 
gluconeogenesis and hepatic glucose production seen in individuals with T2D.  Results 
from this study have also shown that hepatic GAPDH acetylation is reduced in mice 
on a HFD, suggesting that hepatic GAPDH acetylation could be regulated at a 
nutritional level.  Further investigation is required to identify the specific GAPDH 
lysine residues that are deacetylated, and the enzymes that deacetylate those lysine 
residues.  Future work could target the KDACs that deacetylate GAPDH, preventing 
GAPDH deacetylation and potentially reducing hepatic gluconeogenesis and glucose 
production in T2D.   
Cell culture studies in this chapter demonstrated that glucose, insulin, and 
forskolin did not affect the acetylation profile of GAPDH, however this contradicts 
previous research and requires further investigation with site specific acetyl-lysine 
antibodies, and systems biology experiments such as SILAC19,22,46,58,65,140-143.  
Previous research has demonstrated that the acetylation of metabolic enzymes and 
GAPDH is increased in high glucose media, however this study showed no 
relationship between GAPDH acetylation and glucose, insulin, norepinephrine, and 
glucagon/forskolin in vitro and in vivo19,83.  The factors that regulate GAPDH 
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acetylation in mammals is still not clear, and further research is required to determine 
these factors. 
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CHAPTER 5 
THE ROLE OF HEPATIC GAPDH LYSINE RESIDUES 
IN THE REGULATION OF GLUCOSE METABOLISM 
IN VIVO 
 
 
5.1 INTRODUCTION 
In healthy individuals gluconeogenesis and the breakdown of stored liver 
glycogen maintain hepatic glucose production, and subsequent blood glucose levels, 
during fasting and exercise144.  Hepatic gluconeogenesis and blood glucose levels are 
elevated in T2D, and the mechanisms involved are incompletely understood5,28.  In 
previous chapters of this thesis, it has been demonstrated that mutation of rat GAPDH 
lysine residues 115, 160, 225, and 252  to arginine (4KR GAPDH) increased glucose 
production in FAO hepatocytes, and that hepatic GAPDH acetylation is reduced in 
T2D and mice on a HFD.  This demonstrated that acetylation of GAPDH has rate 
limiting properties in vitro, which has also been demonstrated in bacteria19,58,140.  
However, the regulation of hepatic GAPDH acetylation, and the effects of reversible 
GAPDH acetylation on hepatic glucose metabolism in vivo, is not fully understood.   
Chapter Four of this thesis investigated the regulation of hepatic GAPDH 
acetylation in vivo, and the total acetylation of hepatic GAPDH in T2D and DIO.  
These studies found that physiological factors that regulate glucose production in 
mammals do not regulate total hepatic GAPDH acetylation (Figures 4.3.2 and 4.3.3).  
However, there was a reduction in total hepatic GAPDH acetylation in T2D and in 
DIO mice (Figures 4.3.4 and 4.3.6), suggesting that reduced GAPDH acetylation may 
only be altered in pathological states.  To determine the factors that regulate GAPDH 
acetylation, in particular the specific lysine sites that are mutated in the 4KR GAPDH 
mutant, further research is required.   
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Previous research has demonstrated that a point mutation of human GAPDH 
lysine K254 (equivalent to GAPDH K252 in rat, Figure 2.1.1) to glutamine reduced 
xenografted tumour growth in rats83.  Mutation of lysine residues to glutamine has 
been traditionally used as an acetylation mimetic, but actually differs substantially, and 
does not function in the same manner as an acetylated lysine64.  It is now considered 
that mutations of lysine residues to glutamine does not mimic an acetylated lysine, and 
that analyses derived from glutamine mutations is the result of a lysine site that cannot 
undergo its normal PTMs64.  Tumours exhibit elevated rates of aerobic glycolysis, 
known as the Warburg effect, and if human GAPDH K254Q inhibited glycolysis this 
could explain the reduction in tumour size.  If deacetylation of rat GAPDH lysine 
residues K115, K160, K225, and K252 increases gluconeogenesis and blood glucose 
levels in mice, then it could provide a new target for the treatment of T2D and certain 
cancers.  
It remains to be determined whether reduced hepatic GAPDH acetylation 
increases gluconeogenesis and blood glucose levels in vivo.  Previous chapters in this 
thesis have shown that 4KR GAPDH increased gluconeogenesis and reduced 
glycolysis in FAO cells, however this needs to be shown in vivo.  Cell culture studies 
do not accurately reflect the conditions that occur in vivo, so it is necessary that the 
results from previous studies in this thesis are validated in an in vivo model.  Glucose 
pathways, regulation, and metabolism in vivo is a complex system that involves 
multiple tissues and signalling pathways, however the cell culture results are based on 
autonomous hepatocytes.    Therefore the aim of this study was to determine whether 
4KR GAPDH increased hepatic gluconeogenesis and blood glucose levels in vivo.  WT 
GAPDH and 4KR GAPDH AAV8 vectors, that co-express GFP, were used to express 
WT GAPDH and 4KR GAPDH specifically in the liver of C57Bl6/J mice.  
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5.2 METHODS 
5.2.1 Permits and ethical approval 
Approval for animal experimentation was obtained from the Deakin 
University Animal Welfare Committee (G15-2014). 
5.2.2 Construction of adeno-associated virus vectors serotyped with AAV8 capsid  
WT GAPDH and 4KR GAPDH AAV8 plasmids and viruses were generated 
by The Department of Neurology, Hope Center Viral Vectors Core, Washington 
University, School of Medicine, Saint Louis, USA.  Virus packaging, purification, and 
measurement of viral titre were all performed by Washington University.  WT 
GAPDH and 4KR GAPDH vectors (Figure 5.2.1) co-expressed GFP via an internal 
ribosome entry site (IRES), and contained the liver specific promoter; thyroxine-
binding globulin (TBG).   
 
 
Figure 5.2.1: TBG-GAPDH-GFP AAV8 plasmid map.  GAPDH AAV8 co-expressing GFP plasmid 
map, generated by The Department of Neurology, Hope Center Viral Vectors Core, Washington 
University, School of Medicine, Saint Louis, USA. 
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Rather than tag GAPDH with GFP, GFP was co-expressed independently to 
prevent any alterations to GAPDH, or effects that could occur due to GAPDH as a 
result of a GFP tag.  
5.2.3 Animals and experimental design 
C57BL/6 male mice (n=16) were acquired from the Animal Resource Center 
in Western Australia, and arrived at Deakin University at four weeks of age.  Mice 
were contained in a controlled environment at the Deakin University animal house at 
22°C, on a twelve hour light/dark cycle.  Mice were fed a diet of standard chow for the 
duration of this study.  At fifteen weeks of age the mice were injected with either WT 
GAPDH-GFP AAV8 (1 x 1012vg) or 4KR GAPDH-GFP AAV8 (1 x 1012vg), via tail 
vein injection.  At seventeen weeks of age weekly measurements of blood glucose, 
food consumption, body weight and composition were obtained.  Weekly blood 
glucose measurements were taken in the fed state.  At eighteen weeks of age a blood 
glucose fasting/ re-feed experiment was conducted, followed by a glucose tolerance 
test (GTT) at nineteen weeks of age.  At twenty weeks of age an insulin tolerance test 
(ITT) was conducted, followed by a glucagon tolerance test (GnTT) at twenty one 
weeks of age.  At twenty two weeks of age, mice were administered deuterated water 
and seventy two hours later 60μl of blood was taken in the fasted and fed state.  Mice 
were then humanely killed two days later (Figure 5.2.2).   
 
 
Figure 5.2.2:  Animal study time line.  Time course for mutant GAPDH AAV8 animal study. 
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5.2.4 Glucose tolerance tests (GTT) 
Mice were fasted for five hours and then administered an intraperitoneal 
injection of glucose (2g/Kg).  Blood samples (30μl) were obtained pre-injection and 
then 15, 30, and 60 minutes post injection via tail cut in heparinised tubes for plasma 
collection.  Blood glucose levels were measured pre-injection and then 15, 30, 45, 60, 
and 90 minutes post injection using an ACCU-CHEK Performa glucose meter 
(ROCHE).  To obtain plasma, blood was spun in a centrifuge at 12,000 rpm, and 
plasma was stored at -80°C. 
5.2.5 Insulin tolerance test (ITT) 
Mice were fasted for five hours and then administered an intraperitoneal 
injection of insulin (0.75U/Kg).    Blood glucose levels were measured pre-injection 
and then 15, 30, 45, 60, and 90 minutes post injection using an ACCU-CHEK Performa 
glucose meter (ROCHE). 
5.2.6 Glucagon tolerance test (GnTT) 
Mice were fasted for five hours and then administered an intraperitoneal 
injection of glucagon (30μg/Kg).  Blood samples (30μl) were obtained pre-injection 
and then 15, 30, and 60 minutes post injection via tail cut in heparinised tubes for 
plasma collection.  Blood glucose levels were measured pre-injection and then 15, 30, 
45, 60, and 90 minutes post injection using an ACCU-CHEK Performa glucose reader 
(ROCHE).  To obtain plasma, blood was spun in a centrifuge at 12,000 rpm, and 
plasma was stored at -80°C. 
5.2.7 Fasting/re-feed blood glucose test  
Mice were fasted for fifteen hours (from 17:00 to 08:00) and then refed.  
Blood samples were taken pre-refeed and then sixty minutes post-refeed via tail cut in 
heparinised tubes for plasma collection.  Blood glucose levels were taken pre-refeed 
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and then 15, 30, 45, 60, and 90 minutes post refeed using an ACCU-CHEK Performa 
glucose meter (ROCHE).  To obtain plasma, blood was spun in a centrifuge at 12,000 
rpm, and plasma was stored at -80°C. 
5.2.8 Hepatic glucose production measured by deuterated water labelling   
2H2O technique recently adapted by Antoniewicz et al was used to determine 
whether hepatic overexpression of 4KR GAPDH had an impact on gluconeogenesis or 
glycogenolysis145.  Following the administration of 2H2O, 2H atoms become 
incorporated into endogenously synthesised glucose. Then by measuring the ratio of 
2H enrichment in plasma glucose at carbon 5 and 2, the proportion of glucose that is 
produced from gluconeogenesis can be calculated. The proportion of glucose being 
produced from glycogenolysis is determined by subtracting the C5/C2 ratio from 1. 
Gluconeogenesis derived from the mitochondria via the TCA cycle was determined by 
measuring the enrichment of 2H at carbon 6 vs 2, while gluconeogenesis derived from 
the cytosol is estimated by calculating the difference between all sources of 
gluconeogenesis. 
At twenty two weeks of age, mice were administered 2H2O (20 mL/Kg, > 
99.9% enriched, Sigma) by intraperitoneal injection, and cage water was substituted 
with 10% 2H2O.  Three days post-injection, mice were fasted for fifteen hours 
overnight (from 17:00 to 08:00), then 60μl of blood was taken via tail cut.  Mice were 
re-fed and 60μl of blood was taken after thirty minutes.  Blood was centrifuged at 
12,000 rpm, and plasma was separated and stored at -80°C. 
The 2H enrichment of glucose from 20μL plasma was determined by 
measuring the enrichment in six ions from three different glucose derivatives: glucose 
aldonitrile pentapropionate, glucose 1,2,5,6-di-isopropylidene propionate, and glucose 
methyloxime pentapropionate. The derivatives were prepared as described by 
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Antoniewicz et al145 and analysed using an Agilent HP 6890 GC system coupled to an 
Agilent HP 5973 MSD (Agilent Technologies) in electron ionisation mode with 
helium as a carrier gas. The injector insert temperature was 270°C and the GC–MS 
transfer line temperature was 250 °C. The oven temperature gradient was set to: 70 °C 
(one minute); 70 °C to 295 °C at 12.5 °C/min; 295 °C to 320 °C at 25 °C/min; 320 °C 
for two minutes.  The mass isotopomer abundances were determined using Mass 
Hunter Workstation (Agilent Technologies) and the enrichment of individual glucose 
positions was calculated using Matlab software (MathWorks).  
5.2.9 Insulin ELISA 
Insulin assays were performed using a Mouse Ultrasensitive Insulin ELISA 
kit (Alpco), per manufacturer’s instructions, with 5μl of plasma in duplicate.  A 5-
parameter logistic curve and insulin concentration were calculated using ELISA 
analysis software (Elisakit, www.elisaanalysis.com/app).  
5.2.10 Body composition analysis 
Lean mass and fat mass were measured weekly from seventeen weeks of age, 
two weeks post AAV injection, and were evaluated by quantitative nuclear magnetic 
resonance imaging.  Mice were transferred into a plastic tube and analysed with an 
EchoMRI-500 (Echo MRI).  Lean and fat mass were then normalised to whole body 
mass. 
5.2.11 Protein extraction, immunoprecipitation, and immunoblotting 
All protein extraction, immunoprecipitation, and immunoblotting were 
performed as outlined in Chapter Two. 
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5.2.12 GAPDH activity assay 
Liver lysate containing no KDAC inhibitors (diluted 1:20) was used to 
determine gluconeogenic and glycolytic GAPDH activity using a colourmetric 
GAPDH assay following the manufactures instructions as outlined in Chapter Two. 
5.2.13 Quantitative measurement of percent haemoglobin A1c in blood 
Percent HbA1c was determined by blood spotting via tail cut into a small 
glass capillary tube, which was then loaded into a DCA Systems Haemoglobin A1c 
Reagent Kit (Siemens).  Percent HbA1c was then measured using a DCA Vantage 
Analyser (Siemens). 
5.2.14 Glycogen concentration assay 
 Glycogen concentration was determined by hydrolysis of glycogen to glucose 
using the acid-hydrolysis method developed by Passonneau and Lauderdale, and 
adapted for mouse liver by Zhang146,147.  Glucose, the hydrolysis product of glycogen, 
can be converted into glucose-6-phosphate (G-6-P) by hexokinase, which is further 
converted into 6-phosphogluconic acid by G-6-P dehydrogenase producing 
NADPH146,147.  NADPH can be measured spectrophotometrically to determine 
glycogen content. 
A portion of frozen liver or quadriceps muscle was excised and weighed 
(approximately 10mg), and digested in 250μl of 2M HCl at 95-100°C for thirty 
minutes.  Samples were then homogenised at 33,000 rpm for 20 seconds, and incubated 
for two hours at 95-100°C with gentle agitation at 15, 30, 60, and 90 minutes.  After 
incubation, 750μl of 0.667M NaOH was added and the samples were gently mixed to 
neutralise the extract.  Glucose concentration was determined using a Glucose (HK) 
assay kit (Sigma, #GAHK20-1KT) according to the manufacturer’s instructions.  
Absorbance was measured at 340nm, and NADPH concentration was determined from 
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a standard curve.  NADPH concentrations were then normalised to samples with a 
known glucose concentration, and further normalised to wet tissue weight (mmol 
glycogen/kg wet tissue). 
5.2.15 Triglyceride quantification 
Triglyceride quantification was performed using a Triglyceride 
Quantification Colorimetric/Fluorometric kit (BioVision), as per manufactures 
instructions.  Diluted (1:30) liver lysate (5μl) containing no KDAC inhibitors was used 
in the Triglyceride quantification assay. 
5.2.16 Histology 
 Histology and hematoxylin and eosin staining of liver sections were performed 
by The Department of Anatomy and Neuroscience, School of Biomedical Sciences, 
University of Melbourne, Parkville, Melbourne. 
5.2.17 Statistical analyses 
Standard curves and incremental area under the curve (iAUC) were generated 
using Microsoft Excel 2013, and statistical analysis was conducted using SPSS 20 and 
MiniTab 16.  A Kolmogorov-Smirnov test was performed to determine normality and 
distribution.  For data that was not normally distributed, a non-parametric test 
(Kruskal–Wallis test) was used to compare means.  To compare means for normally 
distributed data a two tailed T-Test was used, where equal variance was assumed if 
Levene’s significance > 0.05.  For normally distributed data, one-way and two-way 
ANOVA was used to compare groups using Games Howell method (equal variances 
not assumed) or Fisher's Least Significant Difference method (equal variances 
assumed).  Results are presented as mean ± SEM, and P < 0.05 was considered 
significant. 
 
 
 115 
 
5.3 RESULTS 
5.3.1 AAV8 GAPDH expression is liver specific.  Tissue lysates were 
immunoblotted for GFP to confirm liver specific expression of exogenous GAPDH 
AAV8 vectors that co-express GFP.  GFP was expressed in WT GAPDH and 4KR 
GAPDH mice compared with mice that were not administered AAVs (Figure 5.3.1 A).    
GFP was expressed in liver but not heart, kidney, muscle or fat (Figure 5.3.1 B). 
5.3.2 Hepatic total GAPDH acetylation is unchanged in 4KR GAPDH mice.  In 
order to see whether hepatic total GAPDH acetylation was reduced in 4KR GAPDH 
mice, GAPDH acetylation was determined by GAPDH immunoprecipitation and 
immunoblotting for GAPDH and acetyl-lysine.  GAPDH acetylation was normalised 
to total GAPDH.  Hepatic total GAPDH acetylation was unchanged in 4KR GAPDH 
mice compared with WT GAPDH mice (Figure 5.3.2). 
5.3.3 Gluconeogenic GAPDH activity is increased in 4KR GAPDH mice.  To 
determine whether 4KR GAPDH mice had increased gluconeogenic GAPDH activity, 
a GAPDH activity assay was performed using a colourmetric GAPDH activity kit, and 
GAPDH activity was normalised to total protein.  Gluconeogenic GAPDH activity was 
increased in 4KR GAPDH mice compared to WT GAPDH mice (Figure 5.3.3 B).  
Glycolytic hepatic GAPDH activity was reduced in 4KR GAPDH mice compared with 
WT GAPDH mice (Figure 5.3.3 A). 
5.3.4 Fractional contribution of gluconeogenesis to total endogenous glucose is 
elevated in 4KR GAPDH mice.  Deuterated water was administered to mice in order 
to determine the fractional contribution of gluconeogenesis and glycogenolysis to total 
endogenous glucose by mass spectrometry.  4KR GAPDH mice had a higher 
proportion of endogenous glucose produced from gluconeogenesis, and a reduced 
contribution to total endogenous glucose from glycogenolysis, compared with WT 
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GAPDH mice (Figure 5.3.4 A).  Gluconeogenesis derived from glycerol was higher in 
4KR GAPDH mice compared with WT GAPDH mice (Figure 5.3.4 B), and 
gluconeogenesis derived from phosphoenolpyruvate carboxylase (PEP) was not 
statistically different in 4KR GAPDH mice compared with WT GAPDH mice (Figure 
5.3.4 B). 
5.3.5 Food consumption and body composition were unchanged in 4KR GAPDH 
mice.  To determine whether hepatic 4KR GAPDH expression had an effect on body 
composition, whole body, lean, and fat mass were measured weekly by ECHO MRI.   
WT GAPDH mice and 4KR GAPDH mice average daily food intake was not different 
(Figure 5.3.5 A).  Whole body mass was unchanged in 4KR GAPDH mice compared 
with WT GAPDH mice (Figure 5.3.5 B).  Percent fat mass and percent lean mass, 
determined by quantitative nuclear magnetic resonance imaging, were not different in 
4KR GAPDH mice compared with WT GAPDH mice (Figure 5.3.5 C and D).  
5.3.6 Weekly blood glucose levels and percentage HbA1c were unchanged in 4KR 
GAPDH mice.  Mutation of GAPDH lysine residues to arginine increased glucose 
production in FAO hepatocytes, so to determine whether GAPDH acetylation alters 
blood glucose levels in vivo, blood glucose in the fed state was measured weekly, and 
percentage HbA1c was measured in week twenty two before 2H2O administration.  
Blood glucose levels did not change in 4KR GAPDH mice compared with WT 
GAPDH mice (Figure 5.3.6 A).  Percentage HbA1c levels were measured at twenty 
two weeks of age as a proxy measure of long term glucose homeostasis.  Percentage 
HbA1c was unchanged in 4KR GAPDH mice compared with WT GAPDH mice 
(Figure 5.3.6 B) 
5.3.7 Glucose tolerance was altered in 4KR GAPDH mice after injection with 
glucose.  To determine whether mutation of GAPDH lysine residues affected glucose 
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homeostasis, a GTT was performed.  Glucose tolerance was higher in 4KR GAPDH 
mice compared with WT GAPDH mice after injection with glucose (Figure 5.3.7 A 
and B).  Insulin levels were unchanged in 4KR GAPDH mice compared with WT 
GAPDH mice after injection with glucose (Figure 5.3.7 C and D). 
5.3.8 Glucagon action was altered in 4KR GAPDH mice after injection with 
glucagon.  To determine whether mutation of GAPDH lysine residues affected glucose 
homeostasis in response to glucagon, a GnTT was performed.  Mice expressing 4KR 
GAPDH were more glucagon tolerant compared with WT GAPDH mice (Figure 5.3.8 
A and B).  Either the rate of glucose disposal was higher in 4KR GAPDH mice 
compared with WT GAPDH mice after injection with glucagon, or the production of 
glucose in response to glucagon was reduced in 4KR GAPDH mice compared with 
WT GAPDH mice (Figure 5.3.8 A and B).  Insulin levels were unchanged in 4KR 
GAPDH mice compared with WT GAPDH mice after injection with glucagon (Figure 
5.3.8 C and D). 
5.3.9 The post-prandial response after fasting and re-feeding was unchanged in 
4KR GAPDH mice.  To determine whether mutation of GAPDH lysine residues 
affected the post-prandial response after feeding, blood glucose levels were measured 
over ninety minutes after mice were fasted and re-fed.  After a fifteen hour fast blood 
glucose levels were unchanged in 4KR GAPDH mice compared with WT GAPDH 
mice (Figure 5.3.9 A).  After feeding blood glucose levels were not different in 4KR 
GAPDH compared with WT GAPDH mice (Figure 5.3.9 A and B). 
5.3.10 Insulin tolerance is not altered in 4KR GAPDH mice.   To determine whether 
mutation of GAPDH lysine residues to arginine affected insulin tolerance, an ITT was 
performed.  Insulin tolerance was not different in 4KR GAPDH mice compared with 
WT GAPDH mice (Figure 5.3.10 A and B). 
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5.3.11 Hepatic glycogen content was elevated in 4KR GAPDH mice.  To determine 
whether increased glycogen storage was accounting for the normal blood glucose 
levels in 4KR GAPDH mice that exhibited increased gluconeogenic GAPDH activity, 
a glycogen assay was performed on liver and muscle tissue.  Hepatic glycogen 
concentrations were increased in 4KR GAPDH mice compared with WT GAPDH 
mice (Figure 5.3.11 A).  Muscle glycogen concentration in 4KR GAPDH mice was 
not different compared with WT GAPDH mice (Figure 5.3.11 B).  
5.3.12 Hepatocyte morphology and hepatic triglyceride levels are unchanged in 
4KR GAPDH mice.  To ensure that mutation of GAPDH lysine residues to arginine 
did not affect liver morphology hematoxylin and eosin staining was performed.  Liver 
morphology was normal in 4KR GAPDH and WT GAPDH mice (Figure 5.3.12 A).  
Liver triglyceride concentration was determined using a colourmetric TAG assay kit.  
Hepatic triglyceride concentrations were unchanged in 4KR GAPDH mice compared 
with WT GAPDH mice (Figure 5.3.12 B) 
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Figure 5.3.1: Western blot for GFP expression.  (A) GFP expression from liver in WT GAPDH and 
4KR GAPDH mice.  (B) GFP expression in WT GAPDH and 4KR GAPDH mice from liver, heart, 
kidney, muscle and fat. 
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Figure 5.3.2: Hepatic total GAPDH acetylation in 4KR GAPDH and WT GAPDH mice.   Liver 
tissue was homogenised in lysis buffer containing TSA and NAM.  Lysates were then 
immunoprecipitated for GAPDH and western blotted for GAPDH and acetyl-lysine.  Lysine-acetylated 
GAPDH was normalised to total GAPDH and expressed as %WT GAPDH, mean ± SEM, n=8 replicates 
per group.  Results were not statistically significant.   
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Figure 5.3.3: Gluconeogenic/glycolytic GAPDH activity in 4KR GAPDH and WT GAPDH mice.  
(A) Gluconeogenic GAPDH activity per mg protein.  (B) Glycolytic GAPDH activity per mg protein.  
All data expressed as %WT GAPDH activity, mean ± SEM, n=8 replicates per group.  * Significantly 
different from WT GAPDH, P < 0.05. 
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Figure 5.3.4:  Percentage of endogenous glucose derived from gluconeogenesis and glycogenolysis 
after fasting.  (A) Fractional contribution of gluconeogenesis and glycogenolysis to total endogenous 
glucose.  (B) Fractional contribution to gluconeogenesis by glycerol and PEP.  All data expressed as 
mean ± SEM, n=8 replicates per group.  * Significantly different from WT GAPDH, P < 0.05. 
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Figure 5.3.5: Body composition and food consumption.  (A) Average daily food consumption per 
mouse.  (B) Whole body mass, measured weekly.  (C) Percent fat mass, measured weekly.  (D) Percent 
lean mass, measured weekly.  All data represented as mean ± SEM, n=8 replicates per group.  Results 
not statistically significant.   
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Figure 5.3.6: Weekly blood glucose levels and percentage HbA1c.  (A) Weekly blood glucose levels 
measured in the fed state.  (B) Percentage HbA1c levels in WT GAPDH and 4KR GAPDH mice at 
twenty two weeks of age, seven weeks post AAV8 injection.  All data represented as mean ± SEM, n=8 
replicates per group.  Results not statistically significant.   
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Figure 5.3.7: Glucose tolerance test (GTT).  (A) Blood glucose time course after intraperitoneal 
injection with glucose (2g/Kg).  (B) iAUC for blood glucose time course.  (C) Insulin ELISA from 
plasma taken during GTT.  (D) iAUC for insulin ELISA.  All data represented as mean ± SEM, n=8 
replicates per group. * Significantly different from WT GAPDH, P < 0.05. 
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Figure 5.3.8: Glucagon tolerance test (GnTT).  (A) Blood glucose time course after intraperitoneal 
injection with glucagon (30μg/kg).  (B) iAUC for blood glucose time course.  (C) Plasma insulin during 
GnTT.  (D) iAUC for insulin ELISA.  All data represented as mean ± SEM, n=8 replicates per group. * 
Significantly different from WT GAPDH, P < 0.05. 
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Figure 5.3.9: Re-feed postprandial response.  (A) Blood glucose time course after re-feeding, post 
fifteen hour fast.  (B) iAUC for blood glucose time course. All data represented as mean ± SEM, n=8 
replicates per group.  Results not statistically significant.   
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Figure 5.3.10:  Insulin tolerance test (ITT).  (A) Blood glucose time course after intraperitoneal 
injection with insulin (0.75U/Kg).  (B) iAUC for blood glucose time course.  All data represented as 
mean ± SEM, n=8 replicates per group.  * Significantly different from WT GAPDH, P < 0.05.  Results 
not statistically significant. 
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Figure 5.3.11: Muscle and liver glycogen concentration in WT GAPDH and 4KR GAPDH mice.  
(A) Liver glycogen concentration.  (B) Muscle glycogen concentration. All data represented as %WT 
GAPDH, mean ± SEM, n=8 replicates per group.  * Significantly different from WT GAPDH, P < 0.05.   
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Figure 5.3.12: Liver morphology and triglyceride quantification in 4KR GAPDH and WT 
GAPDH mice.  (A) Hematoxylin and eosin stain (H & E) of liver sections from WT GAPDH and 4KR 
GAPDH mice.  (B) WT GAPDH and 4KR GAPDH triglyceride concentration.  All data represented as 
mean ± SEM, n=8 replicates per group.  Results not statistically significant.   
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5.4 DISCUSSION 
Chapter Two of this thesis demonstrated that FAO hepatocytes expressing rat 
GAPDH that has residues K115, K160, K225, and K252 mutated to arginine (4KR 
GAPDH) increased gluconeogenesis and reduced glycolysis in vitro.  Palmitate and 
glucose oxidation was also reduced in 4KR GAPDH FAO hepatocytes, which also had 
increased lipid deposits.  Based on these results, it was expected that 4KR GAPDH 
mice would have elevated blood glucose levels, with increased hepatic 
gluconeogenesis and lipid deposits. 
Mice were injected, via tail vein, with either AAV8 WT GAPDH-IRES-GFP 
or AAV8 4KR GAPDH-IRES-GFP, and expression was demonstrated by western 
blotting tissue lysates for GFP expression (Figure 5.3.1 A).  AAV8 has high tropism 
for the liver, and in addition, a liver specific promoter (TBG) was used to prevent 
expression in other tissues148.  Western blot for GFP in liver, heart, kidney, muscle, 
and fat showed that expression of exogenous GAPDH occurred exclusively in the liver 
(Figure 5.3.1 B).  There was no significant difference in total hepatic GAPDH 
acetylation between WT GAPDH and 4KR GAPDH (Figure 5.3.2), however site 
specific acetyl-lysine antibodies are required to determine if rat GAPDH K115, K160, 
K225, and K252 are deacetylated.  This data is difficult to interpret due to the nature 
of the pan acetyl-lysine antibodies, and in addition, endogenous GAPDH could be 
affecting the data.  Chapter Two of this thesis demonstrated that mutation of lysine 
residues in 4KR GAPDH, could not be detected by pan acetyl-lysine antibodies.  If 
GAPDH activity is not affected by the addition of a protein tag, then 
immunoprecipitation of that tag could pull down 4KR GAPDH and WT GAPDH, 
which could potentially show reduced acetylation in 4KR GAPDH compared with WT 
GAPDH.  This study did not incorporate a tag on GAPDH to prevent any loss of 
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activity, or side effects, which might occur as a result of a tag.  It is unclear whether 
the exogenous GAPDH is outcompeting the endogenous GAPDH, but a GAPDH 
knockout model could be used to remove endogenous GAPDH in future research.  One 
such method is to knockout endogenous liver GAPDH using lox-cre or CRISPR/Cas9 
technology, followed by reintroduction of WT GAPDH and 4KR GAPDH. 
In FAO cells 4KR GAPDH increased gluconeogenic GAPDH activity and 
reduced glycolytic GAPDH activity (Figure 2.3.4 B and C).  In 4KR GAPDH mice 
gluconeogenic GAPDH activity was increased and glycolytic GAPDH activity was 
reduced compared with WT GAPDH mice (Figure 5.3.3 A and B).  This demonstrates 
that GAPDH activity of 4KR GAPDH is similar in vivo and in vitro.  In addition, 
analysis of the fractional contribution of gluconeogenesis and glycogenolysis to total 
fasting endogenous glucose, revealed that 4KR GAPDH mice had a higher 
contribution from gluconeogenesis compared with WT GAPDH mice (Figure 5.3.4 
A), and WT GAPDH mice had a higher contribution from glycogenolysis compared 
with 4KR GAPDH mice (Figure 5.3.4 A).  This further suggests that gluconeogenesis 
is elevated in 4KR GAPDH mice compared with WT GAPDH mice.  The major 
contribution to gluconeogenesis in the 4KR GAPDH mice came from glycerol, which 
was unexpected, and further complicates what is occurring in vivo in response to 
mutation of GAPDH lysine residues to arginine (Figure 5.3.4 B).  The preference of 
4KR GAPDH mice to metabolise glycerol suggests that mutation of GAPDH lysine 
residues to arginine could in fact impair GAPDH function in both the glycolytic and 
gluconeogenic direction.  However, both WT GAPDH mice and 4KR GAPDH mice 
could metabolise PEP through gluconeogenesis, which suggests that the function of 
GAPDH in the gluconeogenic direction is normal (Figure 5.3.4 B).   
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4KR GAPDH and WT GAPDH mice food consumption was not different 
(Figure 5.3.5 A), and 4KR GAPDH did not affect whole body mass (Figure 5.3.5 B) 
or body composition (Figure 5.3.5 C and D) compared with WT GAPDH mice.  
Surprisingly, 4KR GAPDH expression had opposing effects on whole body glucose 
homeostasis to those expected based on our previous analyses in vitro.  C57BL/6 mice 
expressing hepatic 4KR GAPDH did not have elevated blood glucose levels (Figure 
5.3.6 A) or increased percentage HbA1c (Figure 5.3.6 B) compared with WT GAPDH 
mice.  In addition, 4KR GAPDH mice were more glucose tolerant compared with WT 
GAPDH mice (Figure 5.3.7 A and B).  Insulin levels after injection with glucose were 
normal and did not vary significantly between WT GAPDH and 4KR GAPDH mice 
(Figure 5.3.7 C and D).  4KR GAPDH mice showed greater control of glucose 
homeostasis following glucagon administration than WT GAPDH mice (Figure 5.3.8 
A and B).  Insulin levels after injection with glucagon were normal and did not vary 
significantly between WT GAPDH and 4KR GAPDH mice (Figure 5.3.8 C and D).  
Based on the cell culture studies, where 4KR GAPDH cells were hypersensitive to 
forskolin, it was predicted that the 4KR GAPDH mice would be hypersensitive to 
glucagon.  However, glucagon activates the cAMP pathway by binding to the glucagon 
receptor which then increases cAMP, and forskolin activates the cAMP pathway by 
activating adenylate cyclase which then increases cAMP, so the effects of these two 
molecules is similar, but could produce different responses in vivo149,150.  A forskolin 
tolerance test could be performed to determine whether there are different glucose 
homeostasis responses to forskolin compared with glucagon.  Blood glucose levels 
after feeding were not significantly different in 4KR GAPDH mice compared with WT 
GAPDH mice (Figure 5.3.9 A and B), however fasting blood glucose levels tended to 
be higher, although not significantly, in WT GAPDH mice (5.3.9 A and 5.3.10 A). 
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This data collectively suggests that mutation of lysine residues may have had 
an overall impact on the function of GAPDH, where hepatic glucose production in 
4KR GAPDH mice could be elevated, but glucose disposal could also be higher in 
4KR GAPDH mice, which maintains normal blood glucose levels.  The glucose 
disposal pathways may be more efficient in 4KR GAPDH mice in order to reduce 
blood glucose levels to normal, compensating for elevated gluconeogenesis.  If 
gluconeogenesis and glucose disposal are elevated, then it needs to be determined 
where the glucose disposal is occurring.  Rather than secreting glucose, elevated 
gluconeogenesis could be producing glucose that is immediately synthesised into 
glycogen.  Analyses of hepatic glycogen content showed that 4KR GAPDH mice had 
higher hepatic glycogen content compared with WT GAPDH mice (Figure 5.3.11 A), 
while 4KR GAPDH mice muscle glycogen content was not different compared with 
WT GAPDH mice (Figure 5.3.11 B).  This could account for the normal blood glucose 
levels in 4KR GAPDH mice that have elevated gluconeogenic GAPDH activity, 
suggesting that excess glucose is synthesised into glycogen, and that glycogenolysis is 
down regulated.  Excess glucose could also be used in the synthesis of glycerol and 
lipids, however TAG quantification did not show elevated TAG levels in 4KR 
GAPDH mice (Figure 5.3.12 B).  A lipid tolerance test measuring the  postprandial 
response could also be useful to determine whether lipid storage and utilisation is 
disrupted in 4KR GAPDH mice151.  
The effects of 4KR GAPDH observed in vivo do not conclusively support the 
hypothesis and results from Chapter Two.  Isolation of primary hepatocytes expressing 
4KR GAPDH could be used to perform similar in vitro experiments that were 
performed in Chapter Two to help validate those results.  Testing whether acetylated 
GAPDH could rescue a T2D phenotype (db/db -/-), by reducing gluconeogenesis and 
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blood glucose levels, could also help validate the regulation of gluconeogenesis by 
reversible GAPDH acetylation.  Together, the in vivo data from this study and Chapter 
Four, suggest that GAPDH deacetylation is a pathological phenotype that perhaps is 
not physiologically relevant in terms of metabolic regulation.  However, GAPDH 
deacetylation on its own may not be sufficient to regulate metabolic pathways, and 
other metabolic enzymes might need to be deacetylated/acetylated.   Other GAPDH 
PTMs like phosphorylation, or PTMs to other metabolic enzymes are probably 
required collectively to regulate metabolic pathways in vivo.  
In conclusion, mutation of hepatic GAPDH lysine residues 115, 160, 225, and 
252 to arginine, increased gluconeogenic GAPDH activity but did not increase blood 
glucose levels in mice.  The glycogen content and the fractional contribution to 
endogenous glucose from gluconeogenesis was higher in 4KR GAPDH mice.  Total 
hepatic GAPDH acetylation was not reduced in 4KR GAPDH mice, and 4KR GAPDH 
did not alter body composition or weight.  Glucose homeostasis was altered in 4KR 
GAPDH mice after glucose and glucagon were administered, but insulin action was 
normal.  Further work is required to determine whether hepatic gluconeogenesis and 
glucose secretion was actually increased in 4KR GAPDH mice. 
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CHAPTER 6 
SUMMARY & CONCLUSIONS 
 
Diabetes is emerging as one of humanity’s greatest medical challenges, and 
is predicted to become the world’s 7th leading cause of death by 20302.  Total deaths 
from diabetes are projected to rise by 50% over the next ten years, where T2D accounts 
for 90% of all diabetes worldwide2.  T2D is characterised by insulin resistance and 
elevated blood glucose levels, and is associated with obesity and physical inactivity.  
Increased hepatic glucose production and reduced uptake of glucose by skeletal muscle 
are the largest contributors to elevated blood glucose levels in T2D5.  Dysfunctional 
metabolism, namely increased gluconeogenesis, is the principal cause of increased 
hepatic glucose production in T2D5.  GAPDH is a metabolic enzyme that catalyses 
one of the forward and reverse reactions of glycolysis/gluconeogenesis, and the 
acetylation profile of GAPDH has been shown to be important in the regulation of 
glycolysis/gluconeogenesis in bacteria and cancer cell lines19,83.  This thesis has 
demonstrated that hepatic GAPDH acetylation is reduced in T2D and DIO, and has a 
regulatory effect on glycolysis/gluconeogenesis in vitro. 
The GAPDH residues K115, K160, K225, and K252 that were mutated to 
arginine were chosen based on previous proteomic studies that have shown that those 
lysine residues can undergo reversible acetylation, and had functional 
importance19,79,83,103.  Computational analysis of crystallography studies showed that 
GAPDH K115 is located in the NAD+ binding site, and that K160, K225 and K252 
are located in the catalytic domain103.  It has also been shown that GAPDH residues 
K115, K160, K225, and K252 are located on the surface of GAPDH where KDACs, 
KATs and other proteins can interact with them.  Recent studies have shown that 
GAPDH has multiple and diverse functions, and that the sub-cellular location of 
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GAPDH plays an important role in determining GAPDH function73,76,100.  Confocal 
imaging demonstrated that 4KR GAPDH and WT GAPDH were both predominantly 
localised to the cytosol where glycolytic/gluconeogenic reactions occur. 
Results from Chapter Two of this thesis established that mutation of GAPDH 
residues K115, K160, K225, and K252 to arginine increased gluconeogenesis and 
reduced glycolysis in FAO hepatocytes.  Individual mutations of GAPDH residues 
K225 and K252 to arginine, which are located in the GAPDH catalytic domain, 
affected glucose production and ECAR, but individual mutations to GAPDH residues 
K115 and K160 to arginine did not.  However, the combination of GAPDH residues 
K115, K160, K225, and K252 mutated to arginine (4KR GAPDH) appeared to have 
the greatest effect on altering hepatic glucose metabolism.  As such, the majority of 
this thesis has focussed on characterising 4KR GAPDH.  Glucose production and 
gluconeogenic GAPDH activity were increased in 4KR GAPDH cells compared with 
WT GAPDH cells.  ECAR and glycolytic GAPDH activity were reduced in 4KR 
GAPDH cells compared with WT GAPDH cells.  This suggests that acetylation of 
GAPDH residues K115, K160, K225, and K252 have regulatory properties that 
determine whether GAPDH participates in glycolytic or gluconeogenic reactions.  
GAPDH residues K225 and K252, located in the catalytic domain and the cleft that is 
formed by the GAPDH tetramer, could regulate glycolysis/gluconeogenesis by 
allowing GAPDH to bind with 3-phosphoglyceraldehyde when acetylated, resulting in 
GAPDH reacting in the glycolytic direction.  Alternatively, when GAPDH residues 
K225 and K252 are deacetylated, GAPDH could bind to 1,3-bisphosphoglycerate, 
resulting in GAPDH reacting in the gluconeogenic direction.  Computational 
simulations could help support this theory, however the computer technology currently 
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available cannot simulate this mechanism of action with WT GAPDH and 4KR 
GAPDH with the corresponding metabolites. 
4KR GAPDH also had effects on the TCA cycle in vitro, where palmitate and 
glucose dependent oxidation were reduced in 4KR GAPDH cells.  Mitochondrial 
energetics showed that mitochondrial function was normal, and Oil Red-O analysis 
showed that there was increased lipid deposits in 4KR GAPDH cells.  This suggests 
that 4KR GAPDH lipid metabolism is impaired, but the mechanisms behind this 
require further investigation.  It is possible that impaired glycolysis is shunting glucose 
through dihydroxyacetone phosphate into glycerol and lipid synthesis.  The build-up 
of lipids in 4KR GAPDH cells could be attributed to an increase in lipid synthesis that 
outweighs lipid catabolism, or an impairment in lipid metabolism.  How lipid 
metabolism is impaired is difficult to determine based on the data in this thesis, but 
impaired TCA anaplerosis could account for the reduction in palmitate and glucose 
dependent OCR.  Another factor to take into account is the ATP required for 
gluconeogenesis to occur.  Glycolysis generates two units of ATP per unit of glucose, 
while gluconeogenesis requires two units of ATP to produce one unit of glucose63.  
Glucose production in 4KR GAPDH cells is increased three-fold, while glycolysis is 
severely impaired, so therefore the 4KR GAPDH cells are not generating ATP through 
glycolysis, and require three times as much ATP to sustain the elevated 
gluconeogenesis that is occurring.  This suggests that the ATP that is utilised for 
gluconeogenesis may be depriving other metabolic pathways of ATP, thereby reducing 
their metabolic function.  However, one cycle of oxidative phosphorylation generates 
thirty six units of ATP, which should adequately cover the increased demand for ATP 
in the 4KR GAPDH cells, although OCR was not increased in 4KR GAPDH cells.  
Further experiments, such as metabolomics could quantify the intermediary 
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metabolites in order to determine if there is impaired TCA anaplerosis, while palmitate 
and glucose tracer studies could determine where glucose and lipid metabolism is 
impaired, and where the additional ATP is sourced from to sustain the elevated rate of 
gluconeogenesis in 4KR GAPDH cells. 
Glucagon and insulin are in vivo regulators of hepatic glucose production in 
mammals, where hepatic insulin resistance in T2D plays a key role in increased hepatic 
gluconeogenesis and glucose production that occurs in T2D.  Insulin reduces hepatic 
glucose production by inhibiting the expression of key gluconeogenic genes, such as 
PEPCK and G-6-Pase.  However, there have been several studies that have now shown 
that the protein levels of key gluconeogenic proteins PEPCK and G-6-Pase are not 
important in the regulation of gluconeogenesis12,68,69.  The activity of PEPCK, G-6-
Pase and other metabolic enzymes are likely regulated by mechanisms such as PTMs.  
Chapters Two and Four in this thesis investigated whether insulin and glucagon could 
modulate GAPDH acetylation, in vitro and in vivo.  Forskolin was used as a glucagon 
mimetic in vitro, as FAO cells have resistance to glucagon98.  Chapter Two showed 
that insulin could suppress glucose production in both WT GAPDH and 4KR GAPDH 
cells, however 4KR GAPDH cells were hyper-sensitive to forskolin with a three-fold 
increase in glucose production.  This suggests that the ability of insulin to suppress 
glucose production is occurring independent of GAPDH acetylation, however the 
actions of forskolin are amplified by GAPDH deacetylation.  This further suggests that 
GAPDH acetylation plays an important role in the cAMP pathway response to 
glucagon and glucose production.  Further experimentation with site specific acetyl-
lysine antibodies is required to monitor the acetylation profile of WT GAPDH cells 
over time in response to insulin and forskolin.  The objective of Chapter Four was to 
validate these findings in vivo, however the total hepatic GAPDH acetylation profile 
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did not change fifteen minutes after glucagon, norepinephrine, insulin and vehicle 
were administered.  This animal study needs to be repeated with site specific acetyl-
lysine antibodies, and the acetylation profile needs to be monitored over several time 
points, as the changes in GAPDH acetylation can occur rapidly152,153.  It cannot be 
conclusively stated that GAPDH acetylation is not affected by glucose regulating 
hormones by effectively taking a snapshot at one time point at fifteen minutes.  Chapter 
Four did demonstrate that hepatic GAPDH acetylation is reduced in T2D and DIO, 
however the relevance of this finding, and its relation to elevated glucose production 
in T2D, is not clear.   
Although in vivo studies in Chapter Four demonstrated that GAPDH 
acetylation is reduced in T2D and DIO, mutation of GAPDH residues K115, K160, 
K225, and K252 to arginine did not increase blood glucose levels in mice.  However, 
there are twenty six lysine residues on GAPDH which can potentially undergo 
reversible acetylation, and the reduced GAPDH acetylation seen in T2D could be a 
result of other GAPDH lysine residues undergoing deacetylation.  The GAPDH lysine 
residues that are deacetylated in T2D need to be identified to further test whether their 
deacetylation regulates glycolysis/gluconeogenesis.  In addition, GAPDH acetylation 
analysis revealed that there was no reduction in total GAPDH acetylation in 4KR 
GAPDH mice, but site specific acetyl-lysine antibodies are required to confirm 
whether the GAPDH residues K115, K160, K225, and K252 are actually deacetylated 
in 4KR GAPDH mice, and in T2D and DIO mouse models.  It is possible that GAPDH 
deacetylation is a pathological phenotype that does not play a role in elevated hepatic 
gluconeogenesis and blood glucose levels.  However, it is possible that the 
deacetylation of other glycolytic/gluconeogenic enzymes in combination with other 
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PTM events, in addition to deacetylated GAPDH, is required to regulate glucose 
metabolism.   
Interestingly, the 4KR GAPDH mice had a higher tolerance to glucose after 
glucose was administered, and also produced less glucose or had higher glucose 
disposal after glucagon was administered.  In both glucose and glucagon tolerance tests 
the insulin levels were normal and were not significantly different.  It is difficult to 
conclusively determine why the 4KR GAPDH mice have higher glucose tolerance 
compared with WT GAPDH mice from the results in this thesis, however there are 
several possibilities that could explain these results.  There was a reduction in 
glycolytic GAPDH activity in 4KR GAPDH mice, and gluconeogenic GAPDH 
activity was increased in the 4KR GAPDH mice, which suggests that hepatic glucose 
production should be increased in the 4KR GAPDH mice, however blood glucose 
levels and percentage HbA1c were normal.  Fractional quantification of total 
endogenous glucose showed that 4KR GAPDH mice had a higher contribution from 
gluconeogenesis and a lower contribution from glycogenolysis compared with WT 
GAPDH mice.  This supports the GAPDH activity data where 4KR GAPDH mice had 
elevated gluconeogenic GAPDH activity, however 4KR GAPDH mice did not have 
elevated blood glucose levels.  Hepatic glycogen content was higher in 4KR GAPDH 
mice, where reduced glycogenolysis and increased glycogenesis could be 
compensating for the elevated gluconeogenesis that could be occurring in 4KR 
GAPDH mice, thereby maintaining normal blood glucose levels.  It is also possible 
that the excess glucose could be synthesised into lipids, however TAG quantification 
showed no difference in TAG levels between 4KR GAPDH and WT GAPDH mice, 
however there could be an increase in lipid metabolism to account for this.  In addition, 
analysis of different lipid species could reveal specific changes in lipid species 
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between WT GAPDH and 4KR GAPDH.  The cell culture studies did show that lipid 
metabolism was impaired, although lipid metabolism could be unaffected in vivo, and 
the excess glucose could be synthesised into lipids and immediately metabolised in 
vivo.  
Although it was shown that PEP fuelled gluconeogenesis was not different in 
4KR GAPDH mice compared with WT GAPDH mice, glycerol fuelled 
gluconeogenesis was higher in 4KR GAPDH mice.  This suggests that 
gluconeogenesis in 4KR GAPDH mice is bypassing GAPDH via glycerol metabolism 
through dihydroxyacetone phosphate (DHAP), which suggests that mutation of 
GAPDH residues K115, K160, K225, and K252 to arginine has removed GAPDH 
function.  However, gluconeogenic GAPDH activity is elevated in 4KR GAPDH mice, 
and PEP fuelled gluconeogenesis is not significantly different compared with WT 
GAPDH mice.  Glycerol could be required to fuel gluconeogenesis in 4KR mice due 
to a depletion of gluconeogenic metabolites, which have not been replenished due to 
impaired glycolysis, resulting in gluconeogenesis being shunted through the glycerol 
pathway.  4KR GAPDH cells had increased lipid accumulation and reduced palmitate 
oxidation, combined with increased glycerol metabolism in 4KR GAPDH mice, 
suggests that 4KR GAPDH has altered lipid metabolism in vitro and in vivo.  Glycerol 
is an important constituent of triglycerides, where it forms the back bone of 
triglycerides, and along with palmitate is important in several aspects of lipid 
metabolism63.  Palmitate, along with dietary fatty acids, are acyl-CoA donors that are 
required for the acylation of glycerol 3-phosphate (G3P) which is an intermediary 
between DHAP, glycerol, and glycerolipid, and is important for the generation of 
phosphatidic acid154.  In 4KR GAPDH FAO cells which lack glycogen storage, a 
reduction in palmitate oxidation through the TCA cycle could be due to increased 
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demand for palmitate required for the generation of glycerol, which is required for 
increased gluconeogenesis.  Glucose, glycerol, and palmitic acid tracer studies could 
be performed in vitro and in vivo to determine the pathways through which they are 
metabolised.  Interestingly, total GAPDH acetylation was reduced in T2D and DIO, 
and 4KR GAPDH resulted in accumulation of lipids in vitro, and potentially increased 
utilisation of lipids via glycerol metabolism in vivo.  These effects could be relevant 
to the progression of T2D, as it has been demonstrated that an increased accumulation 
of fatty acids and dysregulation of lipid metabolism can lead to the development of 
T2D5,7,126. 
The findings from this research suggest that the reduction in hepatic total 
GAPDH acetylation in T2D and DIO are a pathological factor rather than a 
physiological factor.  It should be noted that T2D and DIO are chronic conditions while 
the in vivo study of GAPDH acetylation in response to hormones was an acute 
condition.  If reduced GAPDH acetylation in T2D and DIO is a pathological factor, 
there must be elevated GAPDH deacetylation occurring due to increased activity from 
GAPDH KDACs.  The enzymes that deacetylate and acetylate GAPDH in vivo are 
currently unknown and unsubstantiated.  Lei et al demonstrated that HDAC5 
deacetylated GAPDH K254 in vitro, however this study is unsupported and did not 
take into account that HDAC5 lacks intrinsic HDAC activity83.  Several studies have 
now shown that the class IIa HDACS, which includes HDAC4, 5, 7, and 9, do not 
possess any deacetylase activity, but rather function via the recruitment of other 
KDACs such as HDAC384,85.  It is possible that HDAC5 could play a regulatory role 
in the deacetylation of GAPDH K254, but this would be via the recruitment of other 
KDACs such as HDAC3. 
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Glucose production was reduced in WT GAPDH cells after treatment with 
NAM or TSA, while glucose production in 4KR GAPDH cells was not significantly 
reduced.  This suggests that GAPDH is potentially deacetylated by both HDACs and 
SIRTs.  The focus of this thesis was on HDAC6, due to its cytosolic localisation and 
because it is highly expressed in liver and kidney.  Chapter Three, and previous 
research, has demonstrated that HDAC6 plays a role in metabolism, and that 
deacetylation of proteins by HDAC6 results in increased glucose production and 
reduced ECAR and OCR.  This demonstrates that HDAC6 has similar effects to 4KR 
GAPDH, and suggests that HDAC6 could cause these metabolic alterations via 
deacetylation of GAPDH.  Further glucose production assays using cells that co-
express HDAC6 and GAPDH mutants showed that DN HDAC6 was able to reduce 
glucose production in WT GAPDH cells but not 4KR GAPDH cells.  In addition, 4KR 
GAPDH is hypersensitive to forskolin, and DN HDAC6 was able to reduce glucose 
production in WT GAPDH cells after treatment with forskolin but not 4KR GAPDH 
cells.  This suggests that HDAC6 mediates the forskolin response via GAPDH 
deacetylation, as the decrease in glucose production in WT GAPDH/DN HDAC6 
forskolin treated cells is lost.  Together these results demonstrate that HDAC6 could 
be a GAPDH deacetylase.  
HDAC6 has metabolic regulatory properties, and could potentially be a 
GAPDH deacetylase, but the proteins that are actually deacetylated by HDAC6 and 
that play a role in elevated glucose production, require further investigation.  In 
addition, the factors that regulate HDAC6 activity remain largely unknown, although 
HDAC6 deacetylase activity is zinc dependent111.  Zinc is a co-factor for the activity 
and function of up to ten percent of mammalian proteins155.  Elevated zinc levels, or a 
deficiency in zinc levels, both have catastrophic consequences that have been linked 
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to diabetes and stroke155.  Zinc homeostasis, and the proteins responsible for its 
transport and their function, regulation, and crosstalk by which they operate, is poorly 
understood155.  Defects in the ZnT-8 zinc transporter in the pancreas has been 
associated with T2D and β-cell dysfunction, and it is possible that there is dysfunction 
in other zinc transporters in T2D which could allow increased HDAC6 activity and 
GAPDH deacetylation155.    
Studies in this thesis demonstrated that hepatic GAPDH acetylation was 
reduced in T2D, and that HDAC6 increased glucose production.  The role of GAPDH 
acetylation and HDAC6 in hepatic glucose metabolism requires further investigation, 
but it could become a signalling axis that is an important therapeutic target for the 
treatment of T2D.  However there were several limitations to this project.  Pull down 
of GAPDH from cell lysates after exposure to high glucose was not as efficient as 
GAPDH pull down from glucose free and normal glucose cell lysates.  This could be 
explained by GAPDH translocating to the nucleus to initiate apoptosis in high glucose 
conditions156,157.  There were also limitations to immunoprecipitations and 
immunoblotting using pan acetyl-lysine antibodies, which are not effective for 
investigating individual lysine residue acetylation, and can have variability between 
batches.  For this reason the use of site specific acetyl-lysine antibodies is now 
emerging as an essential requisite for acetylation biology.  Mass spectrometry 
techniques, such as SILAC, have also emerged as important tools for acetylation 
biology. 
The mutation of lysine residues to arginine has been commonly used to mimic 
deacetylated lysine residues in acetylation studies, while mutation of lysine residues 
to glutamine has been commonly used to mimic acetylated lysine residues.  However, 
it is now becoming apparent that these mutations do not accurately reflect the 
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acetylated/deacetylated lysine residue, and actually differ substantially in form and  
function64.  Therefore analyses of results from lysine mutation studies should take this 
into account when analysing the functional importance of lysine mutations64.  In 
addition, lysine residues undergo multiple PTMs by several acyl moieties including: 
formylation, succinylation, malonyation, butyrylation, propionylation, glutarylation, 
and crotonylation64.  Mutation of lysine residues could therefore have an impact on the 
modifications listed above, which would make it difficult to attribute any functional 
changes derived from such mutations solely to acetylation. 
 
In summary, the conclusions that can be drawn from the results presented in this thesis 
are: 
1. Total GAPDH acetylation is reduced in T2D and DIO in vivo  
2. Mutation of rat GAPDH residues K115, K160, K225, and K252 to arginine  
- increased gluconeogenesis and reduced glycolysis in vitro 
- increased lipid deposits in vitro 
- impaired glucose and palmitate oxidation in vitro  
- did not alter blood glucose levels or percentage HbA1c in vivo 
- affected glucose and glucagon tolerance after injection with glucose or 
glucagon 
- increased gluconeogenic GAPDH activity and reduced glycolytic GAPDH 
activity in vivo 
- increased hepatic glycogen concentration in vivo 
3. WT HDAC6 increased glucose production and reduced glycolysis in vitro 
Since its discovery, acetylation has been considered as a modification that 
occurred exclusively on histones, until recent proteomic studies have shown that the 
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majority of acetylation events occur on non-nuclear proteins20,21.  An interesting 
finding from those studies is that acetylation is widespread in the mitochondria, and 
considering the lack of phosphorylation events in the mitochondria, acetylation likely 
plays an important role in mitochondrial function158,159.  Acetylation compared to 
phosphorylation is also more abundant in bacteria, and this supports the mitochondrial 
endosymbiotic theory of prokaryote origin159.  Whether acetylation in mammals plays 
a regulatory role outside of the mitochondria that is as important as it is in bacteria is 
yet to be proven, and it remains to be seen whether lysine acetylation sites are 
conserved in mammals due to their function, or whether this is just a consequence of 
their frequent location in conserved structural features64.  It is possible that the 
acetylation profile of metabolic enzymes collectively can regulate metabolic 
pathways, but not individually, as it is probable that there are compensatory 
mechanisms in place to prevent that from occurring.  However, the outcomes from this 
work could provide one piece of the puzzle for the regulation of 
glycolysis/gluconeogenesis by reversible acetylation of metabolic enzymes.  Further 
investigation could lead to KDAC inhibitors that can be used in conjunction with other 
treatments such as metformin to reduce blood glucose levels in T2D.   
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APPENDIX 
SOLUTIONS AND REAGENTS 
Concentrations in Molarity or Percentage by Weight/Volume. 
Reagent Chemical/Substance Amount Final Concentration 
10 X Running Buffer 
(SDS-PAGE) 
Tris 60 g 0.25 M 
Glycine 288 g 1.92 M 
SDS 20 g 0.04 M 
Milli-Q H2O Up to 2 L - 
 
Reagent Chemical/Substance Amount Final Concentration 
10 X Transfer Buffer 
(SDS-PAGE) 
Tris 60 g 0.25 M 
Glycine 288 g 1.92 M 
Milli-Q H2O Up to 2 L - 
 
Reagent Chemical/Substance Amount Final Concentration 
2 X 1.5 mm 8% Tris-HCl 
gels 
(Separating/Resolving  
Gel) 
MQ H2O 8.64 mL - 
1.5M Tris-HCl pH 8.8 4 mL 0.38 M 
40% Acryl / 0.8% Bis 3.2 mL - 
20% SDS 80 μL 0.05 mM 
10% Aps 80 μL 2.19 μM 
TEMED 12 μL - 
gels 
(Stacking Gel) 
MQ H2O 3.84 mL - 
0.5M Tris-HCl pH 6.8 1.5 mL 0.13 M 
40% Acryl / 0.8% Bis 0.6 mL - 
20% SDS 30 μL 1.87 μM 
10% Aps 30 μL 0.82 μM 
TEMED 10 μL - 
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Reagent Chemical/Substance Amount Final Concentration 
 LB Agar (pH 7.5) 
Bacto-Trytone 10 g 1% 
Yeast extract 5 g 0.5% 
Sodium Chloride 
(NaCl) 10 g 0.17 M 
Agar 15 g 1.5% 
Sodium Hydroxide 
(NaOH) 
pH 
adjustment 
(7.5) 
- 
Milli-Q H2O Up to 1 L - 
 
Reagent Chemical/Substance Amount Final Concentration 
 LB Broth (pH 7.5) 
Bacto-Trytone 10 g 1% 
Yeast extract 5 g 0.5% 
Sodium Chloride 
(NaCl) 10 g 0.17 M 
Sodium Hydroxide 
(NaOH) 
pH 
adjustment 
(7.5) 
- 
Milli-Q H2O Up to 1 L - 
 
Reagent Chemical/Substance Amount Final Concentration 
SeaHorse Running 
Media (pH 7.4) 
Unbuffered DMEM 
(SeaHorse BioScience, 
# 100965-000) 
50 μL - 
100 X Glutamax 500 μL 2 mM 
Sodium Pyruvate 500 μL 1 mM 
5 M Sodium 
Hydrocide (NaOH) 
pH 
adjustment 
(7.4) 
- 
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Reagent Chemical/Substance Amount Final Concentration 
1 X TBST 
Tris pH 7.4 200 mL - 
Sodium Chloride 
(NaCl) 58.44 g 0.05 M 
Tween-20 10 mL - 
Milli-Q H2O Up to 20 L - 
 
 
Reagent Chemical/Substance Amount Final Concentration 
4 X Laemmli Buffer (10 
mL) 
1 M Tris-HCl pH 6.8 2 mL 50 mM 
SDS 0.8 g 0.28 M 
100% glycerol 4 mL 0.4 M 
14.7 M  
β-mercaptoethanol 400 μL 0.59 M 
0.5 M EDTA 1 mL 12.5 mM 
Bromophenol Blue 8 mg 1.19 mM 
 
Reagent Chemical/Substance Amount Final Concentration 
1% BSA in TBST 1 X TBST 500 mL - 
BSA 5 g 1% 
 
Reagent Chemical/Substance Amount Final Concentration 
5 X TBE (2 L) 
Tris-base 108 g 0.9 M 
Boric acid 55 g 0.45 M 
EDTA 9.3 g 15.9 mM 
Milli-Q H2O Up to 2 L - 
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Reagent Chemical/Substance Amount Final Concentration 
Lysis Buffer 
 
 
1 M Tris pH 7.5 50 μL 50 mM 
0.05 M EDTA 20 μL 1 mM 
0.1 M EGTA 10 μL 1 mM 
50% Glycerol 200 μL 1 mM 
10% Triton X-100 100 μL 15 μM 
0.5 M NaF 100 μL 50 mM 
0.05 M Sodium 
Pyrophosphate 
(Na4P2O7) 
100 μL 5 mM 
0.1 M sodium 
orthovanadate 
(Na3VO4) 
10 μL 1 mM 
0.5 M DTT 2 μL 1 mM 
100 X PIC 10 μL - 
Milli-Q H2O 408 μL - 
NAM   
 
TSA   
 
Reagent Chemical/Substance Amount Final Concentration 
Tris solutions (5 M) 
Tris-base 605.5 g 5 M 
Milli-Q H2O Up to 1 L  - 
HCl 
pH 
adjustment 
(Variable) 
- 
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Reagent Chemical/Substance Amount Final Concentration 
HepG2 DMEM Media 
(500 mL) 
#11995 high-glucose  
1 X DMEM 500 mL - 
FBS 50 mL 10% 
Penicillin/streptamycin 5 mL 1% 
Sodium Pyruvate 5 mL 1 mM 
Glutamax 5 mL 2 mM 
 
Reagent Chemical/Substance Amount Final Concentration 
GP media (100mL) 
#11875 glucose free 
RPMI 1640 
Up to 100 
mL - 
Sodium Pyruvate  
100 mM 2 mL 2 mM 
Na-L-Lactate 0.224 g 20 mM 
BSA 0.1 g 0.1% 
 
Reagent Chemical/Substance Amount Final Concentration 
0.12 M Phosphate 
buffer  
(100 mL) 
NaH2PO4.H2O 1.44 g 1.44% 
Phenol (detached 
crystals) 0.1 g 0.1% 
5 M NaOH 
pH 
adjustment 
(variable) 
- 
Milli-Q H2O Up to 100 
mL - 
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Reagent Chemical/Substance Amount Final Concentration 
DYE 
4-aminoantipyrine 0.625 g 0.025% 
0.12 M Phosphate 
buffer  2.5 mL - 
 
Reagent Chemical/Substance Amount Final Concentration 
POD 
Peroxidase 35.43 mg 0.0015% 
0.12 M Phosphate 
buffer  2.5 mL - 
 
Reagent Chemical/Substance Amount Final Concentration 
GOD 
Glucose Oxidase 0.472 g 0.0095% 
0.12 M Phosphate 
buffer  5 mL - 
 
Reagent Chemical/Substance Amount Final Concentration 
Glucose production 
assay buffer (25 mL) 
0.12 M Phosphate 
buffer 25 mL - 
DYE 50 μL - 
POD 25 μL - 
GOD 125 μL - 
 
Reagent Chemical/Substance Amount Final Concentration 
Oil Red-O stock 
Oil Red-O 0.7 g - 
Isopropanol 200 ml - 
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Reagent Chemical/Substance Amount Final Concentration 
KHB buffer 5X 
(1 litre) 
NaCl 32.5 g 555 mM 
KCl 1.75 g 23.5 mM 
MgSO4 1.2 g 10 mM 
Na2HPO4 0.85 g 6 mM 
 
Reagent Chemical/Substance Amount Final Concentration 
IP buffer pH 7.2 
(500 ml) 
NaCl 4.383 g 150 mM 
Tris 1.514 g 25 mM 
 
